22 B
- I
oxacalcitriol I
suppresses O
secondary O
hyperparathyroidism O
without O
inducing O
low O
bone O
turnover O
in O
dogs O
with O
renal O
failure O
. O

BACKGROUND O
: O
Calcitriol B
therapy O
suppresses O
serum O
levels O
of O
parathyroid O
hormone O
( O
PTH O
) O
in O
patients O
with O
renal O
failure O
but O
has O
several O
drawbacks O
, O
including O
hypercalcemia O
and O
/ O
or O
marked O
suppression O
of O
bone O
turnover O
, O
which O
may O
lead O
to O
adynamic O
bone O
disease O
. O

A O
new O
vitamin O
D O
analogue O
, O
22 B
- I
oxacalcitriol I
( O
OCT B
) O
, O
has O
been O
shown O
to O
have O
promising O
characteristics O
. O

This O
study O
was O
undertaken O
to O
determine O
the O
effects O
of O
OCT B
on O
serum O
PTH O
levels O
and O
bone O
turnover O
in O
states O
of O
normal O
or O
impaired O
renal O
function O
. O

Fourteen O
weeks O
after O
the O
start O
of O
phosphate O
supplementation O
, O
half O
of O
the O
Nx O
and O
Sham O
dogs O
received O
doses O
of O
OCT B
( O
three O
times O
per O
week O
) O
; O
the O
other O
half O
were O
given O
vehicle O
for O
60 O
weeks O
. O

Biochemical O
and O
hormonal O
indices O
of O
calcium O
and O
bone O
metabolism O
were O
measured O
throughout O
the O
study O
, O
and O
bone O
biopsies O
were O
done O
at O
baseline O
, O
60 O
weeks O
after O
OCT B
or O
vehicle O
treatment O
, O
and O
at O
the O
end O
of O
the O
crossover O
period O
. O

RESULTS O
: O
In O
Nx O
dogs O
, O
OCT B
significantly O
decreased O
serum O
PTH O
levels O
soon O
after O
the O
induction O
of O
renal O
insufficiency O
. O

In O
long O
- O
standing O
secondary O
hyperparathyroidism O
, O
OCT B
( O
0 O
. O
03 O
microg O
/ O
kg O
) O
stabilized O
serum O
PTH O
levels O
during O
the O
first O
months O
. O

In O
animals O
with O
normal O
renal O
function O
, O
OCT B
induced O
a O
transient O
decrease O
in O
serum O
PTH O
levels O
at O
a O
dose O
of O
0 O
. O
1 O
microg O
/ O
kg O
, O
which O
was O
not O
sustained O
with O
lowering O
of O
the O
doses O
. O

In O
Nx O
dogs O
, O
OCT B
reversed O
abnormal O
bone O
formation O
, O
such O
as O
woven O
osteoid O
and O
fibrosis O
, O
but O
did O
not O
significantly O
alter O
the O
level O
of O
bone O
turnover O
. O

In O
addition O
, O
OCT B
improved O
mineralization O
lag O
time O
, O
( O
that O
is O
, O
the O
rate O
at O
which O
osteoid O
mineralizes O
) O
in O
both O
Nx O
and O
Sham O
dogs O
. O

CONCLUSIONS O
: O
These O
results O
indicate O
that O
even O
though O
OCT B
does O
not O
completely O
prevent O
the O
occurrence O
of O
hypercalcemia O
in O
experimental O
dogs O
with O
renal O
insufficiency O
, O
it O
may O
be O
of O
use O
in O
the O
management O
of O
secondary O
hyperparathyroidism O
because O
it O
does O
not O
induce O
low O
bone O
turnover O
and O
, O
therefore O
, O
does O
not O
increase O
the O
risk O
of O
adynamic O
bone O
disease O
. O

Severe O
immune O
hemolytic O
anemia O
associated O
with O
prophylactic O
use O
of O
cefotetan B
in O
obstetric O
and O
gynecologic O
procedures O
. O

Second O
- O
and O
third O
- O
generation O
cephalosporins O
, O
especially O
cefotetan B
, O
are O
increasingly O
associated O
with O
severe O
, O
sometimes O
fatal O
immune O
hemolytic O
anemia O
. O

We O
noticed O
that O
10 O
of O
our O
35 O
cases O
of O
cefotetan B
- O
induced O
hemolytic O
anemias O
were O
in O
patients O
who O
had O
received O
cefotetan B
prophylactically O
for O
obstetric O
and O
gynecologic O
procedures O
. O

Patients O
with O
aneurysmal O
subarachnoid O
hemorrhage O
( O
SAH O
) O
were O
randomized O
to O
receive O
either O
ketoprofen B
, O
100 O
mg O
, O
three O
times O
a O
day O
( O
ketoprofen B
group O
, O
n O
= O
9 O
) O
or O
a O
weak O
NSAID O
, O
acetaminophen O
, O
1 O
g O
, O
three O
times O
a O
day O
( O
acetaminophen O
group O
, O
n O
= O
9 O
) O
starting O
immediately O
after O
the O
diagnosis O
of O
aneurysmal O
SAH O
. O

Maximal O
platelet O
aggregation O
induced O
by O
6 O
microM O
of O
adenosine O
diphosphate O
decreased O
after O
administration O
of O
ketoprofen B
. O

Aggregation O
was O
lower O
( O
P O
< O
. O
05 O
) O
in O
the O
ketoprofen B
group O
than O
in O
the O
acetaminophen O
group O
just O
before O
surgery O
and O
on O
the O
third O
postoperative O
day O
. O

One O
patient O
in O
the O
ketoprofen B
group O
developed O
a O
postoperative O
intracranial O
hematoma O
. O

Ketoprofen B
but O
not O
acetaminophen O
impaired O
platelet O
function O
in O
patients O
with O
SAH O
. O

If O
ketoprofen B
is O
used O
before O
surgery O
on O
cerebral O
artery O
aneurysms O
, O
it O
may O
pose O
an O
additional O
risk O
factor O
for O
hemorrhage O
. O

Nitric O
oxide O
synthase O
expression O
in O
the O
course O
of O
lead B
- O
induced O
hypertension O
. O

We O
recently O
showed O
elevated O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
reduced O
urinary O
excretion O
of O
NO O
metabolites O
( O
NOx O
) O
, O
and O
increased O
NO O
sequestration O
as O
nitrotyrosine B
in O
various O
tissues O
in O
rats O
with O
lead B
- O
induced O
hypertension O
. O

This O
study O
was O
designed O
to O
discern O
whether O
the O
reduction O
in O
urinary O
NOx O
in O
lead B
- O
induced O
hypertension O
is O
, O
in O
part O
, O
due O
to O
depressed O
NO O
synthase O
( O
NOS O
) O
expression O
. O

Male O
Sprague O
- O
Dawley O
rats O
were O
randomly O
assigned O
to O
a O
lead B
- O
treated O
group O
( O
given O
lead B
acetate I
, O
100 O
ppm O
, O
in O
drinking O
water O
and O
regular O
rat O
chow O
) O
, O
a O
group O
given O
lead B
and O
vitamin O
E O
- O
fortified O
chow O
, O
or O
a O
normal O
control O
group O
given O
either O
regular O
food O
and O
water O
or O
vitamin O
E O
- O
fortified O
food O
for O
12 O
weeks O
. O

The O
lead B
- O
treated O
group O
exhibited O
a O
rise O
in O
blood O
pressure O
and O
plasma O
MDA O
concentration O
, O
a O
fall O
in O
urinary O
NOx O
excretion O
, O
and O
a O
paradoxical O
rise O
in O
vascular O
and O
renal O
tissue O
eNOS O
and O
iNOS O
expression O
. O

The O
study O
also O
revealed O
significant O
inhibition O
of O
NOS O
enzymatic O
activity O
by O
lead B
in O
cell O
- O
free O
preparations O
. O

In O
conclusion O
, O
lead B
- O
induced O
hypertension O
in O
this O
model O
was O
associated O
with O
a O
compensatory O
upregulation O
of O
renal O
and O
vascular O
eNOS O
and O
iNOS O
expression O
. O

This O
is O
, O
in O
part O
, O
due O
to O
ROS O
- O
mediated O
NO O
inactivation O
, O
lead B
- O
associated O
inhibition O
of O
NOS O
activity O
, O
and O
perhaps O
stimulatory O
actions O
of O
increased O
shear O
stress O
associated O
with O
hypertension O
. O

We O
used O
time O
- O
to O
- O
event O
analysis O
to O
identify O
potential O
predictors O
of O
decrease O
in O
renal O
function O
including O
age O
, O
baseline O
ejection O
fraction O
, O
baseline O
creatinine O
, O
low O
systolic O
blood O
pressure O
( O
< O
100 O
mm O
Hg O
) O
, O
history O
of O
hypertension O
, O
diabetes O
, O
and O
use O
of O
antiplatelet O
, O
diuretic B
, O
and O
beta O
- O
blocker O
therapy O
. O

By O
multivariate O
analysis O
, O
in O
both O
the O
placebo O
and O
enalapril O
groups O
older O
age O
, O
diuretic B
therapy O
, O
and O
diabetes O
were O
associated O
with O
decreased O
renal O
function O
, O
whereas O
beta O
- O
blocker O
therapy O
and O
higher O
ejection O
fraction O
were O
renoprotective O
. O

Diuretic B
therapy O
was O
likewise O
associated O
with O
a O
greater O
risk O
of O
decreased O
renal O
function O
in O
the O
enalapril O
group O
( O
RR O
1 O
. O
89 O
, O
95 O
% O
CI O
1 O
. O
70 O
- O
2 O
. O
08 O
) O
than O
in O
the O
placebo O
group O
( O
RR O
1 O
. O
35 O
, O
95 O
% O
CI O
1 O
. O
09 O
- O
1 O
. O
66 O
) O
. O

Diuretic B
use O
and O
advanced O
age O
increased O
this O
risk O
. O

Vasopressin O
in O
the O
treatment O
of O
milrinone B
- O
induced O
hypotension O
in O
severe O
heart O
failure O
. O

The O
use O
of O
phosphodiesterase O
inhibitors O
such O
as O
milrinone B
in O
the O
treatment O
of O
severe O
heart O
failure O
is O
frequently O
restricted O
because O
they O
cause O
vasodilation O
and O
hypotension O
. O

In O
patients O
with O
decompensated O
heart O
failure O
with O
hypotension O
after O
treatment O
with O
milrinone B
, O
low O
doses O
of O
vasopressin O
restored O
blood O
pressure O
without O
inhibiting O
the O
inotropic O
effect O
of O
milrinone B
. O

We O
used O
chloroquine O
or O
hydroxychloroquine B
in O
173 O
of O
210 O
cases O
and O
found O
only O
one O
case O
of O
chorioretinopathy O
attributable O
to O
these O
drugs O
. O

Cyclophosphamide O
( O
CP O
) O
, O
an O
antitumoral O
agent O
known O
to O
produce O
toxic O
effects O
on O
the O
bladder O
wall O
through O
its O
main O
toxic O
metabolite O
acrolein B
, O
was O
used O
to O
induce O
cystitis O
. O

i O
. O
p O
. O
and O
of O
20 O
mg O
. O
by O
the O
intravesical O
route O
, O
and O
acrolein B
at O
doses O
of O
0 O
. O
5 O
mg O
. O
by O
the O
intravesical O
route O
and O
of O
5 O
mg O
. O
/ O
kg O
. O

Administered O
at O
the O
dose O
of O
20 O
mg O
. O
intravesically O
, O
CP O
did O
not O
produce O
any O
behavioral O
effects O
, O
whereas O
acrolein B
at O
0 O
. O
5 O
mg O
. O
intravesically O
induced O
behavioral O
modifications O
identical O
to O
those O
under O
CP O
200 O
mg O
. O
/ O
kg O
. O

Conversely O
, O
acrolein B
5 O
mg O
. O
/ O
kg O
. O

On O
Day O
8 O
, O
the O
nerve O
- O
evoked O
peak O
twitch O
tensions O
, O
tetanic O
tensions O
, O
and O
fatigability O
, O
and O
the O
dose O
- O
response O
curves O
of O
d B
- I
tubocurarine I
in O
the O
tibialis O
cranialis O
muscle O
were O
measured O
in O
vivo O
and O
related O
to O
muscle O
mass O
or O
expression O
of O
AChRs O
. O

The O
50 O
% O
effective O
dose O
of O
d B
- I
tubocurarine I
( O
microg O
/ O
kg O
) O
in O
the O
tibialis O
muscle O
was O
smaller O
in O
the O
P10 O
( O
33 O
. O
6 O
+ O
/ O
- O
5 O
. O
4 O
) O
than O
in O
the O
S O
( O
61 O
. O
9 O
+ O
/ O
- O
5 O
. O
0 O
) O
or O
the O
P100 O
( O
71 O
. O
3 O
+ O
/ O
- O
9 O
. O
6 O
) O
groups O
. O

The O
50 O
% O
effective O
dose O
of O
d B
- I
tubocurarine I
did O
not O
correlate O
with O
muscle O
mass O
or O
AChR O
expression O
. O

This O
study O
assessed O
the O
effect O
of O
normal O
aging O
on O
( O
1 O
) O
the O
tropicamide B
- O
induced O
increase O
in O
pupil O
diameter O
, O
and O
( O
2 O
) O
the O
reversal O
of O
this O
effect O
with O
pilocarpine O
. O

In O
1 O
session O
, O
tropicamide B
( O
20 O
microL O
, O
0 O
. O
01 O
% O
) O
was O
administered O
to O
one O
eye O
and O
placebo O
to O
the O
other O
. O

In O
another O
session O
, O
tropicamide B
( O
20 O
microL O
, O
0 O
. O
01 O
% O
) O
was O
administered O
to O
both O
eyes O
, O
followed O
23 O
minutes O
later O
by O
the O
application O
of O
pilocarpine O
( O
20 O
microL O
, O
0 O
. O
1 O
% O
) O
to O
one O
eye O
and O
placebo O
to O
the O
other O
. O

OUTCOME O
MEASURES O
: O
Pupil O
size O
at O
time O
points O
after O
administration O
of O
tropicamide B
and O
pilocarpine O
; O
scopolamine O
- O
induced O
impairment O
in O
word O
recall O
. O

RESULTS O
: O
There O
was O
no O
significant O
difference O
between O
elderly O
and O
young O
volunteers O
in O
pupillary O
response O
to O
tropicamide B
at O
any O
time O
point O
( O
p O
> O
0 O
. O
05 O
) O
. O

CONCLUSION O
: O
There O
is O
an O
age O
- O
related O
pupillary O
response O
to O
pilocarpine O
that O
is O
not O
found O
with O
tropicamide B
. O

By O
using O
a O
placebo O
- O
controlled O
, O
two O
- O
way O
factorial O
design O
, O
tolerance O
to O
cold O
- O
pressor O
( O
CP O
) O
pain O
was O
examined O
, O
both O
before O
and O
after O
oral O
administration O
of O
therapeutic O
doses O
of O
common O
opioid O
( O
hydromorphone B
2 O
mg O
) O
and O
nonsteroidal O
anti O
- O
inflammatory O
( O
ketorolac B
10 O
mg O
) O
analgesic O
agents O
. O

Metoprolol O
was O
dosed O
to O
achieve O
a O
resting O
predobutamine B
heart O
rate O
below O
65 O
beats O
/ O
minute O
or O
a O
total O
intravenous O
dose O
of O
20 O
mg O
. O

CONCLUSIONS O
: O
During O
this O
study O
period O
, O
routine O
plasma O
screening O
for O
cocaine O
and O
amphetamines B
in O
adult O
seizure O
patients O
had O
a O
low O
yield O
. O

METHODS O
: O
The O
alteration O
in O
the O
NO O
pathway O
was O
assessed O
by O
measuring O
nitrite B
levels O
in O
serum O
/ O
urine O
and O
by O
evaluating O
the O
changes O
in O
vascular O
reactivity O
of O
the O
isolated O
perfused O
rat O
kidney O
( O
IPRK O
) O
system O
. O

These O
two O
groups O
were O
then O
divided O
into O
: O
group O
1 O
, O
animals O
receiving O
saline O
; O
and O
group O
2 O
, O
animals O
receiving O
aminoguanidine B
( O
AG B
) O
which O
is O
a O
specific O
inhibitor O
of O
inducible O
- O
NO O
synthase O
. O

Urine O
nitrite B
levels O
were O
significantly O
increased O
in O
the O
ADR O
- O
nephropathy O
group O
( O
P O
< O
0 O
. O
05 O
) O
. O

Treatment O
with O
AG B
prevented O
the O
impairment O
of O
renal O
vascular O
bed O
responses O
and O
reduced O
both O
urine O
nitrite B
levels O
and O
apoptosis O
to O
control O
levels O
. O

Dual O
effects O
of O
melatonin B
on O
barbiturate B
- O
induced O
narcosis O
in O
rats O
. O

Melatonin B
affects O
the O
circadian O
sleep O
/ O
wake O
cycle O
, O
but O
it O
is O
not O
clear O
whether O
it O
may O
influence O
drug O
- O
induced O
narcosis O
. O

Sodium O
thiopenthal O
was O
administered O
intraperitoneally O
into O
male O
rats O
pre O
- O
treated O
with O
melatonin B
( O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mg O
/ O
kg O
) O
. O

Melatonin B
pre O
- O
treatment O
affected O
in O
a O
dual O
manner O
barbiturate B
narcosis O
, O
however O
, O
no O
dose O
- O
effect O
correlation O
was O
found O
. O

In O
particular O
, O
low O
doses O
reduced O
the O
latency O
to O
and O
prolonged O
the O
duration O
of O
barbiturate B
narcosis O
. O

In O
contrast O
, O
the O
highest O
dose O
of O
melatonin B
( O
50 O
mg O
/ O
kg O
) O
caused O
a O
paradoxical O
increase O
in O
the O
latency O
and O
produced O
a O
sustained O
reduction O
of O
the O
duration O
of O
narcosis O
, O
and O
a O
reduction O
in O
mortality O
rate O
. O

Melatonin B
0 O
. O
5 O
and O
5 O
mg O
/ O
kg O
influenced O
the O
duration O
but O
not O
the O
latency O
of O
ketamine O
- O
or O
diazepam O
- O
induced O
narcosis O
. O

Thus O
, O
the O
dual O
action O
of O
melatonin B
on O
pharmacological O
narcosis O
seems O
to O
be O
specific O
for O
the O
barbiturate B
mechanism O
of O
action O
. O

METHODS O
: O
To O
evaluate O
the O
potential O
mechanisms O
of O
AF O
promotion O
by O
Ca O
( O
2 O
+ O
) O
channel O
blockers O
, O
we O
administered O
verapamil O
to O
morphine O
- O
chloralose B
anesthetized O
dogs O
. O

Diltiazem O
was O
used O
as O
a O
comparison O
drug O
and O
autonomic O
blockade O
with O
atropine O
and O
nadolol B
was O
applied O
in O
some O
experiments O
. O

Fluconazole B
- O
induced O
torsade O
de O
pointes O
. O

OBJECTIVE O
: O
To O
present O
a O
case O
of O
fluconazole B
- O
associated O
torsade O
de O
pointes O
( O
TDP O
) O
and O
discuss O
fluconazole B
' O
s O
role O
in O
causing O
TDP O
. O

CASE O
SUMMARY O
: O
A O
68 O
- O
year O
- O
old O
white O
woman O
with O
Candida O
glabrata O
isolated O
from O
a O
presacral O
abscess O
developed O
TDP O
eight O
days O
after O
commencing O
oral O
fluconazole B
The O
patient O
had O
no O
other O
risk O
factors O
for O
TDP O
, O
including O
coronary O
artery O
disease O
, O
cardiomyopathy O
, O
congestive O
heart O
failure O
, O
and O
electrolyte O
abnormalities O
There O
was O
a O
temporal O
association O
between O
the O
initiation O
of O
fluconazole B
and O
TDP O
. O

The O
TDP O
resolved O
when O
fluconazole B
was O
discontinued O
; O
however O
, O
the O
patient O
continued O
to O
have O
premature O
ventricular O
contractions O
and O
nonsustained O
ventricular O
tachycardia O
( O
NSVT O
) O
until O
six O
days O
after O
drug O
cessation O
DISCUSSION O
: O
Use O
of O
the O
Naranjo O
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
use O
of O
fluconazole B
and O
the O
development O
of O
TDP O
. O

In O
our O
patient O
, O
there O
was O
no O
other O
etiology O
identified O
that O
could O
explain O
QT O
prolongation O
or O
TDP O
The O
complete O
disappearance O
of O
NSVT O
and O
premature O
ventricular O
contractions O
followed O
by O
normalization O
of O
QT O
interval O
after O
the O
drug O
was O
stopped O
strongly O
suggests O
fluconazole B
as O
the O
etiology O
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
that O
fluconazole B
, O
even O
at O
low O
doses O
, O
may O
cause O
prolongation O
of O
the O
QT O
interval O
, O
leading O
to O
TDP O
. O

Serial O
electrocardiographic O
monitoring O
may O
be O
considered O
when O
fluconazole B
is O
administered O
in O
patients O
who O
are O
at O
risk O
for O
ventricular O
arrhythmias O
. O

Cutaneous O
leucocytoclastic O
vasculitis O
associated O
with O
oxacillin B
. O

A O
67 O
- O
year O
- O
old O
man O
who O
was O
treated O
with O
oxacillin B
for O
one O
week O
because O
of O
Staphylococcus O
aureus O
bacteremia O
, O
developed O
renal O
failure O
and O
diffuse O
, O
symmetric O
, O
palpable O
purpuric O
lesions O
on O
his O
feet O
. O

Oxacillin B
was O
discontinued O
and O
patient O
was O
treated O
with O
corticosteroids O
. O

Oxacillin B
should O
be O
included O
among O
the O
drugs O
that O
can O
cause O
leucocytoclastic O
vasculitis O
. O

Cholestatic O
jaundice O
associated O
with O
the O
use O
of O
metformin B
. O

We O
report O
a O
patient O
who O
developed O
cholestatic O
jaundice O
shortly O
after O
initiation O
of O
treatment O
with O
metformin B
hydrochloride I
. O

Metformin B
hydrochloride I
was O
discontinued O
, O
and O
the O
patient O
' O
s O
jaundice O
resolved O
slowly O
over O
a O
period O
of O
several O
months O
. O

Given O
the O
onset O
of O
his O
jaundice O
2 O
wk O
after O
the O
initiation O
of O
metformin B
, O
we O
believe O
that O
this O
case O
represents O
an O
example O
of O
metformin B
- O
associated O
hepatotoxicity O
, O
the O
first O
such O
case O
reported O
. O

Systemic O
toxicity O
and O
resuscitation O
in O
bupivacaine O
- O
, O
levobupivacaine B
- O
, O
or O
ropivacaine B
- O
infused O
rats O
. O

We O
compared O
the O
systemic O
toxicity O
of O
bupivacaine O
, O
levobupivacaine B
, O
and O
ropivacaine B
in O
anesthetized O
rats O
. O

Bupivacaine O
, O
levobupivacaine B
, O
or O
ropivacaine B
was O
infused O
at O
a O
rate O
of O
2 O
mg O
. O

The O
cumulative O
doses O
of O
levobupivacaine B
and O
ropivacaine B
that O
produced O
seizures O
were O
similar O
and O
were O
larger O
than O
those O
of O
bupivacaine O
. O

The O
cumulative O
doses O
of O
levobupivacaine B
that O
produced O
dysrhythmias O
and O
asystole O
were O
smaller O
than O
the O
corresponding O
doses O
of O
ropivacaine B
, O
but O
they O
were O
larger O
than O
those O
of O
bupivacaine O
. O

However O
, O
a O
smaller O
dose O
of O
epinephrine O
was O
required O
in O
the O
Ropivacaine B
group O
than O
in O
the O
other O
groups O
. O

We O
conclude O
that O
the O
systemic O
toxicity O
of O
levobupivacaine B
is O
intermediate O
between O
that O
of O
ropivacaine B
and O
bupivacaine O
when O
administered O
at O
the O
same O
rate O
and O
that O
ropivacaine B
- O
induced O
cardiac O
arrest O
appears O
to O
be O
more O
susceptible O
to O
treatment O
than O
that O
induced O
by O
bupivacaine O
or O
levobupivacaine B
. O

The O
patients O
concurrent O
medications O
included O
didanosine O
, O
hydroxyzine B
, O
promethazine B
, O
hydrocortisone O
, O
and O
prochlorperazine O
. O

Despite O
administration O
of O
phenytoin O
and O
lorazepam B
, O
the O
seizures O
persisted O
and O
occurred O
only O
during O
amphotercin O
B O
administration O
. O

Tolerability O
of O
nimesulide B
and O
paracetamol O
in O
patients O
with O
NSAID B
- O
induced O
urticaria O
/ O
angioedema O
. O

Previous O
studies O
evaluated O
the O
tolerance O
of O
nimesulide B
and O
paracetamol O
in O
subjects O
with O
cutaneous O
, O
respiratory O
and O
anaphylactoid O
reactions O
induced O
by O
nonsteroidal B
anti I
- I
inflammatory I
drugs I
( O
NSAIDs B
) O
. O

In O
this O
study O
we O
investigated O
tolerability O
and O
reliability O
of O
nimesulide B
and O
paracetamol O
in O
a O
very O
large O
number O
of O
patients O
with O
an O
exclusive O
well O
- O
documented O
history O
of O
NSAID B
- O
induced O
urticaria O
/ O
angioedema O
. O

Furthermore O
, O
we O
evaluated O
whether O
some O
factors O
have O
the O
potential O
to O
increase O
the O
risk O
of O
reaction O
to O
paracetamol O
and O
nimesulide B
. O

A O
single O
- O
placebo O
- O
controlled O
oral O
challenge O
procedure O
with O
nimesulide B
or O
paracetamol O
was O
applied O
to O
829 O
patients O
with O
a O
history O
of O
NSAID B
- O
induced O
urticaria O
/ O
angioedema O
. O

A O
total O
of O
75 O
/ O
829 O
( O
9 O
. O
4 O
% O
) O
patients O
experienced O
reactions O
to O
nimesulide B
or O
paracetamol O
. O

Of O
the O
715 O
patients O
tested O
with O
nimesulide B
62 O
( O
8 O
. O
6 O
% O
) O
showed O
a O
positive O
test O
, O
while O
of O
114 O
subjects O
submitted O
to O
the O
challenge O
with O
paracetamol O
, O
13 O
( O
9 O
. O
6 O
% O
) O
did O
not O
tolerate O
this O
drug O
. O

Furthermore O
, O
18 O
. O
28 O
% O
of O
patients O
with O
a O
history O
of O
chronic O
urticaria O
and O
11 O
. O
8 O
% O
of O
subjects O
with O
an O
history O
of O
NSAID B
- O
induced O
urticaria O
/ O
angioedema O
or O
angioedema O
alone O
( O
with O
or O
without O
chronic O
urticaria O
) O
resulted O
to O
be O
intolerant O
to O
alternative O
drugs O
. O

Taken O
together O
, O
our O
results O
confirm O
the O
good O
tolerability O
of O
nimesulide B
and O
paracetamol O
in O
patients O
who O
experienced O
urticaria O
/ O
angioedema O
caused O
by O
NSAIDs B
. O

However O
, O
the O
risk O
of O
reaction O
to O
these O
alternative O
study O
drugs O
is O
statistically O
increased O
by O
a O
history O
of O
chronic O
urticaria O
and O
, O
above O
all O
, O
by O
a O
history O
of O
NSAID B
- O
induced O
angioedema O
. O

OBJECTIVES O
: O
Recently O
published O
studies O
have O
demonstrated O
increased O
efficacy O
and O
cost O
- O
effectiveness O
of O
combination O
therapy O
with O
interferon O
and O
alpha O
- O
2b O
/ O
ribavirin O
compared O
with O
interferon B
- I
alpha I
monotherapy O
in O
the O
treatment O
of O
chronic O
hepatitis O
C O
( O
CHC O
) O
. O

We O
report O
the O
successful O
treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia O
with O
cabergoline B
in O
youth O
. O

METHODS O
: O
We O
undertook O
a O
retrospective O
case O
review O
of O
four O
children O
with O
risperidone O
- O
induced O
hyperprolactinemia O
treated O
with O
cabergoline B
. O

RESULTS O
: O
Four O
males O
( O
age O
6 O
- O
11 O
years O
) O
with O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
( O
fourth O
edition O
) O
bipolar O
disorder O
or O
psychoses O
, O
with O
risperidone O
- O
induced O
elevations O
in O
serum O
prolactin O
levels O
( O
57 O
. O
5 O
- O
129 O
ng O
/ O
mL O
, O
normal O
5 O
- O
15 O
ng O
/ O
mL O
) O
, O
were O
treated O
with O
cabergoline B
( O
mean O
dose O
2 O
. O
13 O
+ O
/ O
- O
0 O
. O
09 O
mg O
/ O
week O
) O
. O

When O
serum O
prolactin O
levels O
normalized O
in O
all O
four O
subjects O
( O
mean O
11 O
. O
2 O
+ O
/ O
- O
10 O
. O
9 O
ng O
/ O
mL O
) O
, O
the O
cabergoline B
dose O
was O
reduced O
to O
1 O
mg O
/ O
week O
in O
three O
of O
four O
subjects O
. O

The O
mean O
duration O
of O
therapy O
with O
cabergoline B
was O
523 O
. O
5 O
+ O
/ O
- O
129 O
. O
7 O
days O
, O
and O
the O
mean O
duration O
of O
therapy O
with O
risperidone O
was O
788 O
. O
5 O
+ O
/ O
- O
162 O
. O
5 O
days O
. O

Cabergoline B
was O
well O
tolerated O
without O
adverse O
effects O
. O

CONCLUSIONS O
: O
Cabergoline B
may O
be O
useful O
for O
the O
treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia O
in O
youth O
; O
however O
, O
further O
research O
is O
needed O
. O

Steroid O
structure O
and O
pharmacological O
properties O
determine O
the O
anti O
- O
amnesic O
effects O
of O
pregnenolone B
sulphate I
in O
the O
passive O
avoidance O
task O
in O
rats O
. O

Pregnenolone B
sulphate I
( O
PREGS B
) O
has O
generated O
interest O
as O
one O
of O
the O
most O
potent O
memory O
- O
enhancing O
neurosteroids O
to O
be O
examined O
in O
rodent O
learning O
studies O
, O
with O
particular O
importance O
in O
the O
ageing O
process O
. O

This O
hypothesis O
stems O
from O
findings O
that O
PREGS B
is O
a O
potent O
positive O
modulator O
of O
N O
- O
methyl O
- O
d O
- O
aspartate O
receptors O
( O
NMDARs O
) O
and O
a O
negative O
modulator O
of O
gamma O
- O
aminobutyric O
acid O
( O
A O
) O
receptors O
( O
GABA O
( O
A O
) O
Rs O
) O
. O

Moreover O
, O
PREGS B
is O
able O
to O
reverse O
the O
amnesic O
- O
like O
effects O
of O
NMDAR O
and O
GABA O
( O
A O
) O
R O
ligands O
. O

To O
investigate O
this O
hypothesis O
, O
the O
present O
study O
in O
rats O
examined O
the O
memory O
- O
altering O
abilities O
of O
structural O
analogs O
of O
PREGS B
, O
which O
differ O
in O
their O
modulation O
of O
NMDAR O
and O
/ O
or O
GABA O
( O
A O
) O
R O
function O
. O

The O
analogs O
tested O
were O
: O
11 B
- I
ketopregnenolone I
sulphate I
( O
an O
agent O
that O
is O
inactive O
at O
GABA O
( O
A O
) O
Rs O
and O
NMDARs O
) O
, O
epipregnanolone B
( I
[ I
3beta I
- I
hydroxy I
- I
5beta I
- I
pregnan I
- I
20 I
- I
one I
] I
sulphate I
, O
an O
inhibitor O
of O
both O
GABA O
( O
A O
) O
Rs O
and O
NMDARs O
) O
, O
and O
a O
newly O
synthesized O
( O
- O
) O
PREGS B
enantiomer O
( O
which O
is O
identical O
to O
PREGS B
in O
effects O
on O
GABA O
( O
A O
) O
Rs O
and O
NMDARs O
) O
. O

The O
memory O
- O
enhancing O
effects O
of O
PREGS B
and O
its O
analogs O
were O
tested O
in O
the O
passive O
avoidance O
task O
using O
the O
model O
of O
scopolamine O
- O
induced O
amnesia O
. O

Both O
PREGS B
and O
its O
( O
- O
) O
enantiomer O
blocked O
the O
effects O
of O
scopolamine O
. O

The O
results O
show O
that O
, O
unlike O
PREGS B
, O
11 B
- I
ketopregnenolone I
sulphate I
and O
epipregnanolone B
sulphate I
failed O
to O
block O
the O
effect O
of O
scopolamine O
, O
suggesting O
that O
altering O
the O
modulation O
of O
NMDA O
receptors O
diminishes O
the O
memory O
- O
enhancing O
effects O
of O
PREGS B
. O

Moreover O
, O
enantioselectivity O
was O
demonstrated O
by O
the O
ability O
of O
natural O
PREGS B
to O
be O
an O
order O
of O
magnitude O
more O
effective O
than O
its O
synthetic O
enantiomer O
in O
reversing O
scopolamine O
- O
induced O
amnesia O
. O

Activation O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
contributes O
to O
development O
of O
doxorubicin O
- O
induced O
heart O
failure O
. O

Activation O
of O
the O
nuclear O
enzyme O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
by O
oxidant O
- O
mediated O
DNA O
damage O
is O
an O
important O
pathway O
of O
cell O
dysfunction O
and O
tissue O
injury O
in O
conditions O
associated O
with O
oxidative O
stress O
. O

Using O
a O
dual O
approach O
of O
PARP O
- O
1 O
suppression O
, O
by O
genetic O
deletion O
or O
pharmacological O
inhibition O
with O
the O
phenanthridinone O
PARP O
inhibitor O
PJ34 B
, O
we O
now O
demonstrate O
the O
role O
of O
PARP O
in O
the O
development O
of O
cardiac O
dysfunction O
induced O
by O
DOX O
. O

Similar O
experiments O
were O
conducted O
in O
BALB O
/ O
c O
mice O
treated O
with O
PJ34 B
or O
vehicle O
. O

Treatment O
with O
a O
PJ34 B
significantly O
improved O
cardiac O
dysfunction O
and O
increased O
the O
survival O
of O
the O
animals O
. O

In O
addition O
PJ34 B
significantly O
reduced O
the O
DOX O
- O
induced O
increase O
in O
the O
serum O
lactate O
dehydrogenase O
and O
creatine O
kinase O
activities O
but O
not O
metalloproteinase O
activation O
in O
the O
heart O
. O

Risperidone O
- O
associated O
, O
benign O
transient O
visual O
disturbances O
in O
schizophrenic O
patients O
with O
a O
past O
history O
of O
LSD B
abuse O
. O

Two O
schizophrenic O
patients O
, O
who O
had O
a O
prior O
history O
of O
LSD B
abuse O
and O
who O
had O
previously O
developed O
EPS O
with O
classic O
antipsychotics O
, O
were O
successfully O
treated O
with O
risperidone O
. O

This O
imagery O
resembled O
visual O
disturbances O
previously O
experienced O
as O
" O
flashbacks O
" O
related O
to O
prior O
LSD B
consumption O
. O

These O
factors O
can O
lead O
to O
the O
development O
of O
calcium B
phosphate I
nephrolithiasis O
. O

Experience O
is O
greatest O
with O
intravenous O
ribavirin O
and O
cidofovir B
. O

Ribavirin O
, O
a O
guanosine B
analogue O
, O
has O
broad O
antiviral O
activity O
against O
both O
RNA O
and O
DNA O
viruses O
, O
including O
documented O
activity O
against O
adenovirus O
in O
vitro O
. O

The O
use O
of O
cidofovir B
in O
severe O
adenovirus O
infection O
has O
been O
limited O
by O
adverse O
effects O
, O
the O
most O
significant O
of O
which O
is O
nephrotoxicity O
. O

The O
bone O
marrow O
transplant O
patient O
also O
received O
intravenous O
cidofovir B
for O
progressive O
disseminated O
disease O
. O

Use O
of O
cidofovir B
in O
1 O
child O
was O
associated O
with O
progressive O
renal O
failure O
and O
neutropenia O
. O

A O
51 O
year O
old O
man O
took O
a O
mixed O
overdose O
including O
1 O
. O
8 O
- O
3 O
. O
6 O
g O
of O
diltiazem O
, O
paracetamol O
, O
aspirin O
, O
isosorbide B
nitrate B
, O
and O
alcohol O
. O

Low B
- I
molecular I
- I
weight I
heparin I
for O
the O
treatment O
of O
patients O
with O
mechanical O
heart O
valves O
. O

Low B
- I
molecular I
- I
weight I
heparin I
( O
LMWH B
) O
offers O
theoretical O
advantages O
over O
UH O
, O
but O
is O
not O
currently O
considered O
in O
clinical O
guidelines O
as O
an O
alternative O
to O
UH O
in O
patients O
with O
prosthetic O
valves O
. O

HYPOTHESIS O
: O
The O
aim O
of O
the O
present O
study O
was O
to O
review O
the O
data O
accumulated O
so O
far O
on O
the O
use O
of O
LMWH B
in O
this O
patient O
population O
and O
to O
discuss O
its O
applicability O
in O
common O
practice O
. O

METHODS O
: O
For O
this O
paper O
, O
the O
current O
medical O
literature O
on O
LMWH B
in O
patients O
with O
mechanical O
heart O
valves O
was O
extensively O
reviewed O
. O

CONCLUSIONS O
: O
In O
patients O
with O
mechanical O
heart O
valves O
, O
short O
- O
term O
LMWH B
therapy O
compares O
favorably O
with O
UH O
. O

Data O
on O
mid O
- O
and O
long O
- O
term O
LMWH B
administration O
in O
these O
patients O
are O
sparse O
. O

Further O
randomized O
studies O
are O
needed O
to O
confirm O
the O
safety O
and O
precise O
indications O
for O
the O
use O
of O
LMWH B
in O
patients O
with O
mechanical O
heart O
valves O
. O

Immunohistochemical O
study O
on O
inducible O
type O
of O
nitric O
oxide O
( O
iNOS O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
and O
tumor O
growth O
factor O
- O
beta1 O
( O
TGF O
- O
beta1 O
) O
in O
arteritis O
induced O
in O
rats O
by O
fenoldopam B
and O
theophylline O
, O
vasodilators O
. O

Arteritis O
induced O
in O
rats O
by O
vasodilators O
, O
fenoldopam B
and O
theophylline O
, O
was O
examined O
immunohistochemically O
for O
expressions O
of O
inducible O
type O
of O
nitric O
oxide O
synthase O
( O
iNOS O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
and O
tumor O
growth O
factor O
- O
beta1 O
( O
TGF O
- O
beta1 O
) O
. O

Rats O
were O
administered O
fenoldopam B
for O
24 O
hours O
by O
intravenous O
infusion O
with O
or O
without O
following O
repeated O
daily O
oral O
administrations O
of O
theophylline O
. O

Irrespective O
of O
theophylline O
administration O
, O
iNOS O
antigens O
were O
remarkably O
abundant O
in O
ED O
- O
1 O
- O
positive O
cells O
on O
day O
5 O
and O
8 O
post O
- O
fenoldopam B
- O
infusion O
( O
DPI O
) O
; O
bFGF O
antigens O
were O
remarkably O
abundant O
in O
ED O
- O
1 O
- O
positive O
cells O
on O
1 O
and O
3 O
DPI O
; O
TGF O
- O
beta1 O
antigens O
were O
observed O
in O
ED O
- O
1 O
- O
positive O
cells O
on O
and O
after O
5 O
DPI O
. O

( B
RS I
) I
- I
1 I
- I
aminoindan I
- I
1 I
, I
5 I
- I
dicarboxylic I
acid I
( O
AIDA B
; O
0 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
potent O
and O
selective O
mGluR1 O
antagonist O
, O
or O
( B
2R I
, I
4R I
) I
- I
4 I
- I
aminopyrrolidine I
- I
2 I
, I
4 I
- I
dicarboxylate I
( O
2R B
, I
4R I
- I
APDC I
; O
7 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
selective O
group O
II O
agonist O
, O
was O
injected O
bilaterally O
into O
the O
striatum O
of O
haloperidol O
- O
treated O

AIDA B
in O
doses O
of O
7 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
diminished O
the O
haloperidol O
- O
induced O
muscle O
rigidity O
. O

In O
contrast O
, O
2R B
, I
4R I
- I
APDC I
injections O
were O
ineffective O
. O

Group O
PS O
, O
the O
control O
group O
, O
received O
normal O
saline O
and O
succinylcholine O
1 O
. O
5 O
mg O
x O
kg O
( O
- O
1 O
) O
; O
Group O
LS O
, O
lidocaine O
1 O
. O
5 O
mg O
x O
kg O
( O
- O
1 O
) O
and O
succinylcholine O
1 O
. O
5 O
mg O
x O
kg O
( O
- O
1 O
) O
; O
Group O
PR O
, O
normal O
saline O
and O
rocuronium B
0 O
. O
6 O
mg O
x O
kg O
( O
- O
1 O
) O
. O

Anesthesia O
was O
induced O
with O
5 O
mg O
. O
kg O
( O
- O
1 O
) O
thiopental O
iv O
. O
followed O
by O
succinylcholine O
( O
Group O
PS O
, O
LS O
) O
or O
rocuronium B
( O
Group O
PR O
) O
for O
tracheal O
intubation O
. O

Measurements O
of O
[ O
( O
3 O
) O
H O
] O
saxitoxin B
( O
STX B
) O
binding O
showed O
a O
significant O
reduction O
in O
the O
level O
of O
plasma O
membrane O
sodium O
channels O
in O
beta2 O
( O
- O
/ O
- O
) O
neurons O
. O

METHODS O
: O
We O
conducted O
a O
randomized O
, O
double O
- O
blind O
, O
prospective O
, O
multicenter O
study O
comparing O
the O
nephrotoxic O
effects O
of O
an O
iso O
- O
osmolar O
, O
dimeric O
, O
nonionic O
contrast O
medium O
, O
iodixanol O
, O
with O
those O
of O
a O
low O
- O
osmolar O
, O
nonionic O
, O
monomeric O
contrast O
medium O
, O
iohexol B
. O

From O
day O
0 O
to O
day O
3 O
, O
the O
mean O
peak O
increase O
in O
creatinine O
was O
0 O
. O
13 O
mg O
per O
deciliter O
in O
the O
iodixanol O
group O
and O
0 O
. O
55 O
mg O
per O
deciliter O
in O
the O
iohexol B
group O
( O
P O
= O
0 O
. O
001 O
; O
the O
increase O
with O
iodixanol O
minus O
the O
increase O
with O
iohexol B
, O
- O
0 O
. O
42 O
mg O
per O
deciliter O
[ O
95 O
percent O
confidence O
interval O
, O
- O
0 O
. O
73 O
to O
- O
0 O
. O
22 O
] O
) O
. O

Two O
of O
the O
64 O
patients O
in O
the O
iodixanol O
group O
( O
3 O
percent O
) O
had O
an O
increase O
in O
the O
creatinine O
concentration O
of O
0 O
. O
5 O
mg O
per O
deciliter O
or O
more O
, O
as O
compared O
with O
17 O
of O
the O
65 O
patients O
in O
the O
iohexol B
group O
( O
26 O
percent O
) O
( O
P O
= O
0 O
. O
002 O
; O
odds O
ratio O
for O
such O
an O
increase O
in O
the O
iodixanol O
group O
, O
0 O
. O
09 O
[ O
95 O
percent O
confidence O
interval O
, O
0 O
. O
02 O
to O
0 O
. O
41 O
] O
) O
. O

No O
patient O
receiving O
iodixanol O
had O
an O
increase O
of O
1 O
. O
0 O
mg O
per O
deciliter O
or O
more O
, O
but O
10 O
patients O
in O
the O
iohexol B
group O
( O
15 O
percent O
) O
did O
. O

The O
mean O
change O
in O
the O
creatinine O
concentration O
from O
day O
0 O
to O
day O
7 O
was O
0 O
. O
07 O
mg O
per O
deciliter O
in O
the O
iodixanol O
group O
and O
0 O
. O
24 O
mg O
per O
deciliter O
in O
the O
iohexol B
group O
( O
P O
= O
0 O
. O
003 O
; O
value O
in O
the O
iodixanol O
group O
minus O
the O
value O
in O
the O
iohexol B
group O
, O
- O
0 O
. O
17 O
mg O
per O
deciliter O
[ O
95 O
percent O
confidence O
interval O
, O
- O
0 O
. O
34 O
to O
- O
0 O
. O
07 O
] O
) O
. O

Protective O
effect O
of O
edaravone B
against O
streptomycin O
- O
induced O
vestibulotoxicity O
in O
the O
guinea O
pig O
. O

This O
study O
investigated O
alleviation O
of O
streptomycin O
- O
induced O
vestibulotoxicity O
by O
edaravone B
in O
guinea O
pigs O
. O

Edaravone B
, O
a O
free O
radical O
scavenger O
, O
has O
potent O
free O
radical O
quenching O
action O
and O
is O
used O
in O
clinical O
practice O
to O
treat O
cerebral O
infarction O
. O

Streptomycin O
was O
administered O
to O
the O
inner O
ear O
by O
osmotic O
pump O
for O
24 O
h O
, O
and O
edaravone B
( O
n O
= O
8 O
) O
or O
saline O
( O
n O
= O
6 O
) O
was O
intraperitoneally O
injected O
once O
a O
day O
for O
7 O
days O
. O

Animals O
injected O
with O
saline O
showed O
statistically O
smaller O
gains O
than O
those O
injected O
with O
edaravone B
. O

These O
results O
suggest O
that O
edaravone B
suppresses O
streptomycin O
- O
induced O
vestibulotoxicity O
. O

Oral O
administration O
of O
lindane O
( O
2 O
. O
5 O
, O
5 O
, O
10 O
and O
15 O
mg O
/ O
kg O
, O
body O
weight O
) O
for O
5 O
days O
was O
found O
to O
produce O
a O
dose O
- O
dependent O
increase O
in O
the O
activity O
of O
P450 O
dependent O
7 O
- O
ethoxyresorufin O
- O
O O
- O
deethylase O
( O
EROD O
) O
, O
7 O
- O
pentoxyresorufin O
- O
O O
- O
dealkylase O
( O
PROD O
) O
and O
N B
- I
nitrosodimethylamine I
demethylase O
( O
NDMA B
- O
d O
) O
in O
rat O
brain O
and O
liver O
. O

In O
vitro O
studies O
using O
organic O
inhibitors O
specific O
for O
individual O
P450 O
isoenzymes O
and O
antibody O
inhibition O
experiments O
have O
further O
demonstrated O
that O
the O
increase O
in O
the O
activity O
of O
PROD O
, O
EROD O
and O
NDMA B
- O
d O
are O
due O
to O
the O
increase O
in O
the O
levels O
of O
P450 O
2B1 O
/ O
2B2 O
, O
1A1 O
/ O
1A2 O
and O
2E1 O
isoenzymes O
, O
respectively O
. O

Induction O
studies O
have O
further O
shown O
that O
while O
pretreatment O
of O
3 B
- I
methylcholanthrene I
( O
MC B
) O
, O
an O
inducer O
of O
P4501A1 O
/ O
1A2 O
, O
did O
not O
produce O
any O
significant O
effect O
in O
the O
incidence O
of O
lindane O
induced O
convulsions O
, O
pretreatment O
with O
phenobarbital O
( O
PB O
) O
, O
an O
inducer O
of O
P450 O
2B1 O
/ O
2B2 O
or O
ethanol O
, O
an O
inducer O
of O
P450 O
2E1 O
catalysed O
reactions O
, O
significantly O
increased O
the O
incidence O
of O
lindane O
induced O
convulsions O
. O

Similarly O
, O
when O
the O
P450 O
- O
mediated O
metabolism O
of O
lindane O
was O
blocked O
by O
cobalt B
chloride I
incidence O
of O
convulsions O
was O
increased O
in O
animals O
treated O
with O
lindane O
indicating O
that O
lindane O
per O
se O
or O
its O
metabolites O
formed O
by O
PB O
or O
ethanol O
inducible O
P450 O
isoenzymes O
are O
involved O
in O
its O
neurobehavioral O
toxicity O
. O

OBJECTIVE O
: O
To O
achieve O
absolute O
risk O
estimates O
of O
venous O
thromboembolism O
( O
VTE O
) O
among O
women O
on O
cyproterone O
acetate O
plus O
ethinylestradiol O
( O
CPA O
/ O
EE O
) O
, O
and O
among O
women O
on O
combined B
oral I
contraceptives I
( O
COCs B
) O
. O

COC B
use O
was O
ascertained O
through O
mailed O
questionnaires O
. O

Sales O
statistics O
of O
COCs B
and O
CPA O
/ O
EE O
were O
provided O
through O
Danish O
Drug O
Statistics O
. O

RESULTS O
: O
During O
the O
time O
frame O
of O
the O
study O
, O
330 O
women O
were O
found O
to O
have O
had O
VTE O
while O
on O
COCs B
. O

Of O
these O
women O
, O
67 O
were O
on O
levonorgestrel O
- O
containing O
COCs B
. O

The O
corresponding O
absolute O
risk O
of O
VTE O
was O
3 O
. O
4 O
( O
range O
, O
3 O
. O
1 O
- O
3 O
. O
8 O
) O
per O
10 O
000 O
women O
years O
among O
the O
women O
on O
COCs B
, O
4 O
. O
2 O
( O
range O
, O
3 O
. O
2 O
- O
5 O
. O
2 O
) O
per O
10 O
000 O
women O
years O
among O
women O
on O
levonorgestrel O
- O
containing O
COCs B
, O
and O
3 O
. O
1 O
( O
range O
, O
1 O
. O
3 O
- O
4 O
. O
9 O
) O
per O
10 O
000 O
women O
years O
among O
the O
women O
on O
CPA O
/ O
EE O
. O

CONCLUSION O
: O
Our O
results O
suggest O
the O
absolute O
risk O
of O
VTE O
among O
Danish O
women O
on O
COCs B
is O
similar O
to O
that O
among O
women O
taking O
CPA O
/ O
EE O
. O

Significant O
obsessive O
- O
compulsive O
behavior O
ensued O
but O
diminished O
over O
several O
weeks O
when O
methylphenidate O
was O
replaced O
by O
fluvoxamine B
. O

The O
pressor O
responses O
and O
bradycardia O
to O
the O
alpha O
1 O
- O
agonist O
cirazoline B
( O
0 O
. O
6 O
and O
2 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
, O
the O
alpha O
2 O
- O
agonist O
Abbott B
- I
53693 I
( O
1 O
and O
3 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
, O
and O
noradrenaline O
( O
0 O
. O
1 O
and O
1 O
. O
0 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
were O
determined O
in O
conscious O
SHR O
with O
and O
without O
chronic O
prazosin O
pretreatment O
. O

Both O
the O
pressor O
and O
bradycardia O
effects O
of O
cirazoline B
were O
abolished O
in O
chronic O
prazosin O
treated O
SHR O
( O
n O
= O
4 O
) O
as O
compared O
to O
the O
untreated O
SHR O
( O
n O
= O
4 O
) O
. O

On O
the O
other O
hand O
, O
the O
pressor O
effects O
of O
Abbott B
- I
53693 I
were O
similar O
in O
both O
groups O
of O
SHR O
, O
but O
the O
accompanying O
bradycardia O
was O
greater O
in O
SHR O
with O
chronic O
prazosin O
treatment O
than O
without O
such O
treatment O
. O

Cefotetan B
- O
induced O
immune O
hemolytic O
anemia O
. O

We O
describe O
a O
patient O
who O
developed O
anemia O
while O
receiving O
intravenous O
cefotetan B
. O

Cefotetan B
- O
dependent O
antibodies O
were O
detected O
in O
the O
patient O
' O
s O
serum O
and O
in O
an O
eluate O
prepared O
from O
his O
red O
blood O
cells O
. O

The O
eluate O
also O
reacted O
weakly O
with O
red O
blood O
cells O
in O
the O
absence O
of O
cefotetan B
, O
suggesting O
the O
concomitant O
formation O
of O
warm O
- O
reactive O
autoantibodies O
. O

All B
- I
trans I
- I
retinoic I
acid I
- O
induced O
erythema O
nodosum O
in O
patients O
with O
acute O
promyelocytic O
leukemia O
. O

Erythema O
nodosum O
associated O
with O
all B
- I
trans I
- I
retinoic I
acid I
( O
ATRA B
) O
for O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
very O
rare O
. O

We O
describe O
four O
patients O
with O
classic O
APL O
who O
developed O
erythema O
nodosum O
during O
ATRA B
therapy O
. O

Fever O
and O
subsequent O
multiple O
painful O
erythematous O
nodules O
over O
extremities O
developed O
on O
D11 O
, O
D16 O
, O
D17 O
, O
and O
D19 O
, O
respectively O
, O
after O
ATRA B
therapy O
. O

All O
patients O
achieved O
complete O
remission O
without O
withdrawal O
of O
ATRA B
. O

ATRA B
seemed O
to O
be O
the O
most O
possible O
etiology O
of O
erythema O
nodosum O
in O
our O
patients O
. O

Short O
- O
term O
use O
of O
steroid O
is O
very O
effective O
in O
ATRA B
- O
induced O
erythema O
nodosum O
. O

Effect O
of O
some O
convulsants O
on O
the O
protective O
activity O
of O
loreclezole B
and O
its O
combinations O
with O
valproate O
or O
clonazepam B
in O
amygdala O
- O
kindled O
rats O
. O

Loreclezole B
( O
5 O
mg O
/ O
kg O
) O
exerted O
a O
significant O
protective O
action O
in O
amygdala O
- O
kindled O
rats O
, O
reducing O
both O
seizure O
and O
afterdischarge O
durations O
. O

The O
combinations O
of O
loreclezole B
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
with O
valproate O
, O
clonazepam B
, O
or O
carbamazepine O
( O
applied O
at O
their O
subprotective O
doses O
) O
also O
exhibited O
antiseizure O
effect O
in O
this O
test O
. O

Among O
several O
chemoconvulsants O
, O
bicuculline O
, O
N O
- O
methyl O
- O
D O
- O
aspartic O
acid O
and O
BAY B
k I
- I
8644 I
( O
the O
opener O
of O
L O
- O
type O
calcium O
channels O
) O
reversed O
the O
protective O
activity O
of O
loreclezole B
alone O
and O
its O
combination O
with O
valproate O
. O

On O
the O
other O
hand O
, O
bicuculline O
, O
aminophylline O
and O
BAY B
k I
- I
8644 I
inhibited O
the O
anticonvulsive O
action O
of O
loreclezole B
combined O
with O
clonazepam B
. O

The O
results O
support O
the O
hypothesis O
that O
the O
protective O
activity O
of O
loreclezole B
and O
its O
combinations O
with O
other O
antiepileptics O
may O
involve O
potentiation O
of O
GABAergic O
neurotransmission O
and O
blockade O
of O
L O
- O
type O
of O
calcium O
channels O
. O

Patients O
participating O
in O
a O
randomised O
trial O
of O
anastrozole B
, O
tamoxifen O
alone O
or O
combined O
( O
ATAC O
) O
( O
n O
= O
94 O
) O
and O
a O
group O
of O
women O
without O
breast O
cancer O
( O
n O
= O
35 O
) O
completed O
a O
battery O
of O
neuropsychological O
measures O
. O

Methimazole B
- O
induced O
cholestatic O
jaundice O
. O

Methimazole B
is O
a O
widely O
used O
and O
generally O
well O
- O
tolerated O
antithyroid O
agent O
. O

A O
43 O
- O
year O
- O
old O
woman O
had O
severe O
jaundice O
and O
itching O
1 O
month O
after O
receiving O
methimazole B
( O
10 O
mg O
tid O
) O
and O
propranolol O
( O
20 O
mg O
tid O
) O
for O
treatment O
of O
hyperthyroidism O
. O

Methimazole B
- O
induced O
cholestasis O
was O
diagnosed O
, O
and O
propranolol O
therapy O
was O
resumed O
. O

Over O
the O
following O
9 O
days O
, O
the O
symptoms O
improved O
and O
plasma O
bilirubin O
levels O
were O
normal O
after O
12 O
weeks O
without O
methimazole B
. O

Physicians O
and O
patients O
should O
be O
aware O
of O
this O
adverse O
effect O
so O
that O
, O
upon O
occurrence O
, O
they O
can O
discontinue O
methimazole B
therapy O
and O
avoid O
unnecessary O
invasive O
procedures O
. O

In O
contrast O
, O
the O
protein O
abundances O
of O
Na O
( O
+ O
) O
/ O
H O
( O
+ O
) O
exchanger O
type O
3 O
( O
NHE3 O
) O
, O
Na O
( O
+ O
) O
- O
K O
( O
+ O
) O
- O
2Cl B
( O
- O
) O
cotransporter O
( O
BSC O
- O
1 O
) O
, O
and O
thiazide O
- O
sensitive O
Na O
( O
+ O
) O
- O
Cl B
( O
- O
) O
cotransporter O
( O
TSC O
) O
were O
decreased O
. O

Effects O
of O
the O
cyclooxygenase O
- O
2 O
specific O
inhibitor O
valdecoxib B
versus O
nonsteroidal O
antiinflammatory O
agents O
and O
placebo O
on O
cardiovascular O
thrombotic O
events O
in O
patients O
with O
arthritis O
. O

We O
evaluated O
cardiovascular O
event O
data O
for O
valdecoxib B
, O
a O
new O
COX O
- O
2 O
- O
specific O
inhibitor O
in O
approximately O
8000 O
patients O
with O
osteoarthritis O
and O
rheumatoid O
arthritis O
treated O
with O
this O
agent O
in O
randomized O
clinical O
trials O
. O

The O
incidence O
of O
cardiovascular O
thrombotic O
events O
( O
cardiac O
, O
cerebrovascular O
and O
peripheral O
vascular O
, O
or O
arterial O
thrombotic O
) O
was O
determined O
by O
analyzing O
pooled O
valdecoxib B
( O
10 O
- O
80 O
mg O
daily O
) O
, O
nonselective O
NSAID O
( O
diclofenac O
75 O
mg O
bid O
, O
ibuprofen O
800 O
mg O
tid O
, O
or O
naproxen B
500 O
mg O
bid O
) O
and O
placebo O
data O
from O
10 O
randomized O
osteoarthritis O
and O
rheumatoid O
arthritis O
trials O
that O
were O
6 O
- O
52 O
weeks O
in O
duration O
. O

Crude O
and O
exposure O
- O
adjusted O
incidences O
of O
thrombotic O
events O
were O
similar O
for O
valdecoxib B
, O
NSAIDs O
, O
and O
placebo O
. O

The O
risk O
of O
serious O
thrombotic O
events O
was O
also O
similar O
for O
each O
valdecoxib B
dose O
. O

Thrombotic O
risk O
was O
consistently O
higher O
for O
users O
of O
aspirin O
users O
than O
nonusers O
of O
aspirin O
( O
placebo O
, O
1 O
. O
4 O
% O
vs O
. O
0 O
% O
; O
valdecoxib B
, O
1 O
. O
7 O
% O
vs O
. O
0 O
. O
2 O
% O
; O
NSAIDs O
, O
1 O
. O
9 O
% O
vs O
. O
0 O
. O
5 O
% O
) O
. O

The O
rates O
of O
events O
in O
users O
of O
aspirin O
were O
similar O
for O
all O
3 O
treatment O
groups O
and O
across O
valdecoxib B
doses O
. O

Short O
- O
and O
intermediate O
- O
term O
treatment O
with O
therapeutic O
( O
10 O
or O
20 O
mg O
daily O
) O
and O
supratherapeutic O
( O
40 O
or O
80 O
mg O
daily O
) O
valdecoxib B
doses O
was O
not O
associated O
with O
an O
increased O
incidence O
of O
thrombotic O
events O
relative O
to O
nonselective O
NSAIDs O
or O
placebo O
in O
osteoarthritis O
and O
rheumatoid O
arthritis O
patients O
in O
controlled O
clinical O
trials O
. O

Does O
supplemental O
vitamin B
C I
increase O
cardiovascular O
disease O
risk O
in O
women O
with O
diabetes O
? O

BACKGROUND O
: O
Vitamin B
C I
acts O
as O
a O
potent O
antioxidant O
; O
however O
, O
it O
can O
also O
be O
a O
prooxidant O
and O
glycate O
protein O
under O
certain O
circumstances O
in O
vitro O
. O

These O
observations O
led O
us O
to O
hypothesize O
that O
a O
high O
intake O
of O
vitamin B
C I
in O
diabetic O
persons O
might O
promote O
atherosclerosis O
. O

OBJECTIVE O
: O
The O
objective O
was O
to O
examine O
the O
relation O
between O
vitamin B
C I
intake O
and O
mortality O
from O
cardiovascular O
disease O
. O

DESIGN O
: O
We O
studied O
the O
relation O
between O
vitamin B
C I
intake O
and O
mortality O
from O
total O
cardiovascular O
disease O
( O
n O
= O
281 O
) O
, O
coronary O
artery O
disease O
( O
n O
= O
175 O
) O
, O
and O
stroke O
( O
n O
= O
57 O
) O
in O
1923 O
postmenopausal O
women O
who O
reported O
being O
diabetic O
at O
baseline O
. O

RESULTS O
: O
After O
adjustment O
for O
cardiovascular O
disease O
risk O
factors O
, O
type O
of O
diabetes O
medication O
used O
, O
duration O
of O
diabetes O
, O
and O
intakes O
of O
folate O
, O
vitamin O
E O
, O
and O
beta B
- I
carotene I
, O
the O
adjusted O
relative O
risks O
of O
total O
cardiovascular O
disease O
mortality O
were O
1 O
. O
0 O
, O
0 O
. O
97 O
, O
1 O
. O
11 O
, O
1 O
. O
47 O
, O
and O
1 O
. O
84 O
( O
P O
for O
trend O
< O
0 O
. O
01 O
) O
across O
quintiles O
of O
total O
vitamin B
C I
intake O
from O
food O
and O
supplements O
. O

When O
dietary O
and O
supplemental O
vitamin B
C I
were O
analyzed O
separately O
, O
only O
supplemental O
vitamin B
C I
showed O
a O
positive O
association O
with O
mortality O
endpoints O
. O

Vitamin B
C I
intake O
was O
unrelated O
to O
mortality O
from O
cardiovascular O
disease O
in O
the O
nondiabetic O
subjects O
at O
baseline O
. O

CONCLUSION O
: O
A O
high O
vitamin B
C I
intake O
from O
supplements O
is O
associated O
with O
an O
increased O
risk O
of O
cardiovascular O
disease O
mortality O
in O
postmenopausal O
women O
with O
diabetes O
. O

Optical O
coherence O
tomography O
can O
measure O
axonal O
loss O
in O
patients O
with O
ethambutol B
- O
induced O
optic O
neuropathy O
. O

PURPOSE O
: O
To O
map O
and O
identify O
the O
pattern O
, O
in O
vivo O
, O
of O
axonal O
degeneration O
in O
ethambutol B
- O
induced O
optic O
neuropathy O
using O
optical O
coherence O
tomography O
( O
OCT O
) O
. O

Ethambutol B
is O
an O
antimycobacterial O
agent O
often O
used O
to O
treat O
tuberculosis O
. O

A O
serious O
complication O
of O
ethambutol B
is O
an O
optic O
neuropathy O
that O
impairs O
visual O
acuity O
, O
contrast O
sensitivity O
, O
and O
color O
vision O
. O

METHODS O
: O
Three O
subjects O
with O
a O
history O
of O
ethambutol B
( O
EMB B
) O
- O
induced O
optic O
neuropathy O
of O
short O
- O
, O
intermediate O
- O
, O
and O
long O
- O
term O
visual O
deficits O
were O
administered O
a O
full O
neuro O
- O
ophthalmologic O
examination O
including O
visual O
acuity O
, O
color O
vision O
, O
contrast O
sensitivity O
, O
and O
fundus O
examination O
. O

In O
all O
subjects O
with O
history O
of O
EMB B
- O
induced O
optic O
neuropathy O
, O
there O
was O
a O
mean O
loss O
of O
72 O
% O
nerve O
fiber O
layer O
thickness O
in O
the O
temporal O
quadrant O
( O
patient O
A O
, O
with O
eventual O
recovery O
of O
visual O
acuity O
and O
fields O
, O
58 O
% O
loss O
; O
patient O
B O
, O
with O
intermediate O
visual O
deficits O
, O
68 O
% O
loss O
; O
patient O
C O
, O
with O
chronic O
visual O
deficits O
, O
90 O
% O
loss O
) O
, O
with O
an O
average O
mean O
optic O
nerve O
thickness O
of O
26 O
+ O
/ O
- O
16 O
microm O
. O

CONCLUSIONS O
: O
The O
OCT O
results O
in O
these O
patients O
with O
EMB B
- O
induced O
optic O
neuropathy O
show O
considerable O
loss O
especially O
of O
the O
temporal O
fibers O
. O

Additionally O
, O
in O
terms O
of O
management O
of O
EMB B
- O
induced O
optic O
neuropathy O
, O
it O
is O
important O
to O
properly O
manage O
ethambutol B
dosing O
in O
patients O
with O
renal O
impairment O
and O
to O
achieve O
proper O
transition O
to O
a O
maintenance O
dose O
once O
an O
appropriate O
loading O
dose O
has O
been O
reached O
. O

Adequate O
timing O
of O
ribavirin O
reduction O
in O
patients O
with O
hemolysis O
during O
combination O
therapy O
of O
interferon B
and O
ribavirin O
for O
chronic O
hepatitis O
C O
. O

BACKGROUND O
: O
Hemolytic O
anemia O
is O
one O
of O
the O
major O
adverse O
events O
of O
the O
combination O
therapy O
of O
interferon B
and O
ribavirin O
. O

Serum O
concentrations O
of O
prolactin O
( O
PRL B
) O
and O
testosterone O
( O
T O
) O
were O
measured O
. O

In O
rats O
of O
the O
experimental O
group O
, O
the O
mean O
concentration O
of O
: O
PRL B
was O
more O
than O
twice O
higher O
, O
whereas O
T O
concentration O
was O
almost O
twice O
lower O
than O
that O
in O
the O
control O
group O
. O

Pheochromocytoma O
unmasked O
by O
amisulpride B
and O
tiapride B
. O

OBJECTIVE O
: O
To O
describe O
the O
unmasking O
of O
pheochromocytoma O
in O
a O
patient O
treated O
with O
amisulpride B
and O
tiapride B
. O

CASE O
SUMMARY O
: O
A O
42 O
- O
year O
- O
old O
white O
man O
developed O
acute O
hypertension O
with O
severe O
headache O
and O
vomiting O
2 O
hours O
after O
the O
first O
doses O
of O
amisulpride B
100 O
mg O
and O
tiapride B
100 O
mg O
. O

Both O
drugs O
were O
immediately O
discontinued O
, O
and O
the O
patient O
recovered O
after O
subsequent O
nicardipine B
and O
verapamil O
treatment O
. O

DISCUSSION O
: O
Drug O
- O
induced O
symptoms O
of O
pheochromocytoma O
are O
often O
associated O
with O
the O
use O
of O
substituted O
benzamide B
drugs O
, O
but O
the O
underlying O
mechanism O
is O
unknown O
. O

In O
our O
case O
, O
use O
of O
the O
Naranjo O
probability O
scale O
indicated O
a O
possible O
relationship O
between O
the O
hypertensive O
crisis O
and O
amisulpride B
and O
tiapride B
therapy O
. O

CONCLUSIONS O
: O
As O
of O
March O
24 O
, O
2005 O
, O
this O
is O
the O
first O
reported O
case O
of O
amisulpride B
- O
and O
tiapride B
- O
induced O
hypertensive O
crisis O
in O
a O
patient O
with O
pheochromocytoma O
. O

Physicians O
and O
other O
healthcare O
professionals O
should O
be O
aware O
of O
this O
potential O
adverse O
effect O
of O
tiapride B
and O
amisulpride B
. O

A O
single O
dose O
of O
valproic O
acid O
( O
VPA O
) O
, O
which O
is O
a O
widely O
used O
antiepileptic O
drug O
, O
is O
associated O
with O
oxidative O
stress O
in O
rats O
, O
as O
recently O
demonstrated O
by O
elevated O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
isoprostane I
( O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
) O
. O

Oxidative O
stress O
was O
assessed O
by O
determining O
plasma O
and O
liver O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
, O
lipid B
hydroperoxides I
( O
LPO B
) O
, O
and O
thiobarbituric B
acid I
reactive I
substances I
( O
TBARs B
) O
. O

Plasma O
and O
liver O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
were O
elevated O
and O
reached O
a O
plateau O
after O
day O
2 O
of O
VPA O
treatment O
compared O
to O
control O
. O

Liver O
LPO B
levels O
were O
not O
elevated O
until O
day O
7 O
of O
treatment O
( O
1 O
. O
8 O
- O
fold O
versus O
control O
, O
p O
< O
0 O
. O
05 O
) O
. O

Liver O
and O
plasma O
TBARs B
were O
not O
increased O
until O
14 O
days O
( O
2 O
- O
fold O
vs O
. O
control O
, O
p O
< O
0 O
. O
05 O
) O
. O

The O
liver O
levels O
of O
beta O
- O
oxidation O
metabolites O
of O
VPA O
were O
decreased O
by O
day O
14 O
, O
while O
the O
levels O
of O
4 B
- I
ene I
- I
VPA I
and O
( O
E O
) O
- O
2 B
, I
4 I
- I
diene I
- I
VPA I
were O
not O
elevated O
throughout O
the O
study O
. O

Overall O
, O
these O
findings O
indicate O
that O
VPA O
treatment O
results O
in O
oxidative O
stress O
, O
as O
measured O
by O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
, O
which O
precedes O
the O
onset O
of O
necrosis O
, O
steatosis O
, O
and O
elevated O
levels O
of O
serum O
alpha O
- O
GST O
. O

Dexrazoxane B
protects O
against O
myelosuppression O
from O
the O
DNA O
cleavage O
- O
enhancing O
drugs O
etoposide O
and O
daunorubicin O
but O
not O
doxorubicin O
. O

PURPOSE O
: O
The O
anthracyclines O
daunorubicin O
and O
doxorubicin O
and O
the O
epipodophyllotoxin B
etoposide O
are O
potent O
DNA O
cleavage O
- O
enhancing O
drugs O
that O
are O
widely O
used O
in O
clinical O
oncology O
; O
however O
, O
myelosuppression O
and O
cardiac O
toxicity O
limit O
their O
use O
. O

Dexrazoxane B
( O
ICRF B
- I
187 I
) O
is O
recommended O
for O
protection O
against O
anthracycline O
- O
induced O
cardiotoxicity O
. O

EXPERIMENTAL O
DESIGN O
: O
Because O
of O
their O
widespread O
use O
, O
the O
hematologic O
toxicity O
following O
coadministration O
of O
dexrazoxane B
and O
these O
three O
structurally O
different O
DNA O
cleavage O
enhancers O
was O
investigated O
: O
Sensitivity O
of O
human O
and O
murine O
blood O
progenitor O
cells O
to O
etoposide O
, O
daunorubicin O
, O
and O
doxorubicin O
+ O
/ O
- O
dexrazoxane B
was O
determined O
in O
granulocyte O
- O
macrophage O
colony O
forming O
assays O
. O

Likewise O
, O
in O
vivo O
, O
B6D2F1 O
mice O
were O
treated O
with O
etoposide O
, O
daunorubicin O
, O
and O
doxorubicin O
, O
with O
or O
without O
dexrazoxane B
over O
a O
wide O
range O
of O
doses O
: O
posttreatment O
, O
a O
full O
hematologic O
evaluation O
was O
done O
. O

RESULTS O
: O
Nontoxic O
doses O
of O
dexrazoxane B
reduced O
myelosuppression O
and O
weight O
loss O
from O
daunorubicin O
and O
etoposide O
in O
mice O
and O
antagonized O
their O
antiproliferative O
effects O
in O
the O
colony O
assay O
; O
however O
, O
dexrazoxane B
neither O
reduced O
myelosuppression O
, O
weight O
loss O
, O
nor O
the O
in O
vitro O
cytotoxicity O
from O
doxorubicin O
. O

CONCLUSION O
: O
Although O
our O
findings O
support O
the O
observation O
that O
dexrazoxane B
reduces O
neither O
hematologic O
activity O
nor O
antitumor O
activity O
from O
doxorubicin O
clinically O
, O
the O
potent O
antagonism O
of O
daunorubicin O
activity O
raises O
concern O
; O
a O
possible O
interference O
with O
anticancer O
efficacy O
certainly O
would O
call O
for O
renewed O
attention O
. O

Our O
data O
also O
suggest O
that O
significant O
etoposide O
dose O
escalation O
is O
perhaps O
possible O
by O
the O
use O
of O
dexrazoxane B
. O

Clinical O
trials O
in O
patients O
with O
brain O
metastases O
combining O
dexrazoxane B
and O
high O
doses O
of O
etoposide O
is O
ongoing O
with O
the O
aim O
of O
improving O
efficacy O
without O
aggravating O
hematologic O
toxicity O
. O

Their O
ester O
prodrugs O
6 O
and O
8 O
were O
orally O
active O
in O
three O
models O
of O
pain O
: O
reversal O
of O
formalin B
- O
induced O
paw O
licking O
, O
carrageenan B
- O
induced O
thermal O
hyperalgesia O
, O
and O
capsaicin O
- O
induced O
mechanical O
hyperalgesia O
. O

Discontinuation O
of O
azithromycin O
and O
therapy O
with O
baclofen B
finally O
resolved O
hiccups O
. O

Few O
cases O
of O
drug O
- O
induced O
hiccups O
have O
been O
reported O
related O
to O
macrolide B
antimicrobials O
. O

Using O
the O
Naranjo O
adverse O
effect O
reaction O
probability O
scale O
this O
event O
could O
be O
classified O
as O
possible O
( O
score O
5 O
points O
) O
, O
mostly O
because O
of O
the O
close O
temporal O
sequence O
, O
previous O
reports O
on O
this O
reaction O
with O
other O
macrolides B
and O
the O
absence O
of O
any O
alternative O
explanation O
for O
hiccups O
. O

However O
, O
macrolide B
antimicrobials O
have O
been O
reported O
to O
be O
associated O
with O
hiccups O
and O
vagal O
mechanism O
could O
explain O
the O
development O
of O
this O
side O
- O
effect O
. O

Calcium B
carbonate I
toxicity O
: O
the O
updated O
milk O
- O
alkali O
syndrome O
; O
report O
of O
3 O
cases O
and O
review O
of O
the O
literature O
. O

OBJECTIVE O
: O
To O
describe O
3 O
patients O
with O
calcium B
carbonate I
- O
induced O
hypercalcemia O
and O
gain O
insights O
into O
the O
cause O
and O
management O
of O
the O
milk O
- O
alkali O
syndrome O
. O

RESULTS O
: O
The O
3 O
patients O
had O
acute O
renal O
insufficiency O
, O
relative O
metabolic O
alkalosis O
, O
and O
low O
parathyroid O
hormone O
( O
PTH O
) O
, O
PTH O
- O
related O
peptide O
, O
and O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
concentrations O
. O

The O
2 O
patients O
with O
the O
higher O
serum O
calcium O
concentrations O
received O
pamidronate B
intravenously O
( O
60 O
and O
30 O
mg O
, O
respectively O
) O
, O
which O
caused O
severe O
hypocalcemia O
. O

Of O
the O
3 O
patients O
, O
2 O
were O
ingesting O
acceptable O
doses O
of O
elemental O
calcium O
( O
1 O
g O
and O
2 O
g O
daily O
, O
respectively O
) O
in O
the O
form O
of O
calcium B
carbonate I
. O

CONCLUSION O
: O
Milk O
- O
alkali O
syndrome O
may O
be O
a O
common O
cause O
of O
unexplained O
hypercalcemia O
and O
can O
be O
precipitated O
by O
small O
amounts O
of O
orally O
ingested O
calcium B
carbonate I
in O
susceptible O
persons O
. O

Pamidronate B
treatment O
is O
associated O
with O
considerable O
risk O
for O
hypocalcemia O
, O
even O
in O
cases O
of O
initially O
severe O
hypercalcemia O
. O

Skin O
reactions O
associated O
with O
oral O
coumarin B
- O
derived O
anticoagulants O
are O
an O
uncommon O
occurrence O
. O

Amisulpride B
related O
tic O
- O
like O
symptoms O
in O
an O
adolescent O
schizophrenic O
. O

Tic O
disorders O
can O
be O
effectively O
treated O
by O
atypical O
antipsychotics O
such O
as O
risperidone O
, O
olanzapine O
and O
ziprasidone B
. O

However O
, O
there O
are O
two O
case O
reports O
that O
show O
tic O
- O
like O
symptoms O
, O
including O
motor O
and O
phonic O
variants O
, O
occurring O
during O
treatment O
with O
quetiapine B
or O
clozapine O
. O

We O
present O
a O
15 O
- O
year O
- O
old O
girl O
schizophrenic O
who O
developed O
frequent O
involuntary O
eye O
- O
blinking O
movements O
after O
5 O
months O
of O
amisulpride B
treatment O
( O
1000 O
mg O
per O
day O
) O
. O

The O
tic O
- O
like O
symptoms O
resolved O
completely O
after O
we O
reduced O
the O
dose O
of O
amisulpride B
down O
to O
800 O
mg O
per O
day O
. O

We O
then O
placed O
her O
on O
an O
additional O
100 O
mg O
per O
day O
of O
quetiapine B
. O

Together O
with O
previously O
reported O
cases O
, O
our O
patient O
suggests O
that O
tic O
- O
like O
symptoms O
might O
occur O
in O
certain O
vulnerable O
individuals O
during O
treatment O
with O
atypical O
antipsychotics O
such O
as O
quetiapine B
, O
clozapine O
, O
or O
amisulpride B
. O

Effects O
of O
suprofen B
on O
the O
isolated O
perfused O
rat O
kidney O
. O

Although O
suprofen B
has O
been O
associated O
with O
the O
development O
of O
acute O
renal O
failure O
in O
greater O
than O
100 O
subjects O
, O
the O
mechanism O
of O
damage O
remains O
unclear O
. O

The O
direct O
nephrotoxic O
effects O
of O
a O
single O
dose O
of O
15 O
mg O
of O
suprofen B
were O
compared O
in O
the O
recirculating O
isolated O
rat O
kidney O
perfused O
with O
cell O
- O
free O
buffer O
with O
or O
without O
the O
addition O
of O
5 O
mg O
/ O
dL O
of O
uric O
acid O
. O

There O
were O
no O
significant O
differences O
in O
renal O
sodium O
excretion O
, O
oxygen O
consumption O
, O
or O
urinary O
flow O
rates O
in O
kidneys O
perfused O
with O
suprofen B
compared O
with O
the O
drug O
- O
free O
control O
groups O
. O

In O
contrast O
, O
a O
significant O
decline O
in O
glomerular O
filtration O
rate O
was O
found O
after O
the O
introduction O
of O
suprofen B
to O
the O
kidney O
perfused O
with O
uric O
acid O
; O
no O
changes O
were O
found O
with O
suprofen B
in O
the O
absence O
of O
uric O
acid O
. O

A O
significant O
decrease O
in O
the O
baseline O
excretion O
rate O
of O
uric O
acid O
was O
found O
in O
rats O
given O
suprofen B
, O
compared O
with O
drug O
- O
free O
controls O
. O

In O
summary O
, O
suprofen B
causes O
acute O
declines O
in O
renal O
function O
, O
most O
likely O
by O
directly O
altering O
the O
intrarenal O
distribution O
of O
uric O
acid O
. O

Microinjection O
of O
ritanserin B
into O
the O
CA1 O
region O
of O
hippocampus O
improves O
scopolamine O
- O
induced O
amnesia O
in O
adult O
male O
rats O
. O

The O
effect O
of O
ritanserin B
( O
5 O
- O
HT2 O
antagonist O
) O
on O
scopolamine O
( O
muscarinic O
cholinergic O
antagonist O
) O
- O
induced O
amnesia O
in O
Morris O
water O
maze O
( O
MWM O
) O
was O
investigated O
. O

One O
week O
later O
, O
they O
received O
repeatedly O
vehicles O
( O
saline O
, O
DMSO B
, O
saline O
+ O
DMSO B
) O
, O
scopolamine O
( O
2 O
microg O
/ O
0 O
. O
5 O
microl O
saline O
/ O
side O
; O
30 O
min O
before O
training O
) O
, O
ritanserin B
( O
2 O
, O
4 O
and O
8 O
microg O
/ O
0 O
. O
5 O
microl O
DMSO B
/ O
side O
; O
20 O
min O
before O
training O
) O
and O
scopolamine O
( O
2 O
microg O
/ O
0 O
. O
5 O
microl O
; O
30 O
min O
before O
ritanserin B
injection O
) O
+ O
ritanserin B
( O
4 O
microg O
/ O
0 O
. O
5 O
microl O
DMSO B
) O
through O

Ritanserin B
- O
treated O
rats O
( O
4 O
microg O
/ O
0 O
. O
5 O
microl O
/ O
side O
) O
showed O
a O
significant O
decrease O
in O
the O
mentioned O
parameters O
as O
compared O
to O
DMSO B
- O
treated O
group O
. O

However O
, O
scopolamine O
and O
ritanserin B
co O
- O
administration O
resulted O
in O
a O
significant O
decrease O
in O
escape O
latencies O
and O
traveled O
distances O
as O
compared O
to O
the O
scopolamine O
- O
treated O
rats O
. O

Our O
findings O
show O
that O
microinjection O
of O
ritanserin B
into O
the O
CA1 O
region O
of O
the O
hippocampus O
improves O
the O
scopolamine O
- O
induced O
amnesia O
. O

Daidzein B
activates O
choline O
acetyltransferase O
from O
MC O
- O
IXC O
cells O
and O
improves O
drug O
- O
induced O
amnesia O
. O

Via O
the O
sequential O
isolation O
of O
Pueraria O
thunbergiana O
, O
the O
active O
component O
was O
ultimately O
identified O
as O
daidzein B
( O
4 B
' I
, I
7 I
- I
dihydroxy I
- I
isoflavone I
) O
. O

In O
order O
to O
investigate O
the O
effects O
of O
daidzein B
from O
Pueraria O
thunbergiana O
on O
scopolamine O
- O
induced O
impairments O
of O
learning O
and O
memory O
, O
we O
conducted O
a O
series O
of O
in O
vivo O
tests O
. O

Administration O
of O
daidzein B
( O
4 O
. O
5 O
mg O
/ O
kg O
body O
weight O
) O
to O
mice O
was O
shown O
significantly O
to O
reverse O
scopolamine O
- O
induced O
amnesia O
, O
according O
to O
the O
results O
of O
a O
Y O
- O
maze O
test O
. O

By O
way O
of O
contrast O
, O
mice O
treated O
with O
daidzein B
prior O
to O
the O
scopolamine O
injections O
were O
noticeably O
protected O
from O
this O
performance O
impairment O
( O
an O
approximately O
12 O
% O
- O
21 O
% O
decrease O
in O
alternation O
behavior O
) O
. O

These O
results O
indicate O
that O
daidzein B
might O
play O
a O
role O
in O
acetylcholine O
biosynthesis O
as O
a O
ChAT O
activator O
, O
and O
that O
it O
also O
ameliorates O
scopolamine O
- O
induced O
amnesia O
. O

Urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
Thai O
women O
with O
overactive O
bladder O
after O
tolterodine B
treatment O
. O

OBJECTIVES O
: O
To O
study O
the O
urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
Thai O
women O
with O
overactive O
bladder O
( O
OAB O
) O
after O
tolterodine B
treatment O
. O

Tolterodine B
2 O
mg O
, O
twice O
daily O
was O
given O
. O

CONCLUSION O
: O
Tolterodine B
was O
well O
tolerated O
and O
its O
effects O
improved O
the O
quality O
of O
life O
in O
Thai O
women O
with O
OAB O
. O

Remifentanil B
pretreatment O
reduces O
myoclonus O
after O
etomidate B
. O

STUDY O
OBJECTIVE O
: O
The O
aim O
of O
the O
study O
was O
to O
compare O
the O
effect O
of O
pretreatment O
with O
remifentanil B
1 O
microg O
/ O
kg O
and O
the O
effect O
of O
gender O
on O
the O
incidence O
of O
myoclonus O
after O
anesthesia O
induction O
with O
etomidate B
. O

PATIENTS O
: O
Sixty O
patients O
were O
pretreated O
in O
a O
randomized O
double O
- O
blinded O
fashion O
with O
remifentanil B
1 O
microg O
/ O
kg O
or O
placebo O
. O

Two O
minutes O
after O
remifentanil B
or O
placebo O
injection O
, O
etomidate B
0 O
. O
3 O
mg O
/ O
kg O
was O
given O
. O

MAIN O
RESULTS O
: O
The O
incidence O
of O
myoclonus O
was O
significantly O
lower O
in O
the O
remifentanil B
group O
( O
6 O
. O
7 O
% O
) O
than O
in O
the O
placebo O
group O
( O
70 O
% O
) O
( O
P O
< O
0 O
. O
001 O
) O
. O

In O
the O
placebo O
group O
, O
male O
patients O
were O
associated O
with O
significantly O
increased O
incidence O
of O
myoclonus O
after O
etomidate B
administration O
. O

CONCLUSION O
: O
Pretreatment O
with O
remifentanil B
1 O
microg O
/ O
kg O
reduced O
myoclonus O
after O
etomidate B
induction O
without O
side O
effects O
such O
as O
sedation O
, O
apnea O
, O
nausea O
, O
or O
pruritus O
. O

Men O
experience O
increased O
incidence O
of O
myoclonus O
than O
women O
after O
etomidate B
administration O
. O

Role O
of O
mangiferin B
on O
biochemical O
alterations O
and O
antioxidant O
status O
in O
isoproterenol O
- O
induced O
myocardial O
infarction O
in O
rats O
. O

The O
current O
study O
dealt O
with O
the O
protective O
role O
of O
mangiferin B
, O
a O
polyphenol B
from O
Mangifera O
indica O
Linn O
. O

The O
protective O
role O
of O
mangiferin B
was O
analyzed O
by O
triphenyl B
tetrazolium I
chloride I
( O
TTC B
) O
test O
used O
for O
macroscopic O
enzyme O
mapping O
assay O
of O
the O
ischemic O
myocardium O
. O

The O
heart O
tissue O
antioxidant O
enzymes O
such O
as O
superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
, O
glutathione O
transferase O
and O
glutathione O
reductase O
activities O
, O
non O
- O
enzymic O
antioxidants O
such O
as O
cerruloplasmin O
, O
Vitamin B
C I
, O
Vitamin O
E O
and O
glutathione O
levels O
were O
altered O
in O
MI O
rats O
. O

Upon O
pretreatment O
with O
mangiferin B
( O
100 O
mg O
/ O
kg O
body O
weight O
suspended O
in O
2 O
ml O
of O
dimethyl B
sulphoxide I
) O
given O
intraperitoneally O
for O
28 O
days O
to O
MI O
rats O
protected O
the O
above O
- O
mentioned O
parameters O
to O
fall O
from O
the O
normal O
levels O
. O

Activities O
of O
heart O
tissue O
enzymic O
antioxidants O
and O
serum O
non O
- O
enzymic O
antioxidants O
levels O
rose O
significantly O
upon O
mangiferin B
administration O
as O
compared O
to O
ISPH O
- O
induced O
MI O
rats O
. O

From O
the O
present O
study O
it O
is O
concluded O
that O
mangiferin B
exerts O
a O
beneficial O
effect O
against O
ISPH O
- O
induced O
MI O
due O
to O
its O
antioxidant O
potential O
, O
which O
regulated O
the O
tissues O
defense O
system O
against O
cardiac O
damage O
. O

Cardiovascular O
risk O
with O
cyclooxygenase B
inhibitors I
: O
general O
problem O
with O
substance O
specific O
differences O
? O

Randomised O
clinical O
trials O
and O
observational O
studies O
have O
shown O
an O
increased O
risk O
of O
myocardial O
infarction O
, O
stroke O
, O
hypertension O
and O
heart O
failure O
during O
treatment O
with O
cyclooxygenase B
inhibitors I
. O

Cyclooxygenase B
inhibitors I
cause O
complex O
changes O
in O
renal O
, O
vascular O
and O
cardiac O
prostanoid O
profiles O
thereby O
increasing O
vascular O
resistance O
and O
fluid O
retention O
. O

A O
comparison O
of O
individual O
selective O
and O
unselective O
cyclooxygenase B
inhibitors I
suggests O
substance O
- O
specific O
differences O
, O
which O
may O
depend O
on O
differences O
in O
pharmacokinetic O
parameters O
or O
inhibitory O
potency O
and O
may O
be O
contributed O
by O
prostaglandin O
- O
independent O
effects O
. O

Diagnostic O
markers O
such O
as O
N B
- I
terminal I
pro I
brain I
natriuretic I
peptide I
( O
NT B
- I
proBNP I
) O
or O
high O
- O
sensitive O
C O
- O
reactive O
protein O
might O
help O
in O
the O
early O
identification O
of O
patients O
at O
risk O
, O
thus O
avoiding O
the O
occurrence O
of O
serious O
cardiovascular O
toxicity O
. O

NGF O
, O
PGE2 B
, O
PGF2alpha O
and O
PGI2 O
were O
measured O
using O
enzyme O
- O
linked O
immunosorbent O
assay O
and O
compared O
between O
the O
groups O
. O

RESULTS O
: O
Urinary O
NGF O
, O
PGE2 B
and O
PGF2alpha O
were O
significantly O
increased O
in O
patients O
with O
OAB O
compared O
with O
controls O
( O
p O
< O
0 O
. O
05 O
) O
. O

In O
patients O
with O
OAB O
urinary O
PGE2 B
positively O
correlated O
with O
volume O
at O
first O
desire O
to O
void O
and O
maximum O
cystometric O
capacity O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
current O
best O
treatment O
for O
HCV O
infection O
is O
combination O
therapy O
with O
pegylated O
interferon B
and O
ribavirin O
. O

Viramidine B
, O
a O
liver O
- O
targeting O
prodrug O
of O
ribavirin O
, O
has O
the O
potential O
to O
maintain O
the O
virologic O
efficacy O
of O
ribavirin O
while O
decreasing O
the O
risk O
of O
hemolytic O
anemia O
in O
patients O
with O
chronic O
hepatitis O
C O
. O

Ethambutol B
- O
associated O
optic O
neuropathy O
. O

INTRODUCTION O
: O
Ethambutol B
is O
used O
in O
the O
treatment O
of O
tuberculosis O
, O
which O
is O
still O
prevalent O
in O
Southeast O
Asia O
, O
and O
can O
be O
associated O
with O
permanent O
visual O
loss O
. O

CLINICAL O
PICTURE O
: O
Three O
patients O
with O
ethambutol B
- O
associated O
toxic O
optic O
neuropathy O
are O
described O
. O

TREATMENT O
: O
Despite O
stopping O
ethambutol B
on O
diagnosis O
, O
visual O
function O
continued O
to O
deteriorate O
for O
a O
few O
months O
. O

CONCLUSIONS O
: O
Ethambutol B
usage O
is O
associated O
with O
permanent O
visual O
loss O
and O
should O
be O
avoided O
if O
possible O
or O
used O
with O
caution O
and O
proper O
ophthalmological O
follow O
- O
up O
. O

The O
author O
postulates O
that O
in O
cases O
of O
ethambutol B
associated O
chiasmopathy O
, O
ethambutol B
may O
initially O
affect O
the O
optic O
nerves O
and O
subsequently O
progress O
to O
involve O
the O
optic O
chiasm O
. O

Co O
- O
administration O
of O
lidocaine O
, O
bupivacaine O
or O
tricaine B
with O
desipramine O
reversed O
this O
effect O
. O

Plasma O
nitrate B
/ O
nitrite B
( O
NOx O
) O
was O
decreased O
in O
dex O
- O
treated O
rats O
compared O
to O
saline O
- O
treated O
rats O
( O
11 O
. O
2 O
+ O
/ O
- O
1 O
. O
08 O
microm O
, O
15 O
. O
3 O
+ O
/ O
- O
1 O
. O
17 O
microm O
, O
respectively O
, O
P O
< O
0 O
. O
05 O
) O
. O

Peripheral O
neuropathy O
caused O
by O
high O
- O
dose O
cytosine B
arabinoside I
treatment O
in O
a O
patient O
with O
acute O
myeloid O
leukemia O
. O

The O
central O
nervous O
system O
toxicity O
of O
high O
- O
dose O
cytosine B
arabinoside I
is O
well O
recognized O
, O
but O
the O
toxicity O
of O
cytosine B
arabinoside I
in O
the O
peripheral O
nervous O
system O
has O
been O
infrequently O
reported O
. O

After O
he O
achieved O
complete O
remission O
, O
he O
received O
high O
- O
dose O
cytosine B
arabinoside I
treatment O
( O
2 O
g O
/ O
m2 O
twice O
a O
day O
for O
5 O
days O
; O
total O
, O
20 O
g O
/ O
m2 O
) O
as O
consolidation O
therapy O
. O

The O
first O
course O
of O
high O
- O
dose O
cytosine B
arabinoside I
resulted O
in O
no O
unusual O
symptoms O
, O
but O
on O
day O
21 O
of O
the O
second O
course O
of O
treatment O
, O
the O
patient O
complained O
of O
numbness O
in O
his O
right O
foot O
. O

Although O
the O
mechanisms O
of O
peripheral O
neuropathy O
are O
still O
unclear O
, O
high O
- O
dose O
cytosine B
arabinoside I
is O
a O
therapy O
that O
is O
potentially O
toxic O
to O
the O
peripheral O
nervous O
system O
, O
and O
auto O
/ O
alloimmunity O
may O
play O
an O
important O
role O
in O
these O
mechanisms O
. O

Moreover O
, O
both O
hepatitis B
B I
surface I
antigen I
and I
e I
antigen I
were O
observed O
to O
have O
disappeared O
in O
this O
patient O
. O

Antiarrhythmic O
effects O
of O
optical O
isomers O
of O
cibenzoline B
on O
canine O
ventricular O
arrhythmias O
. O

Antiarrhythmic O
effects O
of O
( O
+ O
) O
- O
cibenzoline B
and O
( O
- O
) O
- O
cibenzoline B
were O
examined O
using O
two O
canine O
ventricular O
arrhythmia O
models O
. O

Digitalis B
arrhythmia O
, O
which O
is O
suppressed O
by O
Na O
channel O
blockers O
, O
was O
induced O
by O
intermittent O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
ouabain O
in O
pentobarbital O
- O
anesthetized O
dogs O
. O

Ten O
and O
5 O
mg O
/ O
kg O
i O
. O
v O
. O
( O
+ O
) O
- O
cibenzoline B
suppressed O
digitalis B
- O
and O
adrenaline O
- O
induced O
arrhythmias O
, O
respectively O
. O

The O
minimum O
effective O
plasma O
concentrations O
of O
( O
+ O
) O
- O
cibenzoline B
for O
digitalis B
- O
and O
adrenaline O
- O
induced O
arrhythmias O
were O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
4 O
and O
2 O
. O
0 O
+ O
/ O
- O
0 O
. O
6 O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
SD O
, O
n O
= O
6 O
) O
. O

A O
lower O
dose O
of O
1 O
mg O
/ O
kg O
i O
. O
v O
. O
of O
( O
- O
) O
- O
cibenzoline B
suppressed O
the O
digitalis B
- O
induced O
arrhythmia O
, O
whereas O
5 O
mg O
/ O
kg O
i O
. O
v O
. O
was O
needed O
to O
suppress O
adrenaline O
- O
induced O
arrhythmias O
. O

The O
minimum O
effective O
plasma O
concentrations O
of O
( O
- O
) O
- O
cibenzoline B
for O
digitalis B
- O
and O
adrenaline O
- O
induced O
arrhythmia O
were O
0 O
. O
06 O
+ O
/ O
- O
0 O
. O
04 O
and O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
SD O
, O
n O
= O
6 O
) O
. O

The O
stronger O
antiarrhythmic O
effect O
of O
( O
- O
) O
- O
cibenzoline B
indicates O
that O
( O
- O
) O
- O
isomer O
may O
have O
an O
effect O
nearly O
5 O
- O
20 O
times O
stronger O
in O
suppressing O
Na O
channels O
, O
but O
effects O
of O
both O
drugs O
on O
Ca O
channels O
may O
be O
almost O
equipotent O
. O

Placebo O
- O
level O
incidence O
of O
extrapyramidal O
symptoms O
( O
EPS O
) O
with O
quetiapine B
in O
controlled O
studies O
of O
patients O
with O
bipolar O
mania O
. O

OBJECTIVES O
: O
To O
evaluate O
extrapyramidal O
symptoms O
( O
EPS O
) O
, O
including O
akathisia O
, O
with O
quetiapine B
in O
patients O
with O
bipolar O
mania O
. O

Two O
studies O
evaluated O
quetiapine B
monotherapy O
( O
up O
to O
800 O
mg O
/ O
day O
) O
( O
n O
= O
209 O
) O
versus O
placebo O
( O
n O
= O
198 O
) O
, O
with O
lithium O
or O
haloperidol O
monotherapy O
as O
respective O
active O
controls O
. O

Two O
studies O
evaluated O
quetiapine B
( O
up O
to O
800 O
mg O
/ O
day O
) O
in O
combination O
with O
a O
mood O
stabilizer O
( O
lithium O
or O
divalproex O
, O
QTP B
+ O
Li O
/ O
DVP O
) O
( O
n O
= O
196 O
) O
compared O
to O
placebo O
and O
mood O
stabilizer O
( O
PBO O
+ O
Li O
/ O
DVP O
) O
( O
n O
= O
203 O
) O
. O

RESULTS O
: O
The O
incidence O
of O
EPS O
- O
related O
adverse O
events O
, O
including O
akathisia O
, O
was O
no O
different O
with O
quetiapine B
monotherapy O
( O
12 O
. O
9 O
% O
) O
than O
with O
placebo O
( O
13 O
. O
1 O
% O
) O
. O

Similarly O
, O
EPS O
- O
related O
adverse O
events O
with O
QTP B
+ O
Li O
/ O
DVP O
( O
21 O
. O
4 O
% O
) O
were O
no O
different O
than O
with O
PBO O
+ O
Li O
/ O
DVP O
( O
19 O
. O
2 O
% O
) O
. O

The O
incidence O
of O
akathisia O
was O
low O
and O
similar O
with O
quetiapine B
monotherapy O
( O
3 O
. O
3 O
% O
) O
and O
placebo O
( O
6 O
. O
1 O
% O
) O
, O
and O
with O
QTP B
+ O
Li O
/ O
DVP O
( O
3 O
. O
6 O
% O
) O
and O
PBO O
+ O
Li O
/ O
DVP O
( O
4 O
. O
9 O
% O
) O
. O

Lithium O
was O
associated O
with O
a O
significantly O
higher O
incidence O
( O
p O
< O
0 O
. O
05 O
) O
of O
tremor O
( O
18 O
. O
4 O
% O
) O
than O
quetiapine B
( O
5 O
. O
6 O
% O
) O
; O
cerebellar O
tremor O
, O
which O
is O
a O
known O
adverse O
effect O
of O
lithium O
, O
may O
have O
contributed O
to O
the O
elevated O
rate O
of O
tremor O
in O
patients O
receiving O
lithium O
therapy O
. O

Haloperidol O
induced O
a O
significantly O
higher O
incidence O
( O
p O
< O
0 O
. O
001 O
) O
of O
akathisia O
( O
33 O
. O
3 O
% O
versus O
5 O
. O
9 O
% O
) O
, O
tremor O
( O
30 O
. O
3 O
% O
versus O
7 O
. O
8 O
% O
) O
, O
and O
extrapyramidal O
syndrome O
( O
35 O
. O
4 O
% O
versus O
5 O
. O
9 O
% O
) O
than O
quetiapine B
. O

No O
significant O
differences O
were O
observed O
between O
quetiapine B
and O
placebo O
on O
SAS O
and O
BARS O
scores O
. O

Anticholinergic O
use O
was O
low O
and O
similar O
with O
quetiapine B
or O
placebo O
. O

CONCLUSIONS O
: O
In O
bipolar O
mania O
, O
the O
incidence O
of O
EPS O
, O
including O
akathisia O
, O
with O
quetiapine B
therapy O
is O
similar O
to O
that O
with O
placebo O
. O

The O
extent O
of O
neuronal O
injury O
was O
determined O
by O
2 B
, I
3 I
, I
5 I
- I
triphenyltetrazolium I
staining O
. O

Serotonin O
was O
depleted O
beginning O
on O
postnatal O
day O
26 O
with O
parachlorophenylalanine B
( O
PCPA B
100 O
mg O
/ O
kg O
, O
every O
other O
day O
) O
; O
controls O
received O
saline O
. O

At O
puberty O
( O
P40 O
) O
, O
half O
the O
PCPA B
- O
treated O
rats O
and O
half O
the O
saline O
- O
treated O
rats O
began O
treatment O
with O
testosterone O
( O
T O
, O
5 O
mg O
/ O
kg O
, O
5 O
days O
/ O
week O
) O
. O

Brain O
levels O
of O
5 O
- O
HT O
and O
its O
metabolite O
, O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
, O
were O
determined O
using O
HPLC O
. O

PCPA B
significantly O
and O
substantially O
depleted O
5 O
- O
HT O
and O
5 B
- I
HIAA I
in O
all O
brain O
regions O
examined O
. O

Chronic O
T O
treatment O
significantly O
decreased O
5 O
- O
HT O
and O
5 B
- I
HIAA I
in O
certain O
brain O
areas O
, O
but O
to O
a O
much O
lesser O
extent O
than O
PCPA B
. O

Chronic O
exposure O
to O
PCPA B
alone O
significantly O
decreased O
locomotor O
activity O
and O
increased O
irritability O
but O
had O
no O
effect O
on O
sexual O
behavior O
, O
partner O
preference O
, O
or O
aggression O
. O

The O
most O
striking O
effect O
of O
combining O
T O
+ O
PCPA B
was O
a O
significant O
increase O
in O
attack O
frequency O
as O
well O
as O
a O
significant O
decrease O
in O
the O
latency O
to O
attack O
, O
particularly O
following O
physical O
provocation O
. O

Effects O
of O
UMB24 B
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
, O
putative O
sigma2 O
- O
preferring O
antagonists O
, O
on O
behavioral O
toxic O
and O
stimulant O
effects O
of O
cocaine O
in O
mice O
. O

To O
begin O
addressing O
this O
need O
, O
we O
characterized O
UMB24 B
( O
1 B
- I
( I
2 I
- I
phenethyl I
) I
- I
4 I
- I
( I
2 I
- I
pyridyl I
) I
- I
piperazine I
) O
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
( O
3alpha B
- I
tropanyl I
- I
2 I
- I
( I
4 I
- I
chorophenoxy I
) I
butyrate I
) O
in O
receptor O
binding O
and O
behavioral O
studies O
. O

Receptor O
binding O
studies O
confirmed O
that O
UMB24 B
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
display O
preferential O
affinity O
for O
sigma2 O
over O
sigma1 O
receptors O
. O

In O
behavioral O
studies O
, O
pretreatment O
of O
Swiss O
Webster O
mice O
with O
UMB24 B
or O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
significantly O
attenuated O
cocaine O
- O
induced O
convulsions O
and O
locomotor O
activity O
, O
but O
not O
lethality O
. O

When O
administered O
alone O
, O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
produced O
no O
significant O
effects O
compared O
to O
control O
injections O
of O
saline O
, O
but O
UMB24 B
had O
locomotor O
depressant O
actions O
. O

We O
present O
a O
case O
of O
a O
5 O
- O
year O
- O
old O
child O
with O
cerebral O
palsy O
and O
seizure O
disorder O
, O
receiving O
clonidine O
for O
restlessness O
, O
who O
presented O
for O
placement O
of O
a O
baclofen B
pump O
. O

This O
is O
a O
case O
report O
on O
a O
45 O
- O
year O
old O
African O
- O
American O
female O
with O
newly O
diagnosed O
hypertension O
, O
who O
was O
started O
on O
a O
combination O
pill O
of O
amlodipine B
/ O
benazapril B
10 O
/ O
5 O
mg O
. O

Detection O
of O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
in O
adriamycin O
- O
induced O
cardiomyopathy O
with O
iodine B
- I
125 I
- I
metaiodobenzylguanidine I
. O

Radiolabeled B
metaiodobenzylguanidine I
( O
MIBG B
) O
, O
an O
analog O
of O
norepinephrine O
( O
NE O
) O
, O
serves O
as O
an O
index O
of O
adrenergic O
neuron O
integrity O
and O
function O
. O

Myocardial O
accumulation O
of O
[ O
125I O
] O
MIBG B
4 O
hr O
after O
intravenous O
injection O
did O
not O
differ O
between O
the O
controls O
and O
the O
groups O
treated O
3 O
wk O
or O
less O
. O

In O
the O
5 O
- O
wk O
group O
, O
MIBG B
accumulation O
in O
the O
right O
and O
left O
ventricular O
wall O
was O
35 O
% O
and O
27 O
% O
of O
that O
in O
controls O
, O
respectively O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

In O
the O
8 O
- O
wk O
group O
, O
MIBG B
accumulation O
in O
the O
right O
and O
left O
ventricular O
wall O
was O
18 O
% O
and O
14 O
% O
of O
that O
in O
controls O
, O
respectively O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

Thus O
, O
MIBG B
accumulation O
in O
the O
myocardium O
decreased O
in O
an O
adriamycin O
dose O
- O
dependent O
manner O
. O

The O
appearance O
of O
impaired O
cardiac O
adrenergic O
neuron O
activity O
in O
the O
presence O
of O
slight O
myocardial O
impairment O
( O
scattered O
or O
focal O
vacuolar O
degeneration O
) O
indicates O
that O
MIBG B
scintigraphy O
may O
be O
a O
useful O
method O
for O
detection O
of O
adriamycin O
- O
induced O
cardiomyopathy O
. O

METHODS O
: O
In O
this O
cross O
- O
sectional O
study O
interview O
, O
ECGs O
and O
blood O
samples O
were O
collected O
in O
a O
population O
of O
adult O
heroin O
addicts O
treated O
with O
methadone O
or O
buprenorphine B
on O
a O
daily O
basis O
. O

No O
association O
between O
buprenorphine B
and O
QTc O
was O
found O
. O

None O
of O
the O
subjects O
treated O
with O
buprenorphine B
had O
QTc O
interval O
> O
0 O
. O
440 O
s O
( O
( O
1 O
/ O
2 O
) O
) O
. O

Neuroleptic O
malignant O
syndrome O
induced O
by O
ziprasidone B
on O
the O
second O
day O
of O
treatment O
. O

We O
describe O
a O
case O
of O
neuroleptic O
malignant O
syndrome O
( O
NMS O
) O
associated O
with O
the O
use O
of O
ziprasidone B
. O

Although O
conventional O
neuroleptics O
are O
more O
frequently O
associated O
with O
NMS O
, O
atypical O
antipsychotic O
drugs O
like O
ziprasidone B
may O
also O
be O
a O
cause O
. O

The O
patient O
is O
a O
24 O
- O
year O
- O
old O
male O
with O
a O
history O
of O
schizophrenia O
who O
developed O
signs O
and O
symptoms O
of O
NMS O
after O
2 O
days O
of O
treatment O
with O
an O
80 O
- O
mg O
/ O
day O
dose O
of O
orally O
administrated O
ziprasidone B
. O

This O
case O
is O
the O
earliest O
( O
second O
day O
of O
treatment O
) O
NMS O
due O
to O
ziprasidone B
reported O
in O
the O
literature O
. O

Peripheral O
iron B
dextran I
induced O
degeneration O
of O
dopaminergic O
neurons O
in O
rat O
substantia O
nigra O
. O

To O
demonstrate O
the O
relationship O
between O
peripheral O
iron O
overload O
and O
dopaminergic O
neuron O
loss O
in O
rat O
substantia O
nigra O
( O
SN O
) O
, O
in O
the O
present O
study O
we O
used O
fast O
cyclic O
voltammetry O
, O
tyrosine O
hydroxylase O
( O
TH O
) O
immunohistochemistry O
, O
Perls O
' O
iron O
staining O
, O
and O
high O
performance O
liquid O
chromatography O
- O
electrochemical O
detection O
to O
study O
the O
degeneration O
of O
dopaminergic O
neurons O
and O
increased O
iron O
content O
in O
the O
SN O
of O
iron B
dextran I
overloaded O
animals O
. O

The O
findings O
showed O
that O
peripheral O
iron B
dextran I
overload O
increased O
the O
iron O
staining O
positive O
cells O
and O
reduced O
the O
number O
of O
TH O
- O
immunoreactive O
neurons O
in O
the O
SN O
. O

These O
results O
suggest O
that O
peripheral O
iron B
dextran I
can O
increase O
the O
iron O
level O
in O
the O
SN O
, O
where O
excessive O
iron O
causes O
the O
degeneration O
of O
dopaminergic O
neurons O
. O

The O
serotonin O
- O
1A O
receptor O
agonist O
, O
8 B
- I
OH I
- I
DPAT I
, O
induced O
a O
significant O
disruption O
of O
PPI O
in O
all O
groups O
. O

Intraocular O
pressure O
in O
patients O
with O
uveitis O
treated O
with O
fluocinolone B
acetonide I
implants O
. O

OBJECTIVE O
: O
To O
report O
the O
incidence O
and O
management O
of O
elevated O
intraocular O
pressure O
( O
IOP O
) O
in O
patients O
with O
uveitis O
treated O
with O
the O
fluocinolone B
acetonide I
( O
FA B
) O
intravitreal O
implant O
. O

DESIGN O
: O
Pooled O
data O
from O
3 O
multicenter O
, O
double O
- O
masked O
, O
randomized O
, O
controlled O
, O
phase O
2b O
/ O
3 O
clinical O
trials O
evaluating O
the O
safety O
and O
efficacy O
of O
the O
0 O
. O
59 O
- O
mg O
or O
2 O
. O
1 O
- O
mg O
FA B
intravitreal O
implant O
or O
standard O
therapy O
were O
analyzed O
. O

Gastrointestinal O
tolerability O
of O
etoricoxib B
in O
rheumatoid O
arthritis O
patients O
: O
results O
of O
the O
etoricoxib B
vs O
diclofenac O
sodium O
gastrointestinal O
tolerability O
and O
effectiveness O
trial O
( O
EDGE O
- O
II O
) O
. O

OBJECTIVE O
: O
A O
randomised O
, O
double O
- O
blind O
study O
to O
compare O
the O
gastrointestinal O
( O
GI O
) O
tolerability O
, O
safety O
and O
efficacy O
of O
etoricoxib B
and O
diclofenac O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
. O

PATIENTS O
AND O
METHODS O
: O
A O
total O
of O
4086 O
patients O
( O
mean O
age O
60 O
. O
8 O
years O
) O
diagnosed O
with O
RA O
were O
enrolled O
and O
received O
etoricoxib B
90 O
mg O
daily O
( O
n O
= O
2032 O
) O
or O
diclofenac O
75 O
mg O
twice O
daily O
( O
n O
= O
2054 O
) O
. O

RESULTS O
: O
Mean O
( O
SD O
; O
maximum O
) O
duration O
of O
treatment O
was O
19 O
. O
3 O
( O
10 O
. O
3 O
; O
32 O
. O
9 O
) O
and O
19 O
. O
1 O
( O
10 O
. O
4 O
; O
33 O
. O
1 O
) O
months O
in O
the O
etoricoxib B
and O
diclofenac O
groups O
, O
respectively O
. O

The O
cumulative O
discontinuation O
rate O
due O
to O
GI O
AEs O
was O
significantly O
lower O
with O
etoricoxib B
than O
diclofenac O
( O
5 O
. O
2 O
vs O
8 O
. O
5 O
events O
per O
100 O
patient O
- O
years O
, O
respectively O
; O
hazard O
ratio O
0 O
. O
62 O
( O
95 O
% O
CI O
: O
0 O
. O
47 O
, O
0 O
. O
81 O
; O
p O
< O
or O
= O
0 O
. O
001 O
) O
) O
. O

The O
incidence O
of O
discontinuations O
for O
hypertension O
- O
related O
and O
oedema O
- O
related O
AEs O
were O
significantly O
higher O
with O
etoricoxib B
( O
2 O
. O
5 O
% O
and O
1 O
. O
1 O
% O
respectively O
) O
compared O
with O
diclofenac O
( O
1 O
. O
5 O
% O
and O
0 O
. O
4 O
% O
respectively O
; O
p O
< O
0 O
. O
001 O
for O
hypertension O
and O
p O
< O
0 O
. O
01 O
for O
oedema O
) O
. O

Etoricoxib B
and O
diclofenac O
treatment O
resulted O
in O
similar O
efficacy O
( O
PGADS O
mean O
changes O
from O
baseline O
- O
0 O
. O
62 O
vs O
- O
0 O
. O
58 O
, O
respectively O
) O
. O

CONCLUSIONS O
: O
Etoricoxib B
90 O
mg O
demonstrated O
a O
significantly O
lower O
risk O
for O
discontinuing O
treatment O
due O
to O
GI O
AEs O
compared O
with O
diclofenac O
150 O
mg O
. O

Discontinuations O
from O
renovascular O
AEs O
, O
although O
less O
common O
than O
discontinuations O
from O
GI O
AEs O
, O
were O
significantly O
higher O
with O
etoricoxib B
. O

Anxiogenic O
potential O
of O
ciprofloxacin O
and O
norfloxacin B
in O
rats O
. O

INTRODUCTION O
: O
The O
possible O
anxiogenic O
effects O
of O
fluoroquinolones O
, O
namely O
ciprofloxacin O
and O
norfloxacin B
, O
were O
investigated O
in O
adult O
Charles O
Foster O
albino O
rats O
of O
either O
sex O
, O
weighing O
150 O
- O
200 O
g O
. O

RESULTS O
: O
The O
results O
indicate O
that O
ciprofloxacin O
- O
and O
norfloxacin B
- O
treated O
rats O
showed O
anxious O
behaviour O
in O
comparison O
to O
control O
rats O
in O
all O
the O
parameters O
studied O
. O

However O
, O
ciprofloxacin O
- O
and O
norfloxacin B
- O
treated O
rats O
did O
not O
differ O
significantly O
from O
each O
other O
in O
various O
behavioural O
parameters O
. O

CONCLUSION O
: O
The O
present O
experimental O
findings O
substantiate O
the O
clinically O
observed O
anxiogenic O
potential O
of O
ciprofloxacin O
and O
norfloxacin B
. O

Reduction O
of O
pain O
during O
induction O
with O
target O
- O
controlled O
propofol O
and O
remifentanil B
. O

We O
hypothesized O
that O
propofol O
infusion O
pain O
might O
be O
prevented O
by O
infusing O
remifentanil B
before O
starting O
the O
propofol O
infusion O
in O
a O
clinical O
setting O
where O
target O
- O
controlled O
infusions O
( O
TCI O
) O
of O
both O
drugs O
were O
used O
. O

A O
prospective O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
was O
performed O
to O
determine O
the O
effect O
- O
site O
concentration O
( O
Ce O
) O
of O
remifentanil B
to O
prevent O
the O
pain O
without O
producing O
complications O
. O

METHODS O
: O
A O
total O
of O
128 O
patients O
undergoing O
general O
surgery O
were O
randomly O
allocated O
to O
receive O
normal O
saline O
( O
control O
) O
or O
remifentanil B
to O
a O
target O
Ce O
of O
2 O
ng O
ml O
( O
- O
1 O
) O
( O
R2 O
) O
, O
4 O
ng O
ml O
( O
- O
1 O
) O
( O
R4 O
) O
, O
or O
6 O
ng O
ml O
( O
- O
1 O
) O
( O
R6 O
) O
administered O
via O
TCI O
. O

Remifentanil B
- O
related O
complications O
were O
assessed O
during O
the O
remifentanil B
infusion O
, O
and O
pain O
caused O
by O
propofol O
was O
evaluated O
using O
a O
four O
- O
point O
scale O
during O
the O
propofol O
infusion O
. O

CONCLUSIONS O
: O
During O
induction O
of O
anaesthesia O
with O
TCI O
of O
propofol O
and O
remifentanil B
, O
a O
significant O
reduction O
in O
propofol O
infusion O
pain O
was O
achieved O
without O
significant O
complications O
by O
prior O
administration O
of O
remifentanil B
at O
a O
target O
Ce O
of O
4 O
ng O
ml O
( O
- O
1 O
) O
. O

Dexmedetomidine B
and O
cardiac O
protection O
for O
non O
- O
cardiac O
surgery O
: O
a O
meta O
- O
analysis O
of O
randomised O
controlled O
trials O
. O

We O
conducted O
a O
systematic O
review O
of O
the O
effects O
of O
dexmedetomidine B
on O
cardiac O
outcomes O
following O
non O
- O
cardiac O
surgery O
. O

We O
included O
prospective O
, O
randomised O
peri O
- O
operative O
studies O
of O
dexmedetomidine B
that O
reported O
mortality O
, O
cardiac O
morbidity O
or O
adverse O
drug O
events O
. O

Dexmedetomidine B
was O
associated O
with O
a O
trend O
towards O
improved O
cardiac O
outcomes O
; O
all O
- O
cause O
mortality O
( O
OR O
0 O
. O
27 O
, O
95 O
% O
CI O
0 O
. O
01 O
- O
7 O
. O
13 O
, O
p O
= O
0 O
. O
44 O
) O
, O
non O
- O
fatal O
myocardial O
infarction O
( O
OR O
0 O
. O
26 O
, O
95 O
% O
CI O
0 O
. O
04 O
- O
1 O
. O
60 O
, O
p O
= O
0 O
. O
14 O
) O
, O
and O
myocardial O
ischaemia O
( O
OR O
0 O
. O
65 O
, O
95 O
% O
CI O
0 O
. O
26 O
- O
1 O
. O
63 O
, O
p O
= O
0 O
. O
36 O
) O
. O

A O
randomised O
placebo O
- O
controlled O
trial O
of O
dexmedetomidine B
is O
warranted O
. O

Results O
of O
a O
comparative O
, O
phase O
III O
, O
12 O
- O
week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double O
- O
blind O
assessment O
of O
the O
efficacy O
and O
tolerability O
of O
a O
fixed O
- O
dose O
combination O
of O
telmisartan B
and O
amlodipine B
versus O
amlodipine B
monotherapy O
in O
Indian O
adults O
with O
stage O
II O
hypertension O
. O

OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
a O
new O
fixed O
- O
dose O
combination O
( O
FDC O
) O
of O
telmisartan B
40 O
mg O
+ O
amlodipine B
5 O
mg O
( O
T O
+ O
A O
) O
compared O
with O
amlodipine B
5 O
- O
mg O
monotherapy O
( O
A O
) O
in O
adult O
Indian O
patients O
with O
stage O
II O
hypertension O
. O

High O
dose O
dexmedetomidine B
as O
the O
sole O
sedative O
for O
pediatric O
MRI O
. O

OBJECTIVE O
: O
This O
large O
- O
scale O
retrospective O
review O
evaluates O
the O
sedation O
profile O
of O
dexmedetomidine B
. O

AIM O
: O
To O
determine O
the O
hemodynamic O
responses O
, O
efficacy O
and O
adverse O
events O
associated O
with O
the O
use O
of O
high O
dose O
dexmedetomidine B
as O
the O
sole O
sedative O
for O
magnetic O
resonance O
imaging O
( O
MRI O
) O
studies O
. O

BACKGROUND O
: O
Dexmedetomidine B
has O
been O
used O
at O
our O
institution O
since O
2005 O
to O
provide O
sedation O
for O
pediatric O
radiological O
imaging O
studies O
. O

Over O
time O
, O
an O
effective O
protocol O
utilizing O
high O
dose O
dexmedetomidine B
as O
the O
sole O
sedative O
agent O
has O
evolved O
. O

Data O
were O
analyzed O
from O
all O
747 O
consecutive O
patients O
who O
received O
dexmedetomidine B
for O
MRI O
sedation O
from O
April O
2005 O
to O
April O
2007 O
. O

RESULTS O
: O
Since O
2005 O
, O
the O
10 O
- O
min O
loading O
dose O
of O
our O
dexmedetomidine B
protocol O
increased O
from O
2 O
to O
3 O
microg O
. O
kg O
( O
- O
1 O
) O
, O
and O
the O
infusion O
rate O
increased O
from O
1 O
to O
1 O
. O
5 O
to O
2 O
microg O
. O
kg O
( O
- O
1 O
) O
. O
h O
( O
- O
1 O
) O
. O

The O
current O
sedation O
protocol O
progressively O
increased O
the O
rate O
of O
successful O
sedation O
( O
able O
to O
complete O
the O
imaging O
study O
) O
when O
using O
dexmedetomidine B
alone O
from O
91 O
. O
8 O
% O
to O
97 O
. O
6 O
% O
( O
P O
= O
0 O
. O
009 O
) O
, O
reducing O
the O
requirement O
for O
adjuvant O
pentobarbital O
in O
the O
event O
of O
sedation O
failure O
with O
dexmedetomidine B
alone O
and O
decreased O
the O
mean O
recovery O
time O
by O
10 O
min O
( O
P O
< O
0 O
. O
001 O
) O
. O

Although O
dexmedetomidine B
sedation O
was O
associated O
with O
a O
16 O
% O
incidence O
of O
bradycardia O
, O
all O
concomitant O
mean O
arterial O
blood O
pressures O
were O
within O
20 O
% O
of O
age O
- O
adjusted O
normal O
range O
and O
oxygen O
saturations O
were O
95 O
% O
or O
higher O
. O

CONCLUSION O
: O
Dexmedetomidine B
in O
high O
doses O
provides O
adequate O
sedation O
for O
pediatric O
MRI O
studies O
. O

While O
use O
of O
high O
dose O
dexmedetomidine B
is O
associated O
with O
decreases O
in O
heart O
rate O
and O
blood O
pressure O
outside O
the O
established O
' O
awake O
' O
norms O
, O
this O
deviation O
is O
generally O
within O
20 O
% O
of O
norms O
, O
and O
is O
not O
associated O
with O
adverse O
sequelae O
. O

Dexmedetomidine B
is O
useful O
as O
the O
sole O
sedative O
for O
pediatric O
MRI O
. O

Blood O
samples O
for O
the O
analysis O
of O
plasma O
potassium O
, O
terbutaline O
, O
metoprolol O
( O
racemic O
, O
R O
- O
and O
S O
- O
isomer O
) O
, O
and O
alpha B
- I
hydroxymetoprolol I
concentrations O
were O
taken O
at O
regular O
time O
intervals O
, O
during O
8 O
hr O
after O
metoprolol O
. O

Higher O
metoprolol O
/ O
alpha B
- I
hydroxymetoprolol I
ratios O
in O
PMs O
were O
predictive O
for O
higher O
R O
- O
/ O
S O
- O
isomer O
ratios O
of O
unchanged O
drug O
. O

BACKGROUND O
: O
Unfractionated O
heparin O
sodium O
( O
UFH O
) O
or O
low B
- I
molecular I
weight I
heparin I
( O
LMWH O
) O
is O
used O
in O
anticoagulant O
protocols O
at O
several O
institutions O
to O
prevent O
thrombosis O
after O
liver O
transplantation O
. O

High O
fat B
diet O
- O
fed O
obese O
rats O
are O
highly O
sensitive O
to O
doxorubicin O
- O
induced O
cardiotoxicity O
. O

This O
cardioprotection O
is O
accompanied O
by O
decreased O
cardiac O
oxidative O
stress O
and O
triglycerides B
and O
increased O
cardiac O
fatty O
- O
acid O
oxidation O
, O
ATP O
synthesis O
, O
and O
upregulated O
JAK O
/ O
STAT3 O
pathway O
. O

In O
the O
current O
study O
, O
we O
investigated O
whether O
a O
physiological O
intervention O
by O
feeding O
40 O
% O
high O
fat B
diet O
( O
HFD O
) O
, O
which O
induces O
obesity O
in O
male O
Sprague O
- O
Dawley O
rats O
( O
250 O
- O
275 O
g O
) O
, O
sensitizes O
to O
doxorubicin O
- O
induced O
cardiotoxicity O
. O

We O
propose O
that O
naturally O
occurring O
compounds O
such O
as O
flavonoids B
, O
which O
are O
present O
in O
fruit O
juices O
, O
may O
increase O
the O
potency O
of O
warfarin O
by O
competing O
for O
the O
enzymes O
that O
normally O
inactivate O
warfarin O
. O

Longitudinal O
assessment O
of O
air O
conduction O
audiograms O
in O
a O
phase O
III O
clinical O
trial O
of O
difluoromethylornithine B
and O
sulindac O
for O
prevention O
of O
sporadic O
colorectal O
adenomas O
. O

A O
phase O
III O
clinical O
trial O
assessed O
the O
recurrence O
of O
adenomatous O
polyps O
after O
treatment O
for O
36 O
months O
with O
difluoromethylornithine B
( O
DFMO B
) O
plus O
sulindac O
or O
matched O
placebos O
. O

Temporary O
hearing O
loss O
is O
a O
known O
toxicity O
of O
treatment O
with O
DFMO B
, O
thus O
a O
comprehensive O
approach O
was O
developed O
to O
analyze O
serial O
air O
conduction O
audiograms O
. O

Based O
on O
290 O
subjects O
, O
there O
was O
an O
average O
difference O
of O
0 O
. O
50 O
dB O
between O
subjects O
treated O
with O
DFMO B
plus O
sulindac O
compared O
with O
those O
treated O
with O
placebo O
( O
95 O
% O
confidence O
interval O
, O
- O
0 O
. O
64 O
to O
1 O
. O
63 O
dB O
; O
P O
= O
0 O
. O
39 O
) O
, O
adjusted O
for O
baseline O
values O
, O
age O
, O
and O
frequencies O
. O

There O
were O
14 O
of O
151 O
( O
9 O
. O
3 O
% O
) O
in O
the O
DFMO B
plus O
sulindac O
group O
and O
4 O
of O
139 O
( O
2 O
. O
9 O
% O
) O
in O
the O
placebo O
group O
who O
experienced O
at O
least O
15 O
dB O
hearing O
reduction O
from O
baseline O
in O
2 O
or O
more O
consecutive O
frequencies O
across O
the O
entire O
range O
tested O
( O
P O
= O
0 O
. O
02 O
) O
. O

There O
was O
no O
significant O
difference O
in O
the O
proportion O
of O
subjects O
in O
the O
DFMO B
plus O
sulindac O
group O
who O
experienced O
clinically O
significant O
hearing O
loss O
compared O
with O
the O
placebo O
group O
. O

There O
is O
a O
< O
2 O
dB O
difference O
in O
mean O
threshold O
for O
patients O
treated O
with O
DFMO B
plus O
sulindac O
compared O
with O
those O
treated O
with O
placebo O
. O

DSMM O
XI O
study O
: O
dose O
definition O
for O
intravenous O
cyclophosphamide O
in O
combination O
with O
bortezomib B
/ O
dexamethasone O
for O
remission O
induction O
in O
patients O
with O
newly O
diagnosed O
myeloma O
. O

A O
clinical O
trial O
was O
initiated O
to O
evaluate O
the O
recommended O
dose O
of O
cyclophosphamide O
in O
combination O
with O
bortezomib B
and O
dexamethasone O
as O
induction O
treatment O
before O
stem O
cell O
transplantation O
for O
younger O
patients O
with O
newly O
diagnosed O
multiple O
myeloma O
( O
MM O
) O
. O

Thirty O
patients O
were O
treated O
with O
three O
21 O
- O
day O
cycles O
of O
bortezomib B
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
4 O
, O
8 O
, O
and O
11 O
plus O
dexamethasone O
40 O
mg O
on O
the O
day O
of O
bortezomib B
injection O
and O
the O
day O
after O
plus O
cyclophosphamide O
at O
900 O
, O
1 O
, O
200 O
, O
or O
1 O
, O
500 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
. O

The O
results O
suggest O
that O
bortezomib B
in O
combination O
with O
cyclophosphamide O
at O
900 O
mg O
/ O
m O
( O
2 O
) O
and O
dexamethasone O
is O
an O
effective O
induction O
treatment O
for O
patients O
with O
newly O
diagnosed O
MM O
that O
warrants O
further O
investigation O
. O

Identification O
of O
a O
simple O
and O
sensitive O
microplate O
method O
for O
the O
detection O
of O
oversulfated O
chondroitin B
sulfate I
in O
heparin O
products O
. O

Recently O
, O
a O
number O
of O
commercial O
lots O
of O
heparin O
products O
were O
found O
to O
be O
contaminated O
with O
an O
oversulfated O
chondroitin B
sulfate I
( O
OSCS O
) O
derivative O
that O
could O
elicit O
a O
hypotensive O
response O
in O
pigs O
following O
a O
single O
high O
- O
dose O
infusion O
. O

Using O
a O
mouse O
model O
, O
we O
tested O
whether O
the O
rapid O
reversal O
of O
anticoagulation O
using O
human O
prothrombin B
complex I
concentrate I
( O
PCC B
) O
can O
reduce O
hemorrhagic O
blood O
volume O
. O

First O
, O
we O
showed O
that O
an O
intravenous O
administration O
of O
human O
PCC B
rapidly O
reversed O
anticoagulation O
in O
mice O
. O

Forty O
- O
five O
minutes O
later O
, O
the O
animals O
were O
randomly O
treated O
with O
PCC B
( O
100 O
U O
/ O
kg O
) O
or O
saline O
i O
. O
v O
. O
( O
n O
= O
12 O
per O
group O
) O
. O

The O
mean O
hemorrhagic O
blood O
volume O
was O
reduced O
in O
PCC B
- O
treated O
animals O
( O
6 O
. O
5 O
+ O
/ O
- O
3 O
. O
1 O
microL O
) O
compared O
with O
saline O
controls O
( O
15 O
. O
3 O
+ O
/ O
- O
11 O
. O
2 O
microL O
, O
P O
= O
0 O
. O
015 O
) O
. O

In O
contrast O
, O
such O
extensive O
lesions O
were O
never O
found O
in O
the O
PCC B
group O
. O

We O
provide O
experimental O
data O
suggesting O
PCC B
to O
be O
an O
effective O
acute O
treatment O
for O
W O
- O
ICH O
in O
terms O
of O
reducing O
hemorrhagic O
blood O
volume O
. O

Renal O
failure O
developed O
after O
a O
prolonged O
course O
of O
vancomycin O
therapy O
in O
2 O
patients O
who O
were O
receiving O
tenofovir B
disoproxil I
fumarate I
as O
part O
of O
an O
antiretroviral O
regimen O
. O

Recurrent O
dysosmia O
induced O
by O
pyrazinamide B
. O

Pyrazinamide B
can O
have O
adverse O
effects O
such O
as O
hepatic O
toxicity O
, O
hyperuricemia O
or O
digestive O
disorders O
. O

In O
rare O
cases O
, O
alterations O
in O
taste O
and O
smell O
function O
have O
been O
reported O
for O
pyrazinamide B
when O
combined O
with O
other O
drugs O
. O

We O
report O
a O
case O
of O
reversible O
olfactory O
disorder O
related O
to O
pyrazinamide B
in O
a O
woman O
, O
with O
a O
positive O
rechallenge O
. O

Dysosmia O
disappeared O
completely O
after O
pyrazinamide B
withdrawal O
and O
recurred O
after O
its O
rechallenge O
. O

The O
present O
study O
was O
undertaken O
to O
assess O
lithium O
- O
induced O
polyuria O
in O
mice O
deficient O
in O
microsomal O
prostaglandin B
E I
synthase O
- O
1 O
( O
mPGES O
- O
1 O
) O
. O

This O
was O
associated O
with O
elevated O
renal O
mPGES O
- O
1 O
protein O
expression O
and O
increased O
urine O
PGE B
( I
2 I
) I
excretion O
. O

In O
contrast O
, O
mPGES O
- O
1 O
- O
/ O
- O
mice O
were O
largely O
resistant O
to O
lithium O
- O
induced O
polyuria O
and O
a O
urine O
concentrating O
defect O
, O
accompanied O
by O
nearly O
complete O
blockade O
of O
high O
urine O
PGE B
( I
2 I
) I
and O
cAMP O
output O
. O

Similarly O
, O
the O
total O
protein O
abundance O
of O
the O
Na O
- O
K O
- O
2Cl B
cotransporter O
( O
NKCC2 O
) O
in O
the O
medulla O
but O
not O
in O
the O
cortex O
of O
the O
+ O
/ O
+ O
mice O
was O
significantly O
reduced O
by O
lithium O
treatment O
. O

We O
conclude O
that O
mPGES O
- O
1 O
- O
derived O
PGE B
( I
2 I
) I
mediates O
lithium O
- O
induced O
polyuria O
likely O
via O
inhibition O
of O
AQP2 O
and O
NKCC2 O
expression O
. O

Preservation O
of O
renal O
blood O
flow O
during O
hypotension O
induced O
with O
fenoldopam B
in O
dogs O
. O

Specific O
dopamine O
- O
1 O
, O
( O
DA1 B
) O
and O
dopamine O
- O
2 O
( O
DA2 B
) O
receptor O
agonists O
are O
now O
under O
clinical O
investigation O
. O

Fenoldopam B
mesylate I
is O
a O
specific O
DA1 O
receptor O
agonist O
that O
lowers O
blood O
pressure O
by O
vasodilatation O
. O

The O
hypothesis O
that O
fenoldopam B
could O
be O
used O
to O
induce O
hypotension O
and O
preserve O
blood O
flow O
to O
the O
kidney O
was O
tested O
. O

Systemic O
aortic O
blood O
pressure O
and O
renal O
blood O
flow O
were O
measured O
continuously O
with O
a O
carotid O
arterial O
catheter O
and O
an O
electromagnetic O
flow O
probe O
respectively O
, O
in O
order O
to O
compare O
the O
cardiovascular O
and O
renal O
vascular O
effects O
of O
fenoldopam B
and O
sodium O
nitroprusside O
in O
ten O
dogs O
under O
halothane O
general O
anaesthesia O
. O

Mean O
arterial O
pressure O
was O
decreased O
30 O
+ O
/ O
- O
8 O
per O
cent O
from O
control O
with O
infusion O
of O
fenoldopam B
( O
3 O
. O
4 O
+ O
/ O
- O
2 O
. O
0 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
) O
and O
34 O
+ O
/ O
- O
4 O
per O
cent O
with O
infusion O
of O
sodium O
nitroprusside O
( O
5 O
. O
9 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
) O
( O
NS O
) O
. O

Renal O
blood O
flow O
( O
RBF O
) O
increased O
during O
fenoldopam B
- O
induced O
hypotension O
11 O
+ O
/ O
- O
7 O
per O
cent O
and O
decreased O
21 O
+ O
/ O
- O
8 O
per O
cent O
during O
sodium O
nitroprusside O
- O
induced O
hypotension O
( O
P O
less O
than O
0 O
. O
01 O
) O
. O

Dextran O
- O
etodolac B
conjugates O
: O
synthesis O
, O
in O
vitro O
and O
in O
vivo O
evaluation O
. O

Etodolac B
( O
E B
) O
, O
is O
a O
non O
- O
narcotic O
analgesic O
and O
antiinflammatory O
drug O
. O

A O
biodegradable O
polymer O
dextran O
has O
been O
utilized O
as O
a O
carrier O
for O
synthesis O
of O
etodolac B
- O
dextran O
conjugates O
( O
ED O
) O
to O
improve O
its O
aqueous O
solubility O
and O
reduce O
gastrointestinal O
side O
effects O
. O

An O
activated O
moiety O
, O
i O
. O
e O
. O
N B
- I
acylimidazole I
derivative O
of O
etodolac B
( O
EAI B
) O
, O
was O
condensed O
with O
the O
polysaccharide O
polymer O
dextran O
of O
different O
molecular O
weights O
( O
40000 O
, O
60000 O
, O
110000 O
and O
200000 O
) O
. O

Etodolac B
contents O
were O
evaluated O
by O
UV O
- O
spectrophotometric O
analysis O
. O

At O
pH O
9 O
, O
a O
higher O
rate O
of O
etodolac B
release O
from O
ED O
was O
observed O
as O
compared O
to O
aqueous O
buffer O
of O
pH O
7 O
. O
4 O
and O
80 O
% O
human O
plasma O
( O
pH O
7 O
. O
4 O
) O
, O
following O
first O
- O
order O
kinetics O
. O

Acute O
analgesic O
and O
antiinflammatory O
activities O
were O
ascertained O
using O
acetic B
acid I
induced O
writhing O
model O
( O
mice O
) O
and O
carrageenan B
- O
induced O
rat O
paw O
edema O
model O
, O
respectively O
. O

In O
comparison O
to O
control O
, O
E B
and O
ED1 O
- O
ED4 O
showed O
highly O
significant O
analgesic O
and O
antiinflammatory O
activities O
( O
p O
< O
0 O
. O
001 O
) O
. O

Biological O
evaluation O
suggested O
that O
conjugates O
( O
ED1 O
- O
ED4 O
) O
retained O
comparable O
analgesic O
and O
antiinflammatory O
activities O
with O
remarkably O
reduced O
ulcerogenicity O
as O
compared O
to O
their O
parent O
drug O
- O
- O
etodolac B
. O

This O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
pilocarpine O
and O
explore O
the O
underlying O
ionic O
mechanism O
, O
using O
both O
aconitine B
- O
induced O
rat O
and O
ouabain O
- O
induced O
guinea O
pig O
arrhythmia O
models O
. O

[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
overload O
induced O
by O
aconitine B
or O
ouabain O
was O
reduced O
in O
isolated O
myocytes O
pretreated O
with O
pilocarpine O
. O

These O
data O
suggest O
that O
pilocarpine O
produced O
antiarrhythmic O
actions O
on O
arrhythmic O
rat O
and O
guinea O
pig O
models O
induced O
by O
aconitine B
or O
ouabain O
via O
stimulating O
the O
cardiac O
M O
( O
3 O
) O
- O
mAChR O
. O

The O
beneficial O
effects O
of O
vitamin B
C I
administration O
to O
gentamicin O
- O
treated O
animals O
are O
also O
confirmed O
through O
: O
lower O
level O
of O
blood O
urea O
and O
creatinine O
and O
higher O
level O
of O
potassium O
. O

Vitamin B
C I
administration O
induced O
slowdown O
of O
pressure O
change O
back O
to O
the O
control O
values O
. O

The O
pressure O
dynamic O
properties O
, O
quantitatively O
defined O
by O
comparative O
pressure O
dynamic O
and O
total O
pressure O
dynamic O
, O
confirm O
the O
alteration O
in O
dynamic O
response O
of O
blood O
vessels O
during O
the O
change O
of O
pressure O
in O
gentamicin O
- O
treated O
animals O
and O
beneficial O
effects O
of O
vitamin B
C I
administration O
. O

The O
effects O
of O
N B
, I
N I
' I
- I
dibenzhydrylethane I
- I
1 I
, I
2 I
- I
diamine I
dihydrochloride I
( O
AMN082 B
) O
, O
the O
first O
selective O
allosteric O
activator O
of O
mGlu7 O
receptors O
, O
were O
thus O
tested O
in O
different O
rodent O
models O
of O
PD O
. O

Here O
, O
we O
show O
that O
oral O
( O
5 O
mg O
/ O
kg O
) O
or O
intrastriatal O
administration O
( O
0 O
. O
1 O
and O
0 O
. O
5 O
nmol O
) O
of O
AMN082 B
reverses O
haloperidol O
- O
induced O
catalepsy O
in O
rats O
. O

AMN082 B
( O
2 O
. O
5 O
and O
5 O
mg O
/ O
kg O
) O
reduces O
apomorphine O
- O
induced O
rotations O
in O
unilateral O
6 O
- O
hydroxydopamine O
( O
6 O
- O
OHDA O
) O
- O
lesioned O
rats O
. O

In O
a O
more O
complex O
task O
commonly O
used O
to O
evaluate O
major O
akinetic O
symptoms O
of O
PD O
patients O
, O
5 O
mg O
/ O
kg O
AMN082 B
reverses O
the O
increased O
reaction O
time O
to O
respond O
to O
a O
cue O
of O
bilateral O
6 O
- O
OHDA O
- O
lesioned O
rats O
. O

In O
addition O
, O
AMN082 B
reduces O
the O
duration O
of O
haloperidol O
- O
induced O
catalepsy O
in O
a O
mGlu7 O
receptor O
- O
dependent O
manner O
in O
wild O
- O
type O
but O
not O
mGlu7 O
receptor O
knockout O
mice O
. O

Higher O
doses O
of O
AMN082 B
( O
10 O
and O
20 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
have O
no O
effect O
on O
the O
same O
models O
of O
PD O
. O

Cessation O
of O
sorafenib O
and O
administration O
of O
Ca O
- O
channel O
blocker O
and O
nitrates B
ameliorated O
his O
symptoms O
, O
but O
relapse O
occurred O
after O
resumption O
of O
sorafenib O
. O

Addition O
of O
oral O
nicorandil B
reduced O
his O
symptoms O
and O
maintained O
stable O
angina O
status O
. O

A O
Tween O
80 O
- O
coated O
poly B
- I
L I
- I
lactid I
acid I
nanoparticles O
was O
used O
as O
a O
model O
of O
colloidal O
drug O
delivery O
system O
, O
able O
to O
trespass O
the O
BBB O
. O

Tacrine B
, O
administered O
in O
LiCl O
pre O
- O
treated O
rats O
, O
induces O
electrocorticographic O
seizures O
and O
delayed O
hippocampal O
damage O
. O

The O
toxic O
effects O
of O
tacrine B
- O
loaded O
poly B
- I
L I
- I
lactid I
acid I
nanoparticles O
( O
5mg O
/ O
kg O
) O
, O
a O
saline O
solution O
of O
tacrine B
( O
5mg O
/ O
kg O
) O
and O
an O
empty O
colloidal O
nanoparticle O
suspension O
were O
compared O
following O
i O
. O
p O
. O
administration O
in O
LiCl O
- O
pre O
- O
treated O
Wistar O
rats O
. O

All O
the O
animals O
treated O
with O
tacrine B
- O
loaded O
nanoparticles O
showed O
an O
earlier O
outcome O
of O
CNS O
adverse O
symptoms O
, O
i O
. O
e O
. O
epileptic O
onset O
, O
with O
respect O
to O
those O
animals O
treated O
with O
the O
free O
compound O
( O
10 O
min O
vs O
. O
22 O
min O
respectively O
) O
. O

In O
addition O
, O
tacrine B
- O
loaded O
nanoparticles O
administration O
induced O
damage O
of O
neuronal O
cells O
in O
CA1 O
field O
of O
the O
hippocampus O
in O
all O
treated O
animals O
, O
while O
the O
saline O
solution O
of O
tacrine B
only O
in O
60 O
% O
of O
animals O
. O

In O
conclusion O
, O
the O
evaluation O
of O
time O
- O
to O
- O
onset O
of O
symptoms O
and O
the O
severity O
of O
neurodegenerative O
processes O
induced O
by O
the O
tacrine B
- O
lithium O
model O
of O
epilepsy O
in O
the O
rat O
, O
could O
be O
used O
to O
evaluate O
preliminarily O
the O
capability O
of O
a O
drug O
delivery O
system O
to O
trespass O
( O
or O
not O
) O
the O
BBB O
in O
vivo O
. O

Eight O
patients O
had O
cardiac O
manifestations O
that O
were O
life O
- O
threatening O
in O
five O
while O
taking O
psychotropic O
drugs O
, O
either O
phenothiazines B
or O
tricyclic O
antidepressants O
. O

Although O
most O
patients O
were O
receiving O
several O
drugs O
, O
Mellaril B
( O
thioridazine B
) O
appeared O
to O
be O
responsible O
for O
five O
cases O
of O
ventricular O
tachycardia O
, O
one O
of O
which O
was O
fatal O
in O
a O
35 O
year O
old O
woman O
. O

Aventyl B
( O
nortriptyline B
) O
and O
Elavil O
( O
amitriptyline O
) O
each O
produced O
left O
bundle O
branch O
block O
in O
a O
73 O
year O
old O
woman O
. O

A O
prospective O
clinical O
trial O
is O
suggested O
to O
quantify O
the O
risk O
of O
cardiac O
complications O
to O
patients O
receiving O
phenothiazines B
or O
tricyclic O
antidepressant O
drugs O
. O

The O
mean O
plasma O
levels O
of O
EPO O
observed O
in O
AZT O
treated O
mice O
were O
appropriate O
for O
the O
degree O
of O
anaemia O
observed O
when O
compared O
with O
phenylhydrazine B
( O
PHZ B
) O
treated O
mice O
. O

The O
numbers O
of O
BFU O
- O
e O
and O
the O
percentage O
of O
bone O
marrow O
erythroblasts O
observed O
were O
comparable O
in O
AZT O
and O
PHZ B
treated O
mice O
with O
similar O
degrees O
of O
anaemia O
. O

Metformin B
prevents O
experimental O
gentamicin O
- O
induced O
nephropathy O
by O
a O
mitochondria O
- O
dependent O
pathway O
. O

The O
antidiabetic O
drug O
metformin B
can O
diminish O
apoptosis O
induced O
by O
oxidative O
stress O
in O
endothelial O
cells O
and O
prevent O
vascular O
dysfunction O
even O
in O
nondiabetic O
patients O
. O

Metformin B
treatment O
fully O
blocked O
gentamicin O
- O
mediated O
acute O
renal O
failure O
. O

Metformin B
also O
protected O
the O
kidney O
from O
histological O
damage O
6 O
days O
after O
gentamicin O
administration O
. O

These O
in O
vivo O
markers O
of O
kidney O
dysfunction O
and O
their O
correction O
by O
metformin B
were O
complemented O
by O
in O
vitro O
studies O
of O
mitochondrial O
function O
. O

These O
injuries O
, O
partly O
mediated O
by O
a O
rise O
in O
reactive O
oxygen O
species O
from O
the O
electron O
transfer O
chain O
, O
were O
significantly O
decreased O
by O
metformin B
. O

Thus O
, O
our O
study O
suggests O
that O
pleiotropic O
effects O
of O
metformin B
can O
lessen O
gentamicin O
nephrotoxicity O
and O
improve O
mitochondrial O
homeostasis O
. O

This O
prospective O
study O
determined O
the O
incidence O
of O
CIN O
for O
two O
nonionic O
contrast O
media O
( O
CM O
) O
, O
iopromide B
and O
iohexol B
, O
among O
80 O
patients O
younger O
than O
18 O
years O
and O
compared O
the O
rates O
for O
this O
complication O
in O
relation O
to O
the O
type O
and O
dosage O
of O
CM O
and O
the O
presence O
of O
cyanosis O
. O

The O
80 O
patients O
in O
the O
study O
consecutively O
received O
either O
iopromide B
( O
group O
A O
, O
n O
= O
40 O
) O
or O
iohexol B
( O
group O
B O
, O
n O
= O
40 O
) O
. O

Glomerular O
filtration O
rate O
( O
GFR O
) O
and O
effective O
renal O
plasma O
flow O
( O
ERPF O
) O
were O
measured O
by O
inulin O
and O
para B
- I
aminohippurate I
( O
PAH B
) O
clearance O
, O
respectively O
. O

METHODS O
: O
Male O
Wistar O
rats O
received O
each O
dose O
of O
the O
alpha O
( O
2 O
) O
- O
adrenoceptor O
antagonist O
yohimbine O
( O
0 O
. O
25 O
- O
1 O
. O
0mg O
/ O
kg O
) O
, O
the O
5 O
- O
HT O
( O
2C O
) O
receptor O
agonist O
m B
- I
chlorophenylpiperazine I
( O
mCPP B
, O
0 O
. O
5 O
- O
2 O
. O
0mg O
/ O
kg O
) O
or O
the O
GABA O
( O
A O
) O
inverse O
receptor O
agonist O
pentylenetetrazole O
( O
PTZ O
, O
3 O
- O
30mg O
/ O
kg O
) O
and O
were O
subsequently O
tested O
in O
either O
LES O
or O
FPS O
. O

RESULTS O
: O
None O
of O
the O
drugs O
enhanced O
LES O
, O
whereas O
mCPP B
increased O
percentage O
FPS O
and O
yohimbine O
increased O
absolute O
FPS O
values O
. O

Furthermore O
, O
yohimbine O
increased O
baseline O
startle O
amplitude O
in O
the O
LES O
, O
while O
mCPP B
suppressed O
baseline O
startle O
in O
both O
the O
LES O
and O
FPS O
and O
PTZ O
suppressed O
baseline O
startle O
in O
the O
FPS O
. O

Continuous O
topical O
use O
of O
immunomodulators O
such O
as O
tacrolimus O
or O
pimecrolimus B
should O
be O
regarded O
as O
a O
potential O
cause O
of O
rosaceiform O
dermatitis O
, O
although O
many O
cases O
have O
not O
been O
reported O
. O

Coenzyme B
Q10 I
treatment O
ameliorates O
acute O
cisplatin O
nephrotoxicity O
in O
mice O
. O

The O
nephroprotective O
effect O
of O
coenzyme B
Q10 I
was O
investigated O
in O
mice O
with O
acute O
renal O
injury O
induced O
by O
a O
single O
i O
. O
p O
. O
injection O
of O
cisplatin O
( O
5 O
mg O
/ O
kg O
) O
. O

Coenzyme B
Q10 I
treatment O
( O
10 O
mg O
/ O
kg O
/ O
day O
, O
i O
. O
p O
. O
) O
was O
applied O
for O
6 O
consecutive O
days O
, O
starting O
1 O
day O
before O
cisplatin O
administration O
. O

Coenzyme B
Q10 I
significantly O
reduced O
blood O
urea O
nitrogen O
and O
serum O
creatinine O
levels O
which O
were O
increased O
by O
cisplatin O
. O

Coenzyme B
Q10 I
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced O
glutathione O
level O
and O
superoxide O
dismutase O
activity O
) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor O
necrosis O
factor O
- O
alpha O
, O
nitric O
oxide O
and O
platinum B
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium B
and O
zinc B
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin O
administration O
. O

Also O
, O
histopathological O
renal O
tissue O
damage O
mediated O
by O
cisplatin O
was O
ameliorated O
by O
coenzyme B
Q10 I
treatment O
. O

Immunohistochemical O
analysis O
revealed O
that O
coenzyme B
Q10 I
significantly O
decreased O
the O
cisplatin O
- O
induced O
overexpression O
of O
inducible O
nitric O
oxide O
synthase O
, O
nuclear O
factor O
- O
kappaB O
, O
caspase O
- O
3 O
and O
p53 O
in O
renal O
tissue O
. O

It O
was O
concluded O
that O
coenzyme B
Q10 I
represents O
a O
potential O
therapeutic O
option O
to O
protect O
against O
acute O
cisplatin O
nephrotoxicity O
commonly O
encountered O
in O
clinical O
practice O
. O

The O
arrhythmia O
resolved O
after O
therapy O
with O
atenolol B
, O
but O
recurred O
a O
year O
later O
. O

After O
stopping O
the O
beta O
- O
agonist O
, O
and O
after O
a O
week O
with O
the O
atenolol B
, O
the O
arrhythmia O
disappeared O
. O

Although O
it O
is O
difficult O
to O
define O
causality O
in O
a O
case O
report O
, O
it O
is O
logical O
to O
think O
that O
a O
beta O
- O
agonist O
like O
salbutamol O
( O
known O
to O
induce O
tachycardia O
) O
may O
be O
the O
trigger O
of O
adrenergic O
reflexes O
originating O
in O
the O
esophagus O
while O
swallowing O
and O
that O
a O
beta O
- O
blocker O
such O
as O
atenolol B
( O
that O
blocks O
the O
adrenergic O
activity O
) O
may O
relieve O
it O
. O

Insulin O
treatment O
also O
prevented O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic O
rats O
to O
nerve O
stimulation O
, O
ATP O
, O
and O
bethanechol B
. O

Insulin O
treatment O
reversed O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic O
rats O
to O
nerve O
stimulation O
, O
ATP O
, O
and O
bethanechol B
. O

Haloperidol O
- O
induced O
catalepsy O
was O
challenged O
with O
prior O
intracollicular O
microinjections O
of O
glutamate O
NMDA O
receptor O
antagonists O
, O
MK O
- O
801 O
( O
15 O
or O
30 O
mmol O
/ O
0 O
. O
5 O
microl O
) O
and O
AP7 B
( O
10 O
or O
20 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
, O
or O
of O
the O
NMDA O
receptor O
agonist O
N O
- O
methyl O
- O
d O
- O
aspartate O
( O
NMDA O
, O
20 O
or O
30 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
. O

The O
results O
showed O
that O
intracollicular O
microinjection O
of O
MK O
- O
801 O
and O
AP7 B
previous O
to O
systemic O
injections O
of O
haloperidol O
significantly O
attenuated O
the O
catalepsy O
, O
as O
indicated O
by O
a O
reduced O
latency O
to O
step O
down O
from O
a O
horizontal O
bar O
. O

The O
condition O
is O
treated O
with O
intravenous O
thyroxine O
( O
T4 O
) O
or O
intravenous O
tri B
- I
iodo I
- I
thyronine I
( O
T3 B
) O
. O

Effects O
of O
active O
constituents O
of O
Crocus O
sativus O
L O
. O
, O
crocin B
on O
streptozocin O
- O
induced O
model O
of O
sporadic O
Alzheimer O
' O
s O
disease O
in O
male O
rats O
. O

BACKGROUND O
: O
The O
involvement O
of O
water O
- O
soluble O
carotenoids B
, O
crocins B
, O
as O
the O
main O
and O
active O
components O
of O
Crocus O
sativus O
L O
. O
extract O
in O
learning O
and O
memory O
processes O
has O
been O
proposed O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
crocins B
on O
sporadic O
Alzheimer O
' O
s O
disease O
induced O
by O
intracerebroventricular O
( O
icv O
) O
streptozocin O
( O
STZ O
) O
in O
male O
rats O
was O
investigated O
. O

METHODS O
: O
Male O
adult O
Wistar O
rats O
( O
n O
= O
90 O
and O
260 O
- O
290 O
g O
) O
were O
divided O
into O
1 O
, O
control O
; O
2 O
and O
3 O
, O
crocins B
( O
15 O
and O
30 O
mg O
/ O
kg O
) O
; O
4 O
, O
STZ O
; O
5 O
and O
6 O
, O
STZ O
+ O
crocins B
( O
15 O
and O
30 O
mg O
/ O
kg O
) O
groups O
. O

In O
STZ O
+ O
crocin B
animal O
groups O
, O
crocin B
was O
applied O
in O
doses O
of O
15 O
and O
30 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
one O
day O
pre O
- O
surgery O
and O
continued O
for O
three O
weeks O
. O

Prescription O
of O
crocin B
in O
each O
dose O
was O
repeated O
once O
for O
two O
days O
. O

RESULTS O
: O
It O
was O
found O
out O
that O
crocin B
( O
30 O
mg O
/ O
kg O
) O
- O
treated O
STZ O
- O
injected O
rats O
show O
higher O
correct O
choices O
and O
lower O
errors O
in O
Y O
- O
maze O
than O
vehicle O
- O
treated O
STZ O
- O
injected O
rats O
. O

In O
addition O
, O
crocin B
in O
the O
mentioned O
dose O
could O
significantly O
attenuated O
learning O
and O
memory O
impairment O
in O
treated O
STZ O
- O
injected O
group O
in O
passive O
avoidance O
test O
. O

CONCLUSION O
: O
Therefore O
, O
these O
results O
demonstrate O
the O
effectiveness O
of O
crocin B
( O
30 O
mg O
/ O
kg O
) O
in O
antagonizing O
the O
cognitive O
deficits O
caused O
by O
STZ O
- O
icv O
in O
rats O
and O
its O
potential O
in O
the O
treatment O
of O
neurodegenerative O
diseases O
such O
as O
Alzheimer O
' O
s O
disease O
. O

The O
serotonin O
6 O
( O
5 B
- I
HT6 I
) O
receptor O
is O
therapeutically O
targeted O
by O
several O
second O
generation O
antipsychotics O
, O
such O
as O
clozapine O
and O
olanzapine O
, O
and O
d O
- O
amphetamine O
- O
induced O
hyperactivity O
in O
rats O
is O
corrected O
with O
the O
use O
of O
a O
selective O
5 B
- I
HT6 I
receptor O
antagonist O
. O

In O
addition O
, O
the O
disrupted O
prepulse O
inhibition O
induced O
by O
d O
- O
amphetamine O
or O
phencyclidine O
was O
restored O
by O
5 B
- I
HT6 I
receptor O
antagonist O
in O
an O
animal O
study O
using O
rats O
. O

These O
animal O
models O
were O
considered O
to O
reflect O
the O
positive O
symptoms O
of O
schizophrenia O
, O
and O
the O
above O
evidence O
suggests O
that O
altered O
5 B
- I
HT6 I
receptors O
are O
involved O
in O
the O
pathophysiology O
of O
psychotic O
disorders O
. O

Therefore O
, O
we O
conducted O
an O
analysis O
of O
the O
association O
of O
the O
5 B
- I
HT6 I
gene O
( O
HTR6 O
) O
with O
METH O
- O
induced O
psychosis O
. O

Neural O
correlates O
of O
S B
- I
ketamine I
induced O
psychosis O
during O
overt O
continuous O
verbal O
fluency O
. O

In O
a O
counterbalanced O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
study O
design O
, O
healthy O
subjects O
were O
administered O
a O
continuous O
subanesthetic O
S B
- I
ketamine I
infusion O
while O
differences O
in O
BOLD O
responses O
measured O
with O
fMRI O
were O
detected O
. O

In O
vivo O
characterization O
of O
a O
dual O
adenosine B
A2A I
/ I
A1 I
receptor I
antagonist I
in O
animal O
models O
of O
Parkinson O
' O
s O
disease O
. O

The O
in O
vivo O
characterization O
of O
a O
dual O
adenosine B
A I
( I
2A I
) I
/ I
A I
( I
1 I
) I
receptor I
antagonist I
in O
several O
animal O
models O
of O
Parkinson O
' O
s O
disease O
is O
described O
. O

CCNU B
( O
lomustine B
) O
toxicity O
in O
dogs O
: O
a O
retrospective O
study O
( O
2002 O
- O
07 O
) O
. O

OBJECTIVE O
: O
To O
describe O
the O
incidence O
of O
haematological O
, O
renal O
, O
hepatic O
and O
gastrointestinal O
toxicities O
in O
tumour O
- O
bearing O
dogs O
receiving O
1 B
- I
( I
2 I
- I
chloroethyl I
) I
- I
3 I
- I
cyclohexyl I
- I
1 I
- I
nitrosourea I
( O
CCNU B
) O
. O

DESIGN O
: O
The O
medical O
records O
of O
206 O
dogs O
that O
were O
treated O
with O
CCNU B
at O
the O
Melbourne O
Veterinary O
Specialist O
Centre O
between O
February O
2002 O
and O
December O
2007 O
were O
retrospectively O
evaluated O
. O

RESULTS O
: O
Of O
the O
206 O
dogs O
treated O
with O
CCNU B
, O
185 O
met O
the O
inclusion O
criteria O
for O
at O
least O
one O
class O
of O
toxicity O
. O

CCNU B
was O
used O
most O
commonly O
in O
the O
treatment O
of O
lymphoma O
, O
mast O
cell O
tumour O
, O
brain O
tumour O
, O
histiocytic O
tumours O
and O
epitheliotropic O
lymphoma O
. O

CONCLUSIONS O
: O
CCNU B
- O
associated O
toxicity O
in O
dogs O
is O
common O
, O
but O
is O
usually O
not O
life O
threatening O
. O

Central O
vein O
thrombosis O
and O
topical O
dipivalyl B
epinephrine I
. O

A O
report O
is O
given O
on O
an O
83 O
- O
year O
- O
old O
female O
who O
acquired O
central O
vein O
thrombosis O
in O
her O
seeing O
eye O
one O
day O
after O
having O
started O
topical O
medication O
with O
dipivalyl B
epinephrine I
for O
advanced O
glaucoma O
discovered O
in O
the O
other O
eye O
. O

Benzylacyclouridine B
reverses O
azidothymidine O
- O
induced O
marrow O
suppression O
without O
impairment O
of O
anti O
- O
human O
immunodeficiency O
virus O
activity O
. O

Increased O
extracellular O
concentrations O
of O
uridine B
( O
Urd B
) O
have O
been O
reported O
to O
reduce O
, O
in O
vitro O
, O
azidothymidine O
( O
AZT O
) O
- O
induced O
inhibition O
of O
human O
granulocyte O
- O
macrophage O
progenitor O
cells O
without O
impairment O
of O
its O
antihuman O
immunodeficiency O
virus O
( O
HIV O
) O
activity O
. O

Because O
of O
the O
clinical O
toxicities O
associated O
with O
chronic O
Urd B
administration O
, O
the O
ability O
of O
benzylacyclouridine B
( O
BAU B
) O
to O
effect O
, O
in O
vivo O
, O
AZT O
- O
induced O
anemia O
and O
leukopenia O
was O
assessed O
. O

This O
agent O
inhibits O
Urd B
catabolism O
and O
, O
in O
vivo O
, O
increases O
the O
plasma O
concentration O
of O
Urd B
in O
a O
dose O
- O
dependent O
manner O
, O
without O
Urd B
- O
related O
toxicity O
. O

In O
mice O
rendered O
anemic O
and O
leukopenic O
by O
the O
administration O
of O
AZT O
for O
28 O
days O
in O
drinking O
water O
( O
1 O
. O
5 O
mg O
/ O
mL O
) O
, O
the O
continued O
administration O
of O
AZT O
plus O
daily O
BAU B
( O
300 O
mg O
/ O
kg O
, O
orally O
) O
partially O
reversed O
AZT O
- O
induced O
anemia O
and O
leukopenia O
( O
P O
less O
than O
. O
05 O
) O
, O
increased O
peripheral O
reticulocytes O
( O
to O
4 O
. O
9 O
% O
, O
P O
less O
than O
. O
01 O
) O
, O
increased O
cellularity O
in O
the O
marrow O
, O
and O
improved O
megaloblastosis O
. O

When O
coadministered O
with O
AZT O
from O
the O
onset O
of O
drug O
administration O
, O
BAU B
reduced O
AZT O
- O
induced O
marrow O
toxicity O
. O

In O
vitro O
, O
at O
a O
concentration O
of O
100 O
mumol O
/ O
L O
, O
BAU B
possesses O
minimal O
anti O
- O
HIV O
activity O
and O
has O
no O
effect O
on O
the O
ability O
of O
AZT O
to O
reverse O
the O
HIV O
- O
induced O
cytopathic O
effect O
in O
MT4 O
cells O
. O

Nociceptive O
effects O
induced O
by O
intrathecal O
administration O
of O
prostaglandin B
D2 I
, I
E2 I
, I
or I
F2 I
alpha I
to O
conscious O
mice O
. O

The O
effects O
of O
intrathecal O
administration O
of O
prostaglandins O
on O
pain O
responses O
in O
conscious O
mice O
were O
evaluated O
by O
using O
hot O
plate O
and O
acetic B
acid I
writhing O
tests O
. O

Prostaglandin B
D2 I
( O
0 O
. O
5 O
- O
3 O
ng O
/ O
mouse O
) O
had O
a O
hyperalgesic O
action O
on O
the O
response O
to O
a O
hot O
plate O
during O
a O
3 O
- O
60 O
min O
period O
after O
injection O
. O

Prostaglandin B
E2 I
showed O
a O
hyperalgesic O
effect O
at O
doses O
of O
1 O
pg O
to O
10 O
ng O
/ O
mouse O
, O
but O
the O
effect O
lasted O
shorter O
( O
3 O
- O
30 O
min O
) O
than O
that O
of O
prostaglandin B
D2 I
. O

Similar O
results O
were O
obtained O
by O
acetic B
acid I
writhing O
tests O
. O

The O
hyperalgesic O
effect O
of O
prostaglandin B
D2 I
was O
blocked O
by O
simultaneous O
injection O
of O
a O
substance O
P O
antagonist O
( O
greater O
than O
or O
equal O
to O
100 O
ng O
) O
but O
not O
by O
AH6809 B
, O
a O
prostanoid O
EP1 O
- O
receptor O
antagonist O
. O

Conversely O
, O
prostaglandin B
E2 I
- O
induced O
hyperalgesia O
was O
blocked O
by O
AH6809 B
( O
greater O
than O
or O
equal O
to O
500 O
ng O
) O
but O
not O
by O
the O
substance O
P O
antagonist O
. O

These O
results O
demonstrate O
that O
both O
prostaglandin B
D2 I
and O
prostaglandin B
E2 I
exert O
hyperalgesia O
in O
the O
spinal O
cord O
, O
but O
in O
different O
ways O
. O

We O
describe O
a O
42 O
- O
year O
- O
old O
woman O
who O
developed O
superior O
sagittal O
and O
left O
transverse O
sinus O
thrombosis O
associated O
with O
prolonged O
epsilon B
- I
aminocaproic I
acid I
therapy O
for O
menorrhagia O
. O

Although O
increased O
risk O
of O
thromboembolic O
disease O
has O
been O
reported O
during O
treatment O
with O
epsilon B
- I
aminocaproic I
acid I
, O
cerebral O
sinus O
thrombosis O
has O
not O
been O
previously O
described O
. O

Careful O
use O
of O
epsilon B
- I
aminocaproic I
acid I
therapy O
is O
recommended O
. O

Seizure O
activity O
with O
imipenem B
therapy O
: O
incidence O
and O
risk O
factors O
. O

Two O
elderly O
patients O
with O
a O
history O
of O
either O
cerebral O
vascular O
accident O
( O
CVA O
) O
or O
head O
trauma O
and O
no O
evidence O
of O
renal O
disease O
developed O
seizures O
while O
receiving O
maximum O
doses O
of O
imipenem B
/ I
cilastatin I
. O

In O
spontaneously O
hypertensive O
, O
stroke O
- O
prone O
rats O
, O
microinjection O
of O
methyldopa O
into O
the O
area O
of O
the O
midline O
B3 O
serotonin O
cell O
group O
in O
the O
ventral O
medulla O
caused O
a O
potent O
hypotension O
of O
30 O
- O
40 O
mm O
Hg O
, O
which O
was O
maximal O
2 O
- O
3 O
h O
after O
administration O
and O
was O
abolished O
by O
the O
serotonin O
neurotoxin O
5 B
, I
7 I
- I
dihydroxytryptamine I
( O
5 B
, I
7 I
- I
DHT I
) O
injected O
intracerebroventricularly O
. O

However O
, O
intraspinal O
injection O
of O
5 B
, I
7 I
- I
DHT I
to O
produce O
a O
more O
selective O
lesion O
of O
only O
descending O
serotonin O
projections O
in O
the O
spinal O
cord O
did O
not O
affect O
this O
hypotension O
. O

Further O
, O
5 B
, I
7 I
- I
DHT I
lesion O
of O
serotonin O
nerves O
travelling O
in O
the O
median O
forebrain O
bundle O
, O
one O
of O
the O
main O
ascending O
pathways O
from O
the O
B3 O
serotonin O
cells O
, O
did O
not O
affect O
the O
fall O
in O
blood O
pressure O
associated O
with O
a O
midline O
B3 O
serotonin O
methyldopa O
injection O
. O

Antiarrhythmic O
plasma O
concentrations O
of O
cibenzoline B
on O
canine O
ventricular O
arrhythmias O
. O

Using O
two O
- O
stage O
coronary O
ligation O
- O
, O
digitalis B
- O
, O
and O
adrenaline O
- O
induced O
canine O
ventricular O
arrhythmias O
, O
antiarrhythmic O
effects O
of O
cibenzoline B
were O
examined O
and O
the O
minimum O
effective O
plasma O
concentration O
for O
each O
arrhythmia O
model O
was O
determined O
. O

Cibenzoline B
suppressed O
all O
the O
arrhythmias O
, O
and O
the O
minimum O
effective O
plasma O
concentrations O
for O
arrhythmias O
induced O
by O
24 O
- O
h O
coronary O
ligation O
, O
48 O
- O
h O
coronary O
ligation O
, O
digitalis B
, O
and O
adrenaline O
were O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
9 O
( O
by O
8 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
, O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
5 O
( O
by O
8 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
, O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
2 O
( O
by O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
, O
and O
3 O
. O
5 O
+ O
/ O
- O

This O
pharmacological O
profile O
is O
similar O
to O
those O
of O
mexiletine O
and O
tocainide B
, O
and O
all O
three O
drugs O
have O
central O
nervous O
system O
( O
CNS O
) O
stimulant O
action O
. O

Because O
cibenzoline B
had O
only O
weak O
hypotensive O
and O
sinus O
node O
depressive O
effects O
and O
was O
found O
to O
be O
orally O
active O
when O
given O
to O
coronary O
ligation O
arrhythmia O
dogs O
, O
its O
clinical O
usefulness O
is O
expected O
. O

These O
infants O
are O
treated O
with O
two O
injections O
of O
hepatitis O
B O
immune O
globulin O
( O
HBIG O
) O
and O
at O
least O
three O
injections O
of O
plasma O
derived O
hepatitis B
B I
vaccine I
. O

The O
intradermal O
injection O
of O
mu O
( O
morphine O
, O
Tyr B
- I
D I
- I
Ala I
- I
Gly I
- I
NMe I
- I
Phe I
- I
Gly I
- I
ol I
and O
morphiceptin B
) O
, O
kappa O
( O
trans B
- I
3 I
, I
4 I
- I
dichloro I
- I
N I
- I
methyl I
- I
N I
[ I
2 I
- I
( I
1 I
- I
pyrrolidinyl I
) I
cyclohexyl I
] I
benzeneactemide I
) O
and O
delta O
( O
[ B
D I
- I
Pen2 I
. I
5 I
] I
- I
enkephalin I
and O
[ O
D O
- O
Ser2 O
] O
- O
[ O
Leu O
] O
enkephalin O
- O

Intradermal O
injection O
of O
mu O
, O
but O
not O
delta O
or O
kappa O
opioid O
- O
agonists O
, O
however O
, O
produced O
dose O
- O
dependent O
inhibition O
of O
prostaglandin B
E2 I
- O
induced O
hyperalgesia O
. O

Morphine O
did O
not O
, O
however O
, O
alter O
the O
hyperalgesia O
induced O
by O
8 B
- I
bromo I
cyclic I
adenosine I
monophosphate I
. O

We O
conclude O
that O
the O
analgesic O
action O
of O
opioids O
on O
the O
peripheral O
terminals O
of O
primary O
afferents O
is O
via O
a O
binding O
site O
with O
characteristics O
of O
the O
mu O
- O
opioid O
receptor O
and O
that O
this O
action O
is O
mediated O
by O
inhibition O
of O
the O
cyclic B
adenosine I
monophosphate I
second O
messenger O
system O
. O

Dexmedetomidine B
, O
acting O
through O
central O
alpha O
- O
2 O
adrenoceptors O
, O
prevents O
opiate O
- O
induced O
muscle O
rigidity O
in O
the O
rat O
. O

The O
highly O
- O
selective O
alpha O
- O
2 O
adrenergic O
agonist O
dexmedetomidine B
( O
D B
- I
MED I
) O
is O
capable O
of O
inducing O
muscle O
flaccidity O
and O
anesthesia O
in O
rats O
and O
dogs O
. O

In O
the O
present O
study O
, O
the O
authors O
determined O
if O
treatment O
with O
D B
- I
MED I
prevents O
the O
muscle O
rigidity O
caused O
by O
high O
- O
dose O
alfentanil O
anesthesia O
in O
the O
rat O
. O

Animals O
( O
n O
= O
42 O
) O
were O
treated O
intraperitoneally O
with O
one O
of O
the O
following O
six O
regimens O
: O
1 O
) O
L O
- O
MED O
( O
the O
inactive O
L O
- O
isomer O
of O
medetomidine B
) O
, O
30 O
micrograms O
/ O
kg O
; O
2 O
) O
D B
- I
MED I
, O
10 O
micrograms O
/ O
kg O
; O
3 O
) O
D B
- I
MED I
, O
30 O
micrograms O
/ O
kg O
; O
4 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O
] O
and O
the O
central O
- O
acting O
alpha O
- O
2 O
antagonist O
, O
idazoxan B
[ O
10 O
mg O
/ O
kg O
] O
; O
5 O
) O
D B
- I
MED I
[ O
30 O
micrograms O
/ O
kg O

] O
and O
the O
peripheral O
- O
acting O
alpha O
- O
2 O
antagonist O
DG B
- I
5128 I
[ O
10 O
mg O
/ O
kg O
] O
, O
or O
; O
6 O
) O
saline O
. O

In O
contrast O
, O
D B
- I
MED I
prevented O
alfentanil O
- O
induced O
muscle O
rigidity O
in O
a O
dose O
- O
dependent O
fashion O
. O

The O
small O
EMG O
values O
obtained O
in O
the O
high O
- O
dose O
D B
- I
MED I
group O
were O
comparable O
with O
those O
recorded O
in O
earlier O
studies O
from O
control O
animals O
not O
given O
any O
opiate O
. O

The O
high O
- O
dose O
D B
- I
MED I
animals O
were O
flaccid O
, O
akinetic O
, O
and O
lacked O
a O
startle O
response O
during O
the O
entire O
experimental O
period O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Some O
central O
effects O
of O
repeated O
treatment O
with O
fluvoxamine B
. O

We O
investigated O
the O
effect O
of O
repeated O
treatment O
with O
fluvoxamine B
, O
a O
selective O
serotonin O
uptake O
inhibitor O
, O
on O
behavioral O
effects O
of O
dopaminomimetics O
and O
methoxamine B
and O
on O
the O
animal O
behavior O
in O
the O
" O
behavioral O
despair O
" O
test O
. O

A O
repeated O
treatment O
with O
fluvoxamine B
( O
twice O
daily O
for O
14 O
days O
) O
potentiated O
in O
mice O
and O
in O
rats O
( O
weaker O
) O
the O
amphetamine O
- O
induced O
hyperactivity O
. O

The O
hyperactivity O
induced O
by O
nomifensine B
in O
mice O
remained O
unaffected O
by O
fluvoxamine B
. O

The O
stimulation O
of O
locomotor O
activity O
by O
intracerebroventricularly O
administered O
methoxamine B
was O
not O
affected O
by O
repeated O
treatment O
with O
fluvoxamine B
. O

Given O
three O
times O
fluvoxamine B
had O
no O
effect O
on O
the O
immobilization O
time O
in O
the O
" O
behavioral O
despair O
" O
test O
in O
rats O
. O

The O
results O
indicate O
that O
fluvoxamine B
given O
repeatedly O
acts O
differently O
than O
citalopram O
, O
another O
selective O
serotonin O
uptake O
inhibitor O
, O
and O
differs O
also O
from O
other O
antidepressant O
drugs O
. O

Protective O
effect O
of O
a O
specific O
platelet O
- O
activating O
factor O
antagonist O
, O
BN B
52021 I
, O
on O
bupivacaine O
- O
induced O
cardiovascular O
impairments O
in O
rats O
. O

Intravenous O
injection O
of O
the O
specific O
platelet O
- O
activating O
factor O
( O
PAF O
) O
antagonist O
BN B
52021 I
( O
10 O
mg O
/ O
kg O
) O
, O
30 O
min O
before O
bupivacaine O
administration O
( O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
suppressed O
both O
the O
decrease O
of O
MBP O
and O
HR O
. O

In O
contrast O
, O
doses O
of O
1 O
mg O
/ O
kg O
BN B
52021 I
given O
30 O
min O
before O
or O
10 O
mg O
/ O
kg O
administered O
5 O
min O
before O
i O
. O
v O
. O
injection O
of O
bupivacaine O
were O
ineffective O
. O

When O
BN B
52021 I
( O
20 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
was O
injected O
immediately O
after O
bupivacaine O
( O
2 O
mg O
/ O
kg O
) O
, O
a O
partial O
reversion O
of O
the O
decrease O
of O
MBP O
and O
HR O
was O
observed O
, O
whereas O
the O
dose O
of O
10 O
mg O
/ O
kg O
was O
ineffective O
. O

A O
partial O
recovery O
of O
bupivacaine O
- O
induced O
ECG O
alterations O
was O
observed O
after O
pretreatment O
of O
the O
rats O
with O
BN B
52021 I
. O

Since O
the O
administration O
of O
BN B
52021 I
, O
at O
all O
doses O
studied O
, O
did O
not O
alter O
MBP O
and O
HR O
at O
the O
doses O
used O
, O
the O
bulk O
of O
these O
results O
clearly O
demonstrate O
a O
protective O
action O
of O
BN B
52021 I
, O
a O
specific O
antagonist O
of O
PAF O
, O
against O
bupivacaine O
- O
induced O
cardiovascular O
toxicity O
. O

The O
epidemiology O
of O
the O
acute O
flank O
pain O
syndrome O
from O
suprofen B
. O

Suprofen B
, O
a O
new O
nonsteroidal O
anti O
- O
inflammatory O
drug O
, O
was O
marketed O
in O
early O
1986 O
as O
an O
analgesic O
agent O
. O

To O
elucidate O
the O
epidemiology O
of O
the O
syndrome O
, O
a O
case O
- O
control O
study O
was O
performed O
, O
comparing O
62 O
of O
the O
case O
patients O
who O
had O
been O
reported O
to O
the O
spontaneous O
reporting O
system O
to O
185 O
suprofen B
- O
exposed O
control O
subjects O
who O
did O
not O
have O
the O
syndrome O
. O

Phlorizin B
- O
induced O
glycosuria O
does O
not O
prevent O
gentamicin O
nephrotoxicity O
in O
rats O
. O

The O
protection O
from O
gentamicin O
nephrotoxicity O
was O
studied O
in O
non O
- O
diabetic O
rats O
with O
chronic O
solute O
diuresis O
induced O
by O
blockage O
of O
tubular O
glucose O
reabsorption O
with O
phlorizin B
( O
P B
) O
. O

DM O
rats O
with O
mild O
glycosuria O
( O
similar O
in O
degree O
to O
that O
of O
the O
P B
treated O
animals O
) O
were O
also O
studied O
. O

Group O
1 O
( O
P B
alone O
) O
received O
P B
, O
360 O
mg O
/ O
day O
, O
for O
15 O
days O
; O
Group O
II O
( O
P B
+ O
gentamicin O
) O
; O
Group O
III O
( O
gentamicin O
alone O
) O
and O
Group O
IV O
( O
mild O
DM O
+ O
gentamicin O
) O
. O

In O
Group O
I O
, O
P B
induced O
a O
moderate O
and O
stable O
glycosuria O
( O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
1 O
g O
/ O
day O
, O
SE O
) O
, O
and O
no O
functional O
or O
morphologic O
evidence O
of O
renal O
dysfunction O
( O
baseline O
CCr O
2 O
. O
1 O
+ O
/ O
- O
0 O
. O
1 O
ml O
/ O
min O
, O
undetectable O
lysozymuria O
) O
or O
damage O
( O
tubular O
necrosis O
score O
[ O
maximum O
4 O
] O
, O
zero O
) O
. O

In O
Group O
II O
, O
P B
did O
not O
prevent O
gentamicin O
- O
ARF O
( O
maximal O
decrease O
in O
CCr O
at O
day O
9 O
. O
89 O
% O
, O
P B
less O
than O
0 O
. O
001 O
; O
peak O
lysozymuria O
, O
1863 O
+ O
/ O
- O
321 O
micrograms O
/ O
day O
; O
and O
tubular O
necrosis O
score O
, O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
1 O
) O
. O

These O
values O
were O
not O
different O
from O
those O
of O
Group O
III O
: O
maximal O
decrease O
in O
CCr O
73 O
% O
( O
P B
less O
than O
0 O
. O
001 O
) O
; O
lysozymuria O
, O
2147 O
+ O
/ O
- O
701 O
micrograms O
/ O
day O
; O
tubular O
necrosis O
score O
, O
3 O
. O
8 O
+ O
/ O
- O
0 O
. O
1 O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Neuromuscular O
blockade O
with O
magnesium B
sulfate I
and O
nifedipine O
. O

A O
patient O
who O
received O
tocolysis O
with O
nifedipine O
developed O
neuromuscular O
blockade O
after O
500 O
mg O
of O
magnesium B
sulfate I
was O
administered O
. O

Beta O
- O
2 O
- O
adrenoceptor O
- O
mediated O
hypokalemia O
and O
its O
abolishment O
by O
oxprenolol B
. O

Subsequently O
we O
investigated O
the O
efficacy O
of O
oxprenolol B
in O
antagonizing O
such O
hypokalemia O
, O
together O
with O
the O
pharmacokinetic O
interaction O
between O
both O
drugs O
. O

Six O
healthy O
subjects O
were O
given O
a O
0 O
. O
5 O
mg O
subcutaneous O
dose O
of O
terbutaline O
on O
two O
occasions O
: O
1 O
hour O
after O
oral O
administration O
of O
a O
placebo O
and O
1 O
hour O
after O
80 O
mg O
oxprenolol B
orally O
. O

Oxprenolol B
caused O
decreases O
of O
65 O
% O
and O
56 O
% O
of O
terbutaline O
volume O
of O
distribution O
and O
clearance O
, O
respectively O
, O
and O
an O
increase O
of O
130 O
% O
of O
its O
AUC O
. O

In O
spite O
of O
higher O
terbutaline O
concentrations O
after O
oxprenolol B
pretreatment O
, O
the O
hypokalemia O
was O
almost O
completely O
antagonized O
by O
the O
beta O
2 O
- O
blocking O
action O
. O

A O
dystonia O
- O
like O
syndrome O
after O
neuropeptide O
( O
MSH B
/ O
ACTH B
) O
stimulation O
of O
the O
rat O
locus O
ceruleus O
. O

However O
, O
it O
is O
not O
certain O
as O
to O
the O
following O
: O
( O
a O
) O
what O
receptors O
were O
stimulated O
by O
the O
ACTH B
N O
- O
terminal O
fragments O
at O
the O
LC O
that O
resulted O
in O
this O
disorder O
; O
( O
b O
) O
whether O
NE O
, O
released O
onto O
Purkinje O
cell O
synapses O
located O
at O
terminals O
of O
the O
ceruleo O
- O
cerebellar O
pathway O
, O
did O
indeed O
cause O
the O
long O
- O
term O
depression O
at O
Purkinje O
cell O
synapses O
( O
previously O
described O
by O
others O
) O
that O
resulted O
in O
the O
long O
duration O
of O
the O
movement O
disorder O
; O
( O
c O
) O
whether O
the O
inhibition O
of O
inhibitory O
Purkinje O
cells O
resulted O
in O
disinhibition O
or O

Pretreatment O
of O
rats O
with O
thiosemicarbazide B
for O
30 O
minutes O
abolished O
the O
anesthetic O
action O
as O
well O
as O
the O
respiratory O
depressant O
action O
of O
thiopental O
. O

However O
, O
the O
diazepam O
enhancement O
of O
adrenaline O
- O
induced O
reflex O
bradycardia O
was O
antagonized O
by O
pretreatment O
of O
rats O
with O
an O
intravenous O
dose O
of O
picrotoxin O
( O
an O
agent O
blocks O
chloride B
channels O
by O
binding O
to O
sites O
associated O
with O
the O
benzodiazepine O
- O
GABA O
- O
chloride B
channel O
macromolecular O
complex O
) O
. O

The O
data O
indicate O
that O
diazepam O
acts O
through O
the O
benzodiazepine O
- O
GABA O
- O
chloride B
channel O
macromolecular O
complex O
within O
the O
central O
nervous O
system O
to O
facilitate O
reflex O
bradycardia O
mediated O
through O
baroreceptor O
reflexes O
in O
response O
to O
an O
acute O
increase O
in O
arterial O
pressure O
. O

Initial O
potassium O
loss O
and O
hypokalaemia O
during O
chlorthalidone B
administration O
in O
patients O
with O
essential O
hypertension O
: O
the O
influence O
of O
dietary O
sodium O
restriction O
. O

Chlorthalidone B
( O
50 O
mg O
daily O
) O
was O
given O
for O
14 O
days O
. O

Reversal O
of O
neuroleptic O
- O
induced O
catalepsy O
by O
novel O
aryl B
- I
piperazine I
anxiolytic O
drugs O
. O

The O
novel O
anxiolytic O
drug O
, O
buspirone B
, O
reverses O
catalepsy O
induced O
by O
haloperidol O
. O

A O
series O
of O
aryl B
- I
piperazine I
analogues O
of O
buspirone B
and O
other O
5 B
- I
hydroxytryptaminergic I
agonists I
were O
tested O
for O
their O
ability O
to O
reverse O
haloperidol O
induced O
catalepsy O
. O

Those O
drugs O
with O
strong O
affinity O
for O
5 B
- I
hydroxytryptamine1a I
receptors O
were O
able O
to O
reverse O
catalepsy O
. O

Glycopyrronium O
requirements O
for O
antagonism O
of O
the O
muscarinic O
side O
effects O
of O
edrophonium B
. O

We O
have O
compared O
, O
in O
60 O
adult O
patients O
, O
the O
cardiovascular O
effects O
of O
glycopyrronium O
5 O
micrograms O
kg O
- O
1 O
and O
10 O
micrograms O
kg O
- O
1 O
given O
either O
simultaneously O
or O
1 O
min O
before O
edrophonium B
1 O
mg O
kg O
- O
1 O
. O

Use O
of O
glycopyrronium O
5 O
micrograms O
kg O
- O
1 O
provided O
greater O
cardiovascular O
stability O
and O
, O
given O
1 O
min O
before O
the O
edrophonium B
, O
was O
sufficient O
to O
minimize O
early O
, O
edrophonium B
- O
induced O
bradycardias O
. O

Selective O
injection O
of O
iopentol B
, O
iohexol B
and O
metrizoate B
into O
the O
left O
coronary O
artery O
of O
the O
dog O
. O

In O
twenty O
beagle O
dogs O
selective O
injections O
were O
made O
into O
the O
left O
coronary O
artery O
with O
iopentol B
, O
iohexol B
and O
metrizoate B
in O
doses O
of O
4 O
ml O
, O
8 O
ml O
and O
16 O
ml O
. O

Thirty O
- O
six O
iopentol B
injections O
, O
35 O
iohexol B
injections O
and O
37 O
metrizoate B
injections O
were O
made O
. O

Frequencies O
of O
ventricular O
fibrillation O
were O
significantly O
lower O
( O
p O
less O
than O
0 O
. O
05 O
) O
after O
iopentol B
( O
0 O
% O
) O
and O
iohexol B
( O
3 O
% O
) O
than O
after O
metrizoate B
( O
22 O
% O
) O
. O

Iopentol B
and O
iohexol B
also O
produced O
significantly O
less O
decrease O
in O
aortic O
blood O
pressure O
than O
metrizoate B
at O
the O
different O
doses O
. O

Multicenter O
, O
double O
- O
blind O
, O
multiple O
- O
dose O
, O
parallel O
- O
groups O
efficacy O
and O
safety O
trial O
of O
azelastine B
, O
chlorpheniramine B
, O
and O
placebo O
in O
the O
treatment O
of O
spring O
allergic O
rhinitis O
. O

Azelastine B
, O
a O
novel O
antiallergic O
medication O
, O
was O
compared O
with O
chlorpheniramine B
maleate I
and O
placebo O
for O
efficacy O
and O
safety O
in O
the O
treatment O
of O
spring O
allergic O
rhinitis O
in O
a O
multicenter O
, O
double O
- O
blind O
, O
multiple O
- O
dose O
, O
parallel O
- O
groups O
study O
. O

Medications O
were O
given O
four O
times O
daily O
; O
the O
azelastine B
groups O
received O
0 O
. O
5 O
, O
1 O
. O
0 O
, O
or O
2 O
. O
0 O
mg O
in O
the O
morning O
and O
evening O
with O
placebo O
in O
the O
early O
and O
late O
afternoon O
; O
the O
chlorpheniramine B
group O
received O
4 O
. O
0 O
mg O
four O
times O
daily O
. O

Symptoms O
relief O
in O
the O
group O
receiving O
the O
highest O
concentration O
of O
azelastine B
( O
2 O
. O
0 O
mg O
twice O
daily O
) O
was O
statistically O
greater O
than O
in O
the O
placebo O
group O
during O
all O
weeks O
of O
the O
study O
. O

Lower O
doses O
of O
azelastine B
were O
statistically O
more O
effective O
than O
placebo O
only O
during O
portions O
of O
the O
first O
3 O
weeks O
of O
the O
study O
. O

In O
contrast O
, O
although O
the O
chlorpheniramine B
group O
did O
have O
fewer O
symptoms O
than O
the O
placebo O
group O
during O
the O
study O
, O
the O
difference O
never O
reached O
statistical O
significance O
during O
any O
week O
of O
the O
study O
. O

Drowsiness O
and O
altered O
taste O
perception O
were O
increased O
significantly O
over O
placebo O
only O
in O
the O
high O
- O
dose O
azelastine B
group O
. O

Azelastine B
appears O
to O
be O
a O
safe O
, O
efficacious O
medication O
for O
seasonal O
allergic O
rhinitis O
. O

A O
strong O
association O
has O
been O
found O
between O
nephritis O
and O
dermatitis O
due O
to O
Tiopronin B
( O
a O
D O
- O
Penicillamine O
like O
compound O
) O
and O
class O
I O
antigens O
B35 O
- O
Cw4 O
, O
and O
between O
dermatitis O
due O
to O
gold B
thiosulphate B
and O
B35 O
. O

Compared O
to O
healthy O
controls O
a O
lower O
DR5 O
frequency O
was O
observed O
in O
patients O
with O
RA O
except O
for O
the O
Tiopronin B
related O
nephritis O
group O
. O

Mitomycin B
C I
associated O
hemolytic O
uremic O
syndrome O
. O

Mitomycin B
C I
associated O
Hemolytic O
Uremic O
Syndrome O
( O
HUS O
) O
is O
a O
potentially O
fatal O
but O
uncommon O
condition O
that O
is O
not O
yet O
widely O
recognised O
. O

It O
consists O
of O
microangiopathic O
hemolytic O
anemia O
, O
thrombocytopenia O
and O
progressive O
renal O
failure O
associated O
with O
mitomycin B
C I
treatment O
and O
affects O
about O
10 O
% O
of O
patients O
treated O
with O
this O
agent O
. O

The O
renal O
failure O
usually O
develops O
about O
8 O
- O
10 O
mth O
after O
start O
of O
mitomycin B
C I
treatment O
and O
the O
mortality O
is O
approximately O
60 O
% O
from O
renal O
failure O
or O
pulmonary O
edema O
. O

The O
mechanism O
of O
action O
is O
postulated O
as O
mitomycin B
C I
- O
induced O
endothelial O
cell O
damage O
. O

We O
describe O
the O
clinical O
course O
and O
pathological O
findings O
in O
a O
65 O
yr O
- O
old O
man O
with O
gastric O
adenocarcinoma O
who O
developed O
renal O
failure O
and O
thrombocytopenia O
while O
on O
treatment O
with O
mitomycin B
C I
and O
died O
in O
pulmonary O
edema O
. O

Ketanserin B
pretreatment O
reverses O
alfentanil O
- O
induced O
muscle O
rigidity O
. O

Systemic O
pretreatment O
with O
ketanserin B
, O
a O
relatively O
specific O
type O
- O
2 O
serotonin O
receptor O
antagonist O
, O
significantly O
attenuated O
the O
muscle O
rigidity O
produced O
in O
rats O
by O
the O
potent O
short O
- O
acting O
opiate O
agonist O
alfentanil O
. O

Intraperitoneal O
ketanserin B
administration O
at O
doses O
of O
0 O
. O
63 O
and O
2 O
. O
5 O
mg O
/ O
kg O
prevented O
the O
alfentanil O
- O
induced O
increase O
in O
electromyographic O
activity O
compared O
with O
animals O
pretreated O
with O
saline O
. O

Chlordiazepoxide B
at O
doses O
up O
to O
10 O
mg O
/ O
kg O
failed O
to O
significantly O
influence O
the O
rigidity O
produced O
by O
alfentanil O
. O

Despite O
the O
absence O
of O
rigidity O
, O
animals O
that O
received O
ketanserin B
( O
greater O
than O
0 O
. O
31 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
followed O
by O
alfentanil O
were O
motionless O
, O
flaccid O
, O
and O
less O
responsive O
to O
external O
stimuli O
than O
were O
animals O
receiving O
alfentanil O
alone O
. O

Rats O
that O
received O
ketanserin B
and O
alfentanil O
exhibited O
less O
rearing O
and O
exploratory O
behavior O
at O
the O
end O
of O
the O
60 O
- O
min O
recording O
period O
than O
did O
animals O
that O
received O
ketanserin B
alone O
. O

Co O
- O
carcinogenic O
effect O
of O
retinyl B
acetate I
on O
forestomach O
carcinogenesis O
of O
male O
F344 O
rats O
induced O
with O
butylated B
hydroxyanisole I
. O

The O
potential O
modifying O
effect O
of O
retinyl B
acetate I
( O
RA O
) O
on O
butylated B
hydroxyanisole I
( O
BHA B
) O
- O
induced O
rat O
forestomach O
tumorigenesis O
was O
examined O
. O

Male O
F344 O
rats O
, O
5 O
weeks O
of O
age O
, O
were O
maintained O
on O
diet O
containing O
1 O
% O
or O
2 O
% O
BHA B
by O
weight O
and O
simultaneously O
on O
drinking O
water O
supplemented O
with O
RA O
at O
various O
concentrations O
( O
w O
/ O
v O
) O
for O
52 O
weeks O
. O

In O
groups O
given O
2 O
% O
BHA B
, O
although O
marked O
hyperplastic O
changes O
of O
the O
forestomach O
epithelium O
were O
observed O
in O
all O
animals O
, O
co O
- O
administration O
of O
0 O
. O
25 O
% O
RA O
significantly O
( O
P O
less O
than O
0 O
. O
05 O
) O
increased O
the O
incidence O
of O
forestomach O
tumors O
( O
squamous O
cell O
papilloma O
and O
carcinoma O
) O
to O
60 O
% O
( O
9 O
/ O
15 O
, O
2 O
rats O
with O
carcinoma O
) O
from O
15 O
% O
( O
3 O
/ O
20 O
, O
one O
rat O
with O
carcinoma O
) O
in O
the O
group O
given O
RA O
- O
free O
water O
. O

In O
rats O
given O
1 O
% O
BHA B
, O
RA O
co O
- O
administered O
at O
a O
dose O
of O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
0 O
. O
2 O
or O
0 O
. O
25 O
% O
showed O
a O
dose O
- O
dependent O
enhancing O
effect O
on O
the O
development O
of O
the O
BHA B
- O
induced O
epithelial O
hyperplasia O
. O

These O
findings O
indicate O
that O
RA O
acted O
as O
a O
co O
- O
carcinogen O
in O
the O
BHA B
forestomach O
carcinogenesis O
of O
the O
rat O
. O

A O
prospective O
study O
on O
the O
dose O
dependency O
of O
cardiotoxicity O
induced O
by O
mitomycin B
C I
. O

Since O
1975 O
mitomycin B
C I
( O
MMC B
) O
has O
been O
suggested O
to O
be O
cardiotoxic O
, O
especially O
when O
combined O
with O
or O
given O
following O
doxorubicin O
. O

Forty O
- O
four O
MMC B
- O
treated O
patients O
were O
studied O
, O
37 O
of O
them O
could O
be O
evaluated O
. O

One O
of O
the O
patients O
developed O
cardiac O
failure O
after O
30 O
mg O
m O
- O
2 O
MMC B
and O
only O
150 O
mg O
m O
- O
2 O
doxorubicin O
. O

Based O
on O
the O
combined O
data O
from O
the O
present O
study O
and O
the O
literature O
, O
we O
suggest O
that O
MMC B
- O
related O
cardiotoxicity O
is O
dose O
dependent O
, O
occurring O
at O
cumulative O
dose O
levels O
of O
30 O
mg O
m O
- O
2 O
or O
more O
, O
mainly O
in O
patients O
also O
( O
previously O
or O
simultaneously O
) O
treated O
with O
doxorubicin O
. O

Reversible O
cerebral O
lesions O
associated O
with O
tiazofurin B
usage O
: O
MR O
demonstration O
. O

Tiazofurin B
is O
an O
experimental O
chemotherapeutic O
agent O
currently O
undergoing O
clinical O
evaluation O
. O

At O
the O
end O
of O
each O
pretreatment O
period O
, O
animals O
were O
used O
for O
( O
i O
) O
determining O
their O
locomotor O
response O
to O
acutely O
injected O
nicotine O
( O
0 O
. O
2 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
and O
( O
ii O
) O
measuring O
the O
density O
of O
L O
- O
[ O
3H O
] O
nicotine O
and O
[ O
3H O
] O
spiperone B
binding O
sites O
in O
the O
striatum O
. O

We O
observed O
no O
changes O
in O
nicotine O
- O
induced O
locomotor O
response O
, O
striatal O
L O
- O
[ O
3H O
] O
nicotine O
and O
[ O
3H O
] O
spiperone B
binding O
in O
the O
animals O
pretreated O
with O
nicotine O
for O
1 O
day O
. O

The O
number O
of O
striatal O
[ O
3H O
] O
spiperone B
binding O
sites O
was O
not O
affected O
. O

However O
, O
this O
response O
was O
correlated O
with O
an O
elevated O
number O
of O
striatal O
[ O
3H O
] O
spiperone B
binding O
sites O
, O
whereas O
the O
number O
of O
striatal O
L O
- O
[ O
3H O
] O
nicotine O
binding O
sites O
and O
the O
striatal O
DA O
level O
were O
normal O
. O

Amelioration O
of O
bendrofluazide B
- O
induced O
hypokalemia O
by O
timolol O
. O

The O
beta O
adrenergic O
blocking O
drug O
, O
timolol O
, O
tended O
to O
correct O
the O
hypokalemia O
of O
short O
- O
term O
bendrofluazide B
treatment O
in O
6 O
healthy O
male O
subjects O
and O
although O
the O
effect O
was O
small O
it O
was O
significant O
. O

Timolol O
also O
reduced O
the O
rise O
in O
plasma O
aldosterone O
and O
urine O
potassium O
excretion O
following O
bendrofluazide B
and O
increased O
the O
urine O
sodium O
/ O
potassium O
ratio O
. O

A O
rare O
case O
of O
morbid O
vasospasm O
, O
together O
with O
striking O
angiographic O
findings O
, O
is O
described O
secondary O
to O
the O
ingestion O
of O
methysergide B
by O
a O
48 O
- O
year O
- O
old O
woman O
. O

A O
discussion O
of O
the O
history O
of O
ergot B
includes O
its O
original O
discovery O
, O
the O
epidemics O
of O
gangrene O
that O
it O
has O
caused O
through O
the O
ages O
and O
its O
past O
and O
present O
role O
in O
the O
management O
of O
migraine O
headache O
. O

Despite O
the O
advent O
of O
calcium O
channel O
blockers O
and O
beta O
- O
adrenergic O
antagonists O
, O
ergot B
preparations O
continue O
to O
play O
a O
major O
role O
in O
migraine O
therapy O
, O
so O
that O
the O
danger O
of O
St O
. O

Ethopropazine B
and O
benztropine B
in O
neuroleptic O
- O
induced O
parkinsonism O
. O

In O
a O
12 O
- O
week O
controlled O
study O
ethopropazine B
was O
compared O
to O
benztropine B
in O
the O
treatment O
of O
parkinsonism O
induced O
by O
fluphenazine B
enanthate I
in O
60 O
schizophrenic O
outpatients O
. O

Ethopropazine B
and O
benztropine B
were O
found O
to O
be O
equally O
effective O
in O
controlling O
parkinsonian O
symptoms O
and O
were O
as O
efficacious O
as O
procyclidine B
, O
their O
previous O
antiparkinsonian O
drug O
. O

However O
, O
benztropine B
treated O
patients O
had O
a O
significant O
increase O
in O
tardive O
dyskinesia O
compared O
to O
their O
condition O
during O
procyclindine B
treatment O
, O
and O
significantly O
more O
anxiety O
and O
depression O
than O
ethopropazine B
treated O
patients O
. O

This O
suggests O
that O
benztropine B
is O
not O
the O
anticholinergic O
drug O
of O
choice O
in O
the O
treatment O
of O
neuroleptic O
- O
induced O
parkinsonian O
symptoms O
, O
because O
of O
its O
more O
toxic O
central O
and O
peripheral O
atropinic O
effect O
. O

Quinidine B
phenylethylbarbiturate I
- O
induced O
fulminant O
hepatitis O
in O
a O
pregnant O
woman O
. O

We O
report O
the O
case O
of O
a O
19 O
- O
year O
- O
old O
Laotian O
patient O
affected O
by O
fulminant O
hepatitis O
during O
the O
third O
trimester O
of O
her O
pregnancy O
after O
a O
1 O
- O
month O
administration O
of O
quinidine B
phenylethylbarbiturate I
. O

Quinidine B
itself O
or O
phenylethylbarbiturate B
may O
be O
responsible O
for O
fulminant O
hepatitis O
in O
this O
patient O
. O

Recent O
preclinical O
and O
clinical O
studies O
with O
the O
thymidylate O
synthase O
inhibitor O
N10 B
- I
propargyl I
- I
5 I
, I
8 I
- I
dideazafolic I
acid I
( O
CB B
3717 I
) O
. O

CB B
3717 I
, O
N10 B
- I
propargyl I
- I
5 I
, I
8 I
- I
dideazafolic I
acid I
, O
is O
a O
tight O
- O
binding O
inhibitor O
of O
thymidylate O
synthase O
( O
TS O
) O
whose O
cytotoxicity O
is O
mediated O
solely O
through O
the O
inhibition O
of O
this O
enzyme O
. O

Recent O
preclinical O
studies O
have O
focused O
on O
the O
intracellular O
formation O
of O
CB B
3717 I
polyglutamates O
. O

Following O
a O
12 O
- O
hour O
exposure O
of O
L1210 O
cells O
to O
50 O
microM O
[ O
3H O
] O
CB B
3717 I
, O
30 O
% O
of O
the O
extractable O
radioactivity O
could O
be O
accounted O
for O
as O
CB B
3717 I
tetra O
- O
and O
pentaglutamate O
, O
as O
determined O
by O
high O
- O
pressure O
liquid O
chromatography O
( O
HPLC O
) O
analyses O
. O

As O
inhibitors O
of O
isolated O
L1210 O
TS O
, O
CB O
3717 O
di O
- O
, O
tri O
- O
, O
tetra O
- O
and O
pentaglutamate O
are O
26 O
- O
, O
87 O
- O
, O
119 O
- O
and O
114 O
- O
fold O
more O
potent O
than O
CB B
3717 I
, O
respectively O
, O
and O
their O
formation O
may O
, O
therefore O
, O
be O
an O
important O
determinant O
of O
CB B
3717 I
cytotoxicity O
. O

In O
early O
clinical O
studies O
with O
CB B
3717 I
, O
activity O
has O
been O
seen O
in O
breast O
cancer O
, O
ovarian O
cancer O
, O
hepatoma O
, O
and O
mesothelioma O
. O

This O
latter O
effect O
is O
thought O
to O
be O
due O
to O
drug O
precipitation O
within O
the O
renal O
tubule O
as O
a O
result O
of O
the O
poor O
solubility O
of O
CB B
3717 I
under O
acidic O
conditions O
. O

In O
an O
attempt O
to O
overcome O
this O
problem O
, O
a O
clinical O
trial O
of O
CB B
3717 I
administered O
with O
alkaline O
diuresis O
is O
under O
way O
. O

Pharmacokinetic O
investigations O
have O
shown O
that O
alkaline O
diuresis O
does O
not O
alter O
CB B
3717 I
plasma O
levels O
or O
urinary O
excretion O
and O
that O
satisfactory O
urinary O
alkalinization O
can O
be O
readily O
achieved O
. O

More O
than O
50 O
% O
of O
Lobund O
- O
Wistar O
( O
L O
- O
W O
) O
strain O
rats O
developed O
large O
, O
palpable O
prostate O
adenocarcinomas O
( O
PAs O
) O
following O
treatments O
with O
N O
- O
nitroso O
- O
N O
- O
methylurea O
( O
CAS O
: O
684 O
- O
93 O
- O
5 O
) O
and O
testosterone B
propionate I
[ O
( O
TP B
) O
CAS O
: O
57 O
- O
85 O
- O
2 O
] O
, O
and O
most O
of O
the O
tumor O
- O
bearing O
rats O
manifested O
metastatic O
lesions O
. O

Within O
the O
same O
timeframe O
, O
no O
L O
- O
W O
rat O
developed O
a O
similar O
palpable O
PA O
when O
treated O
only O
with O
TP B
. O

In O
L O
- O
W O
rats O
, O
TP B
acted O
as O
a O
tumor O
enhancement O
agent O
, O
with O
primary O
emphasis O
on O
the O
development O
of O
prostate O
cancer O
. O

Relative O
efficacy O
and O
toxicity O
of O
netilmicin B
and O
tobramycin O
in O
oncology O
patients O
. O

We O
prospectively O
compared O
the O
efficacy O
and O
safety O
of O
netilmicin B
sulfate I
or O
tobramycin O
sulfate O
in O
conjunction O
with O
piperacillin B
sodium I
in O
118 O
immunocompromised O
patients O
with O
presumed O
severe O
infections O
. O

Nephrotoxicity O
occurred O
in O
a O
similar O
proportion O
in O
patients O
treated O
with O
netilmicin B
and O
tobramycin O
( O
17 O
% O
vs O
11 O
% O
) O
. O

Ototoxicity O
occurred O
in O
four O
( O
9 O
. O
5 O
% O
) O
of O
42 O
netilmicin B
and O
piperacillin B
and O
in O
12 O
( O
22 O
% O
) O
of O
54 O
tobramycin O
and O
piperacillin B
- O
treated O
patients O
. O

Of O
those O
evaluated O
with O
posttherapy O
audiograms O
, O
three O
of O
four O
netilmicin B
and O
piperacillin B
- O
treated O
patients O
had O
auditory O
thresholds O
return O
to O
baseline O
compared O
with O
one O
of O
nine O
tobramycin O
and O
piperacillin B
- O
treated O
patients O
. O

The O
number O
of O
greater O
than O
or O
equal O
to O
15 O
- O
dB O
increases O
in O
auditory O
threshold O
as O
a O
proportion O
of O
total O
greater O
than O
or O
equal O
to O
15 O
- O
dB O
changes O
( O
increases O
and O
decreases O
) O
was O
significantly O
lower O
in O
netilmicin B
and O
piperacillin B
- O
vs O
tobramycin O
and O
piperacillin B
- O
treated O
patients O
( O
18 O
of O
78 O
vs O
67 O
of O
115 O
) O
. O

We O
conclude O
that O
aminoglycoside O
- O
associated O
ototoxicity O
was O
less O
severe O
and O
more O
often O
reversible O
with O
netilmicin B
than O
with O
tobramycin O
. O

Acute O
experimental O
models O
of O
renal O
damage O
to O
the O
proximal O
tubular O
, O
glomerular O
, O
and O
papillary O
regions O
of O
the O
rat O
were O
produced O
by O
administration O
of O
hexachloro B
- I
1 I
: I
3 I
- I
butadiene I
( O
HCBD B
) O
, O
puromycin O
aminonucleoside O
( O
PAN O
) O
, O
and O
2 B
- I
bromoethylamine I
( O
BEA B
) O
, O
respectively O
. O

Tubular O
damage O
produced O
by O
HCBD B
or O
BEA B
was O
discriminated O
both O
quantitatively O
and O
qualitatively O
from O
glomerular O
damage O
produced O
by O
PAN O
. O

Proximal O
tubular O
damage O
caused O
by O
HCBD B
and O
papillary O
damage O
caused O
by O
BEA B
were O
distinguished O
both O
by O
conventional O
urinalysis O
( O
volume O
and O
specific O
gravity O
) O
and O
by O
measurement O
of O
the O
two O
urinary O
enzymes O
. O

Aspirin O
or O
salicylate B
ingestion O
had O
occurred O
in O
only O
one O
of O
the O
20 O
cases O
( O
5 O
% O
) O
, O
and O
paracetamol O
( O
acetaminophen O
) O
had O
been O
administered O
in O
only O
six O
of O
the O
cases O
( O
30 O
% O
) O
. O

Reye O
syndrome O
may O
be O
disappearing O
from O
Australia O
despite O
a O
total O
lack O
of O
association O
with O
salicylates B
or O
aspirin O
ingestion O
, O
since O
there O
were O
no O
cases O
found O
at O
The O
Children O
' O
s O
Hospital O
in O
1983 O
, O
1984 O
, O
or O
1985 O
. O

Thus O
, O
myocardial O
electrical O
excitability O
was O
measured O
in O
patients O
with O
mild O
essential O
hypertension O
and O
known O
coronary O
artery O
disease O
after O
8 O
weeks O
of O
treatment O
with O
a O
potassium O
- O
conserving O
diuretic O
( O
amiloride O
) O
and O
a O
similar O
period O
on O
a O
potassium O
- O
losing O
diuretic O
( O
chlorthalidone B
) O
in O
a O
randomised O
study O
. O

Plasma O
potassium O
concentrations O
were O
on O
average O
1 O
mmol O
/ O
L O
lower O
during O
the O
chlorthalidone B
phase O
compared O
to O
amiloride O
therapy O
. O

Compared O
to O
amiloride O
treatment O
, O
the O
chlorthalidone B
phase O
was O
associated O
with O
an O
increased O
frequency O
of O
ventricular O
ectopic O
beats O
( O
24 O
- O
hour O
Holter O
monitoring O
) O
and O
a O
higher O
Lown O
grading O
, O
increased O
upslope O
and O
duration O
of O
the O
monophasic O
action O
potential O
, O
prolonged O
ventricular O
effective O
refractory O
period O
, O
and O
increased O
electrical O
instability O
during O
programmed O
ventricular O
stimulation O
. O

Transketolase O
abnormality O
in O
tolazamide B
- O
induced O
Wernicke O
' O
s O
encephalopathy O
. O

We O
studied O
a O
thiamine O
- O
dependent O
enzyme O
, O
transketolase O
, O
from O
fibroblasts O
of O
a O
diabetic O
patient O
who O
developed O
Wernicke O
' O
s O
encephalopathy O
when O
treated O
with O
tolazamide B
, O
in O
order O
to O
delineate O
if O
this O
patient O
also O
had O
transketolase O
abnormality O
[ O
high O
Km O
for O
thiamine B
pyrophosphate I
( O
TPP B
) O
] O
, O
as O
previously O
reported O
in O
postalcoholic O
Wernicke O
- O
Korsakoff O
syndrome O
. O

We O
found O
that O
the O
above O
- O
mentioned O
patient O
and O
one O
of O
the O
diabetic O
kindreds O
with O
no O
history O
of O
Wernicke O
' O
s O
encephalopathy O
had O
abnormal O
transketolase O
as O
determined O
by O
its O
Km O
for O
TPP B
. O

These O
data O
suggest O
a O
similarity O
between O
postalcoholic O
Wernicke O
- O
Korsakoff O
syndrome O
and O
the O
patient O
with O
tolazamide B
- O
induced O
Wernicke O
' O
s O
encephalopathy O
from O
the O
standpoint O
of O
transketolase O
abnormality O
. O

Anti O
- O
carcinogenic O
action O
of O
phenobarbital O
given O
simultaneously O
with O
diethylnitrosamine B
in O
the O
rat O
. O

The O
present O
work O
has O
been O
planned O
in O
order O
to O
elucidate O
the O
effect O
of O
phenobarbital O
( O
PB O
: O
15 O
mg O
per O
rat O
of O
ingested O
dose O
) O
on O
carcinogenesis O
when O
it O
is O
administered O
simultaneously O
with O
diethylnitrosamine B
( O
DEN B
: O
10 O
mg O
/ O
kg O
/ O
day O
) O
. O

Wistar O
rats O
( O
180 O
g O
) O
were O
treated O
by O
DEN B
alone O
or O
by O
DEN B
+ O
PB O
during O
2 O
, O
4 O
and O
6 O
weeks O
according O
to O
our O
schedule O
for O
hepatocarcinogenesis O
. O

After O
the O
end O
of O
the O
treatment O
, O
the O
number O
and O
the O
size O
of O
induced O
PAS O
positive O
preneoplastic O
foci O
was O
significantly O
reduced O
when O
PB O
was O
given O
simultaneously O
with O
DEN B
for O
4 O
and O
6 O
weeks O
. O

The O
mitotic O
inhibition O
and O
the O
production O
of O
micronuclei O
normally O
observed O
after O
partial O
hepatectomy O
in O
DEN B
treated O
rats O
were O
also O
significantly O
decreased O
in O
DEN B
+ O
PB O
treated O
rats O
. O

In O
DEN B
+ O
PB O
treated O
rats O
, O
the O
survival O
was O
prolonged O
and O
the O
tumor O
incidence O
decreased O
as O
compared O
with O
the O
results O
obtained O
by O
DEN B
alone O
. O

It O
is O
concluded O
that O
PB O
, O
which O
promotes O
carcinogenesis O
when O
administered O
after O
the O
DEN B
treatment O
, O
reduces O
the O
carcinogen O
effect O
when O
given O
simultaneously O
with O
DEN B
. O

Bilateral O
optic O
neuropathy O
due O
to O
combined O
ethambutol B
and O
isoniazid O
treatment O
. O

The O
case O
of O
a O
40 O
- O
year O
- O
old O
patient O
who O
underwent O
an O
unsuccessful O
cadaver O
kidney O
transplantation O
and O
was O
treated O
with O
ethambutol B
and O
isoniazid O
is O
reported O
. O

Ethambutol B
was O
stopped O
and O
only O
small O
improvement O
of O
the O
visual O
acuity O
followed O
. O

The O
hazards O
of O
optic O
nerve O
toxicity O
due O
to O
ethambutol B
are O
known O
. O

We O
emphasize O
the O
potential O
danger O
in O
the O
use O
of O
ethambutol B
and O
isoniazid O
. O

Tri B
- I
ortho I
- I
tolyl I
phosphate I
( O
TOTP B
) O
, O
360 O
mg O
/ O
kg O
, O
po O
, O
and O
0 O
, O
0 O
' O
- O
diisopropyl O
phosphorofluoridate O
( O
DFP O
) O
, O
1 O
mg O
/ O
kg O
sc O
, O
were O
administered O
to O
adult O
White O
Leghorn O
chickens O
24 O
hr O
after O
they O
were O
placed O
on O
diets O
containing O
0 O
to O
300 O
ppm O
corticosterone O
. O

Although O
low O
concentrations O
( O
less O
than O
or O
equal O
to O
50 O
ppm O
) O
of O
corticosterone O
had O
beneficial O
effects O
on O
TOTP B
- O
induced O
neuropathy O
, O
greater O
than O
or O
equal O
to O
200 O
ppm O
exacerbated O
clinical O
signs O
in O
chickens O
given O
either O
TOTP B
or O
DFP O
. O

Neurotoxic O
esterase O
activities O
24 O
hr O
after O
TOTP B
or O
DFP O
were O
less O
than O
20 O
% O
of O
values O
measured O
in O
chickens O
not O
given O
organophosphorous O
compounds O
. O

Chickens O
given O
200 O
ppm O
corticosterone O
without O
TOTP B
or O
DFP O
had O
significantly O
elevated O
activity O
of O
plasma O
cholinesterase O
and O
significantly O
inhibited O
activity O
of O
liver O
carboxylesterase O
. O

Degenerating O
myelinated O
fibers O
were O
also O
evident O
in O
distal O
levels O
of O
the O
peripheral O
nerves O
of O
chickens O
given O
TOTP B
or O
DFP O
. O

Time O
course O
alterations O
of O
QTC O
interval O
due O
to O
hypaque B
76 I
. O

Sequential O
measurement O
of O
QT O
interval O
during O
left O
ventricular O
angiography O
was O
made O
30 O
seconds O
and O
one O
, O
three O
, O
five O
and O
ten O
minutes O
after O
injection O
of O
hypaque B
76 I
. O

Numerous O
periodic B
acid I
Schiff O
( O
PAS O
) O
positive O
, O
diastase O
resistant O
cytoplasmic O
inclusion O
bodies O
which O
appeared O
as O
myelin O
figures O
in O
cytosegresomes O
under O
the O
electron O
microscope O
were O
identified O
in O
the O
proximal O
convoluted O
tubules O
. O

Tiapride B
in O
levodopa O
- O
induced O
involuntary O
movements O
. O

Tiapride B
, O
a O
substituted O
benzamide B
derivative O
closely O
related O
to O
metoclopramide O
, O
reduced O
levodopa O
- O
induced O
peak O
dose O
involuntary O
movements O
in O
16 O
patients O
with O
idiopathic O
Parkinson O
' O
s O
disease O
. O

Tiapride B
had O
no O
effect O
on O
levodopa O
- O
induced O
early O
morning O
of O
" O
off O
- O
period O
" O
segmental O
dystonia O
. O

Quinidine B
hepatitis O
. O

Long O
- O
term O
administration O
of O
quinidine B
was O
associated O
with O
persistent O
elevation O
of O
serum O
concentrations O
of O
SGOT O
, O
lactic O
acid O
dehydrogenase O
, O
and O
alkaline O
phosphatase O
. O

Discontinuance O
of O
quinidine B
therapy O
led O
to O
normalization O
of O
liver O
function O
tests O
. O

A O
challenge O
dose O
of O
quinidine B
caused O
clinical O
symptoms O
and O
abrupt O
elevation O
of O
SGOT O
, O
alkaline O
phosphatase O
, O
and O
lactic O
acid O
dehydrogenase O
values O
. O

We O
concluded O
that O
this O
patient O
had O
quinidine B
hepatotoxicity O
and O
believe O
that O
this O
is O
the O
first O
case O
reported O
with O
liver O
biopsy O
documentation O
. O

Pharmacology O
of O
GYKI B
- I
41 I
099 I
( O
chlorpropanol B
, O
Tobanum B
) O
a O
new O
potent O
beta O
- O
adrenergic O
antagonist O
. O

The O
compound O
GYKI B
- I
41 I
099 I
, O
as O
a O
beta O
- O
adrenergic O
antagonist O
, O
is O
3 O
- O
8 O
times O
more O
potent O
than O
propranolol O
in O
vitro O
and O
in O
vivo O
. O

Its O
antiarrhythmic O
effectiveness O
surpasses O
that O
of O
propranolol O
and O
pindolol B
inhibiting O
the O
ouabain O
arrhythmia O
in O
dogs O
and O
cats O
. O

GYKI B
- I
41 I
900 I
has O
a O
negligible O
cardiodepressant O
activity O
; O
it O
is O
not O
cardioselective O
. O

There O
was O
a O
prolonged O
elimination O
of O
the O
radioactivity O
after O
the O
injection O
of O
14C B
- I
41 I
099 I
to O
rats O
and O
dogs O
. O

Adverse O
reactions O
to O
bendrofluazide B
and O
propranolol O
for O
the O
treatment O
of O
mild O
hypertension O
. O

Participants O
in O
the O
Medical O
Research O
Council O
treatment O
trial O
for O
mild O
hypertension O
are O
randomly O
allocated O
to O
one O
of O
four O
treatment O
groups O
: O
bendrofluazide B
, O
propranolol O
, O
or O
a O
placebo O
for O
either O
of O
these O
drugs O
. O

The O
results O
show O
an O
association O
between O
bendrofluazide B
treatment O
and O
impotence O
, O
and O
impotence O
also O
occurred O
more O
frequently O
in O
patients O
taking O
propranolol O
than O
in O
those O
taking O
placebos O
. O

Other O
adverse O
reactions O
significantly O
linked O
with O
active O
drugs O
include O
impaired O
glucose O
tolerance O
in O
men O
and O
women O
and O
gout O
in O
men O
, O
associated O
with O
bendrofluazide B
treatment O
, O
and O
Raynaud O
' O
s O
phenomenon O
and O
dyspnoea O
in O
men O
and O
women O
taking O
propranolol O
. O

Mean O
serum O
potassium O
level O
fell O
, O
and O
urea O
and O
uric O
acid O
levels O
rose O
, O
in O
men O
and O
women O
taking O
bendrofluazide B
. O

Serotonergic O
drugs O
, O
benzodiazepines O
and O
baclofen B
block O
muscimol B
- O
induced O
myoclonic O
jerks O
in O
a O
strain O
of O
mice O
. O

In O
male O
Swiss O
mice O
, O
muscimol B
produced O
myoclonic O
jerks O
. O

Increasing O
the O
brain O
serotonin O
levels O
by O
the O
administration O
of O
5 O
- O
hydroxytryptophan O
( O
80 O
- O
160 O
mg O
/ O
kg O
) O
in O
combination O
with O
a O
peripheral O
decarboxylase O
inhibitor O
resulted O
in O
an O
inhibition O
of O
the O
muscimol B
effect O
. O

In O
doses O
of O
3 O
- O
10 O
mg O
/ O
kg O
, O
the O
serotonin O
receptor O
agonist O
MK B
- I
212 I
caused O
a O
dose O
- O
dependent O
blockade O
of O
the O
response O
of O
muscimol B
. O

Of O
the O
benzodiazepines O
, O
clonazepam B
( O
0 O
. O
1 O
- O
0 O
. O
3 O
mg O
/ O
kg O
) O
was O
found O
to O
be O
several O
fold O
more O
potent O
than O
diazepam O
( O
0 O
. O
3 O
- O
3 O
mg O
/ O
kg O
) O
in O
blocking O
the O
myoclonic O
jerks O
. O

While O
( O
- O
) O
- O
baclofen B
( O
1 O
- O
3 O
mg O
/ O
kg O
) O
proved O
to O
be O
an O
effective O
antagonist O
of O
muscimol B
, O
its O
( O
+ O
) O
- O
isomer O
( O
5 O
- O
20 O
mg O
/ O
kg O
) O
lacked O
this O
property O
. O

Considering O
the O
fact O
that O
5 O
- O
HTP O
and O
the O
benzodiazepines O
have O
been O
found O
to O
be O
beneficial O
in O
the O
management O
of O
clinical O
myoclonus O
, O
the O
muscimol B
- O
induced O
myoclonus O
seems O
to O
be O
a O
satisfactory O
animal O
model O
that O
may O
prove O
useful O
for O
the O
development O
of O
new O
drug O
treatments O
for O
this O
condition O
. O

Our O
present O
study O
indicated O
the O
possible O
value O
of O
MK B
- I
212 I
and O
( O
- O
) O
- O
baclofen B
in O
the O
management O
of O
clinical O
myoclonus O
. O

Adverse O
interaction O
between O
beta B
- I
adrenergic I
blocking I
drugs I
and O
verapamil O
- O
- O
report O
of O
three O
cases O
. O

Three O
patients O
with O
ischaemic O
heart O
disease O
developed O
profound O
cardiac O
failure O
, O
hypotension O
and O
bradycardia O
during O
combined O
therapy O
with O
verapamil O
and O
beta B
- I
adrenergic I
blocking I
drugs I
. O

Simultaneously O
administration O
of O
beta B
- I
adrenergic I
blocking I
drugs I
and O
verapamil O
may O
result O
in O
profound O
adverse O
interactions O
and O
should O
only O
be O
administered O
with O
great O
caution O
. O

A O
time O
course O
was O
established O
for O
the O
change O
in O
tissue O
mass O
, O
RNA O
and O
DNA O
content O
, O
as O
well O
as O
hydroxyproline B
content O
. O

The O
total O
content O
of O
hydroxyproline B
remained O
stable O
during O
the O
first O
2 O
days O
of O
treatment O
but O
increased O
46 O
% O
after O
4 O
days O
of O
therapy O
. O

One O
case O
of O
acute O
hypercalcaemia O
and O
two O
of O
recurrent O
nephrolithiasis O
are O
reported O
in O
patients O
who O
had O
regularly O
consumed O
large O
amounts O
of O
calcium B
carbon I
- I
ate I
- O
sodium O
bicarbonate O
powders O
for O
more O
than O
20 O
years O
. O

Naloxazone B
pretreatment O
modifies O
cardiorespiratory O
, O
temperature O
, O
and O
behavioral O
effects O
of O
morphine O
. O

Behavioral O
and O
cardiorespiratory O
responses O
to O
a O
lethal O
dose O
of O
morphine O
were O
evaluated O
in O
rats O
pretreated O
with O
saline O
or O
naloxazone B
, O
an O
antagonist O
of O
high O
- O
affinity O
mu O
1 O
opioid O
receptors O
. O

Pretreatment O
with O
naloxazone B
significantly O
blocked O
morphine O
analgesia O
, O
catalepsy O
and O
hypothermia O
at O
a O
dose O
which O
completely O
eliminated O
high O
- O
affinity O
binding O
in O
brain O
membranes O
. O

Moreover O
, O
naloxazone B
significantly O
attenuated O
the O
morphine O
- O
induced O
hypotension O
and O
respiratory O
depression O
, O
whereas O
morphine O
- O
induced O
bradycardia O
was O
less O
affected O
. O

Pretreatment O
with O
ammonium B
acetate I
( O
NH4Ac B
) O
( O
6 O
mmol O
/ O
kg O
s O
. O
c O
. O
) O
approximately O
doubled O
the O
time O
morphine O
- O
treated O
mice O
remained O
on O
a O
hot O
surface O
and O
similarly O
increased O
muscular O
incoordination O
by O
diazepam O
, O
but O
NH4Ac B
treatment O
alone O
had O
no O
effect O
. O

Experiments O
in O
vitro O
showed O
that O
acetylcholine O
- O
induced O
catecholamine O
release O
from O
bovine O
adrenal O
medulla O
is O
depressed O
as O
much O
as O
50 O
% O
by O
0 O
. O
3 O
mM O
NH4Ac B
and O
KCl O
- O
induced O
contractions O
of O
guinea O
- O
pig O
ileum O
were O
inhibited O
20 O
% O
by O
5 O
mM O
NH4Ac B
. O

Addition O
of O
excess O
calcium O
reversed O
the O
depression O
in O
both O
tissues O
, O
but O
calcium O
- O
independent O
catecholamine O
release O
by O
acetaldehyde O
was O
not O
blocked O
by O
NH4Ac B
. O

These O
results O
suggested O
that O
ammonia B
blocks O
calcium O
channels O
. O

Parallels O
in O
the O
actions O
of O
NH4Ac B
and O
the O
calcium O
channel O
blocker O
verapamil O
support O
this O
concept O
. O

Both O
verapamil O
( O
10 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
and O
NH4Ac B
pretreatment O
enhanced O
morphine O
analgesia O
- O
and O
diazepam O
- O
induced O
muscular O
incoordination O
and O
antagonized O
amphetamine O
- O
induced O
motor O
activity O
, O
and O
neither O
verapamil O
nor O
NH4Ac B
affected O
the O
convulsant O
action O
of O
metrazol O
. O

The O
protective O
effect O
of O
oral O
administration O
of O
the O
thiol B
compound O
sodium O
2 O
- O
mercaptoethane O
sulphonate O
( O
MESNA O
) O
against O
urothelial O
toxicity O
induced O
by O
ifosfamide O
( O
IF O
) O
was O
tested O
in O
a O
group O
of O
45 O
patients O
with O
inoperable O
lung O
cancer O
under O
treatment O
with O
IF O
( O
2250 O
mg O
/ O
m2 O
on O
days O
2 O
- O
5 O
) O
as O
part O
of O
a O
polychemotherapy O
regimen O
repeated O
in O
a O
4 O
- O
week O
cycle O
. O

Ibuprofen O
, O
sulindac O
, O
mefenamic B
acid I
, O
and O
low O
dose O
meclofenamic B
acid I
increased O
the O
latency O
- O
to O
- O
onset O
in O
the O
flurothyl O
and O
/ O
or O
PTZ O
models O
; O
the O
electroshock O
, O
picrotoxin O
and O
bicuculline O
models O
were O
not O
significantly O
affected O
by O
any O
of O
the O
pretreatment O
agents O
. O

Acute O
changes O
of O
blood O
ammonia B
may O
predict O
short O
- O
term O
adverse O
effects O
of O
valproic O
acid O
. O

Ammonia B
( O
NH3 B
) O
was O
higher O
in O
patients O
who O
, O
during O
continuous O
therapy O
, O
complained O
of O
drowsiness O
( O
7 O
patients O
) O
than O
in O
those O
who O
were O
symptom O
- O
free O
( O
17 O
patients O
) O
, O
although O
VPA O
plasma O
levels O
were O
similar O
in O
both O
groups O
. O

By O
measuring O
VPA O
- O
induced O
changes O
of O
blood O
NH3 B
content O
, O
it O
may O
be O
possible O
to O
identify O
patients O
at O
higher O
risk O
of O
obtundation O
when O
VPA O
is O
given O
chronically O
. O

However O
, O
ketone B
bodies O
were O
consistently O
present O
in O
urine O
and O
several O
lethalities O
occurred O
during O
multiple O
dosing O
of O
captopril O
in O
SHR O
. O

Complete O
heart O
block O
following O
a O
single O
dose O
of O
trazodone B
. O

Forty O
minutes O
after O
receiving O
a O
single O
starting O
dose O
of O
trazodone B
, O
a O
patient O
developed O
complete O
heart O
block O
. O

The O
case O
illustrates O
that O
, O
despite O
the O
results O
of O
earlier O
studies O
, O
trazodone B
' O
s O
effect O
on O
cardiac O
conduction O
may O
be O
severe O
in O
individuals O
at O
risk O
for O
conduction O
delay O
. O

Serotonin O
and O
N B
- I
acetyl I
serotonin I
which O
augmented O
ketamine O
DOC O
, O
did O
not O
do O
so O
in O
the O
absence O
of O
the O
pineal O
gland O
, O
whereas O
melatonin B
potentiated O
the O
ketamine O
DOC O
in O
both O
the O
intact O
and O
pinealectomized O
chick O
. O

Ketamine O
was O
more O
potent O
in O
the O
hypophysectomized O
chick O
and O
the O
circadian O
rhythm O
noted O
in O
the O
intact O
chick O
was O
absent O
; O
furthermore O
, O
melatonin B
did O
not O
augment O
the O
ketamine O
DOC O
whereas O
dopamine O
continued O
to O
do O
so O
. O

In O
addition O
, O
these O
data O
indicate O
a O
direct O
role O
of O
the O
pituitary O
in O
the O
augmentation O
of O
ketamine O
DOC O
induced O
by O
melatonin B
. O

Ventricular O
fibrillation O
from O
diatrizoate B
with O
and O
without O
chelating O
agents O
. O

The O
toxicity O
of O
Renografin B
76 I
% I
was O
compared O
with O
that O
of O
Hypaque B
76 I
% I
by O
selective O
injection O
of O
each O
into O
the O
right O
coronary O
artery O
of O
dogs O
. O

Renografin B
contains O
the O
chelating O
agents O
sodium O
citrate O
and O
disodium B
edetate I
, O
while O
Hypaque B
contains O
calcium B
disodium I
edetate I
and O
no O
sodium O
citrate O
. O

Ventricular O
fibrillation O
occurred O
significantly O
more O
often O
with O
Renografin B
, O
suggesting O
that O
chelating O
agents O
contribute O
to O
toxicity O
in O
coronary O
angiography O
. O

Why O
may O
epsilon B
- I
aminocaproic I
acid I
( O
EACA B
) O
induce O
myopathy O
in O
man O
? O

A O
case O
of O
necrotizing O
myopathy O
due O
to O
a O
short O
epsilon B
- I
aminocaproic I
acid I
( O
EACA B
) O
treatment O
in O
a O
72 O
year O
- O
old O
patient O
with O
subarachnoid O
haemorrhage O
( O
SAH O
) O
is O
described O
. O

Renal O
papillary O
necrosis O
due O
to O
naproxen B
. O

A O
31 O
- O
year O
- O
old O
man O
with O
rheumatoid O
arthritis O
, O
who O
had O
previously O
been O
treated O
with O
sulindac O
, O
fenoprofen B
calcium I
, O
high O
dose O
salicylates B
and O
gold B
salts O
, O
developed O
renal O
papillary O
necrosis O
( O
RPN O
) O
4 O
months O
after O
institution O
of O
naproxen B
therapy O
. O

Sulindac O
was O
substituted O
for O
naproxen B
and O
no O
further O
adverse O
renal O
effects O
occurred O
over O
the O
next O
12 O
months O
. O

To O
quantify O
the O
effects O
of O
gentamicin O
, O
kanamycin O
and O
netilmicin B
on O
renal O
protein O
reabsorption O
and O
accumulation O
, O
these O
drugs O
were O
administered O
to O
rats O
intraperitoneally O
( O
30 O
mg O
/ O
kg O
/ O
day O
) O
for O
7 O
, O
14 O
or O
21 O
days O
. O

Kanamycin O
and O
netilmicin B
appeared O
to O
have O
no O
effect O
at O
the O
dose O
used O
. O

While O
gentamicin O
and O
kanamycin O
decreased O
the O
percentage O
reabsorption O
and O
accumulation O
of O
lysozyme O
after O
i O
. O
v O
. O
administration O
of O
egg O
- O
white O
lysozyme O
netilmicin B
had O
no O
effect O
. O

Induction O
of O
the O
obstructive O
sleep O
apnea O
syndrome O
in O
a O
woman O
by O
exogenous O
androgen B
administration O
. O

We O
documented O
airway O
occlusion O
during O
sleep O
and O
an O
abnormally O
high O
supraglottic O
resistance O
while O
awake O
in O
a O
54 O
- O
yr O
- O
old O
woman O
who O
had O
developed O
physical O
changes O
and O
the O
syndrome O
of O
obstructive O
sleep O
apnea O
while O
being O
administered O
exogenous O
androgens B
. O

When O
the O
androgens B
were O
withdrawn O
, O
the O
patient O
' O
s O
physical O
changes O
, O
symptoms O
, O
sleep O
study O
, O
and O
supraglottic O
resistance O
all O
returned O
to O
normal O
. O

A O
rechallenge O
with O
androgen B
produced O
symptoms O
of O
obstructive O
sleep O
apnea O
that O
abated O
upon O
withdrawal O
of O
the O
hormone O
. O

Previous O
reports O
have O
favored O
a O
role O
of O
androgens B
in O
the O
pathogenesis O
of O
sleep O
apnea O
. O

Structural O
and O
functional O
measurements O
indicate O
that O
androgens B
exert O
a O
permissive O
or O
necessary O
action O
on O
the O
structural O
configuration O
of O
the O
oropharynx O
that O
predisposes O
to O
obstruction O
during O
sleep O
. O

Development O
of O
the O
obstructive O
sleep O
apnea O
syndrome O
must O
be O
considered O
a O
possible O
side O
effect O
of O
androgen B
therapy O
. O

Effects O
of O
the O
novel O
compound O
aniracetam B
( O
Ro B
13 I
- I
5057 I
) O
upon O
impaired O
learning O
and O
memory O
in O
rodents O
. O

The O
effect O
of O
aniracetam B
( O
Ro B
13 I
- I
5057 I
, O
1 B
- I
anisoyl I
- I
2 I
- I
pyrrolidinone I
) O
was O
studied O
on O
various O
forms O
of O
experimentally O
impaired O
cognitive O
functions O
( O
learning O
and O
memory O
) O
in O
rodents O
and O
produced O
the O
following O
effects O
: O
( O
1 O
) O
almost O
complete O
prevention O
of O
the O
incapacity O
to O
learn O
a O
discrete O
escape O
response O
in O
rats O
exposed O
to O
sublethal O
hypercapnia O
immediately O
before O
the O
acquisition O
session O
; O
( O
2 O
) O
partial O
( O
rats O
) O
or O
complete O
( O
mice O
) O
prevention O
of O
the O
scopolamine O
- O
induced O
short O
- O
term O
amnesia O
for O
a O
passive O
avoidance O
task O
; O
( O
3 O

) O
complete O
protection O
against O
amnesia O
for O
a O
passive O
avoidance O
task O
in O
rats O
submitted O
to O
electroconvulsive O
shock O
immediately O
after O
avoidance O
acquisition O
; O
( O
4 O
) O
prevention O
of O
the O
long O
- O
term O
retention O
- O
or O
retrieval O
- O
deficit O
for O
a O
passive O
avoidance O
task O
induced O
in O
rats O
and O
mice O
by O
chloramphenicol B
or O
cycloheximide O
administered O
immediately O
after O
acquisition O
; O
( O
5 O
) O
reversal O
, O
when O
administered O
as O
late O
as O
1 O
h O
before O
the O
retention O
test O
, O
of O
the O
deficit O
in O
retention O
or O
retrieval O
of O
a O
passive O
avoidance O
task O
induced O
by O
cycloheximide O
injected O
2 O
days O
previously O
; O
( O
6 O
) O

These O
improvements O
or O
normalizations O
of O
impaired O
cognitive O
functions O
were O
seen O
at O
oral O
aniracetam B
doses O
of O
10 O
- O
100 O
mg O
/ O
kg O
. O

The O
mechanisms O
underlying O
the O
activity O
of O
aniracetam B
and O
its O
' O
therapeutic O
window O
' O
are O
unknown O
. O

Piracetam B
, O
another O
pyrrolidinone B
derivative O
was O
used O
for O
comparison O
. O

It O
was O
active O
only O
in O
six O
of O
nine O
tests O
and O
had O
about O
one O
- O
tenth O
the O
potency O
of O
aniracetam B
. O

The O
results O
indicate O
that O
aniracetam B
improves O
cognitive O
functions O
which O
are O
impaired O
by O
different O
procedure O
and O
in O
different O
phases O
of O
the O
learning O
and O
memory O
process O
. O

We O
treated O
38 O
patients O
( O
22 O
low O
renin O
, O
16 O
normal O
renin O
) O
with O
moderate O
diastolic O
hypertension O
with O
hydrochlorothiazide B
( O
HCTC B
) O
administered O
on O
a O
twice O
daily O
schedule O
. O

The O
serum O
K O
during O
the O
control O
period O
was O
4 O
. O
5 O
+ O
/ O
- O
0 O
. O
2 O
mEq O
/ O
l O
an O
on O
50 O
, O
100 O
, O
150 O
and O
200 O
mg O
HCTZ B
daily O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
3 O
, O
3 O
. O
4 O
+ O
/ O
- O
0 O
. O
2 O
, O
2 O
. O
9 O
+ O
/ O
- O
0 O
. O
2 O
, O
and O
2 O
. O
4 O
+ O
/ O
- O
0 O
. O
3 O
mEq O
/ O
l O
, O
respectively O
. O

In O
13 O
patients O
we O
observed O
the O
effects O
of O
HCTZ B
therapy O
( O
100 O
mg O
daily O
) O
on O
the O
occurrence O
of O
PVC O
' O
s O
during O
rest O
as O
well O
as O
during O
static O
and O
dynamic O
exercise O
. O

Corresponding O
figures O
during O
HCTZ B
therapy O
100 O
mg O
daily O
were O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
1 O
, O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
7 O
and O
5 O
. O
7 O
4 O
/ O
- O
0 O
. O
8 O
, O
respectively O
. O

Hepatic O
veno O
- O
occlusive O
disease O
caused O
by O
6 B
- I
thioguanine I
. O

Clinically O
reversible O
veno O
- O
occlusive O
disease O
of O
the O
liver O
developed O
in O
a O
23 O
- O
year O
- O
old O
man O
with O
acute O
lymphocytic O
leukemia O
after O
10 O
months O
of O
maintenance O
therapy O
with O
6 B
- I
thioguanine I
. O

This O
case O
presented O
a O
unique O
opportunity O
to O
observe O
the O
histologic O
features O
of O
clinically O
reversible O
hepatic O
veno O
- O
occlusive O
disease O
over O
time O
, O
and O
may O
be O
the O
first O
case O
of O
veno O
- O
occlusive O
related O
solely O
to O
6 B
- I
thioguanine I
. O

Chlorpropamide B
- O
induced O
optic O
neuropathy O
. O

A O
65 O
- O
year O
- O
old O
woman O
with O
adult O
- O
onset O
diabetes O
treated O
with O
chlorpropamide B
( O
Diabenese B
) O
had O
a O
toxic O
optic O
neuropathy O
that O
resolved O
with O
discontinuation O
of O
chlorpropamide B
therapy O
. O

In O
pre O
- O
nephrotic O
stage O
the O
plasma O
level O
of O
fatty B
acids I
, O
triacylglycerol B
and O
VLDL O
decreased O
while O
that O
of O
phospholipid O
, O
cholesteryl O
esters O
and O
HDL O
remained O
constant O
. O

Fatal O
aplastic O
anemia O
following O
topical O
administration O
of O
ophthalmic O
chloramphenicol B
. O

A O
73 O
- O
year O
- O
old O
woman O
died O
of O
aplastic O
anemia O
less O
than O
two O
months O
after O
undergoing O
cataract O
extraction O
and O
beginning O
topical O
therapy O
with O
chloramphenicol B
. O

The O
pattern O
of O
the O
aplastic O
anemia O
was O
associated O
with O
an O
idiosyncratic O
response O
to O
chloramphenicol B
. O

This O
was O
the O
second O
report O
of O
fatal O
aplastic O
anemia O
after O
topical O
treatment O
with O
chloramphenicol B
for O
ocular O
conditions O
, O
although O
two O
cases O
of O
reversible O
bone O
marrow O
hypoplasia O
have O
also O
been O
reported O
. O

Any O
other O
suspected O
cases O
of O
ocular O
toxicity O
associated O
with O
topically O
applied O
chloramphenicol B
should O
be O
reported O
to O
the O
National O
Registry O
of O
Drug O
- O
Induced O
Ocular O
Side O
Effects O
, O
Oregon O
Health O
Sciences O
University O
, O
Portland O
, O
OR O
97201 O
. O

Akathisia O
was O
controlled O
by O
the O
benzodiazepine O
lorazepam B
in O
14 O
out O
of O
16 O
patients O
, O
while O
prophylactic O
antiparkinsonians O
were O
ineffective O
. O

The O
effects O
of O
REM O
sleep O
deprivation O
( O
REMD O
) O
on O
apomorphine O
- O
induced O
aggressiveness O
and O
quipazine B
- O
induced O
head O
twitches O
in O
rats O
were O
determined O
. O

Forty O
- O
eight O
hr O
of O
REMD O
increased O
apomorphine O
- O
induced O
aggressiveness O
, O
and O
reduced O
( O
immediately O
after O
completing O
of O
REMD O
) O
or O
increased O
( O
96 O
hr O
after O
completing O
of O
REMD O
) O
quipazine B
- O
induced O
head O
twitches O
. O

Subjective O
assessment O
of O
sexual O
dysfunction O
of O
patients O
on O
long O
- O
term O
administration O
of O
digoxin B
. O

Various O
data O
suggest O
that O
male O
patients O
who O
have O
received O
digoxin B
on O
a O
longterm O
basis O
have O
increased O
levels O
of O
serum O
estrogen O
and O
decreased O
levels O
of O
plasma O
testosterone O
and O
luteinizing O
hormone O
( O
LH O
) O
. O

This O
study O
was O
undertaken O
to O
investigate O
the O
links O
between O
the O
long O
- O
term O
administration O
of O
digoxin B
therapy O
and O
sexual O
behavior O
, O
and O
the O
effect O
of O
digoxin B
on O
plasma O
levels O
of O
estradiol O
, O
testosterone O
, O
and O
LH O
. O

The O
patients O
of O
the O
study O
and O
control O
group O
( O
without O
digoxin B
) O
were O
of O
similar O
cardiac O
functional O
capacity O
and O
age O
( O
25 O
- O
40 O
years O
) O
and O
were O
randomly O
selected O
from O
the O
rheumatic O
heart O
disease O
patients O
. O

The O
findings O
support O
the O
reports O
concerning O
digoxin B
effect O
on O
plasma O
estradiol O
, O
testosterone O
, O
and O
LH O
. O

Cyclosporin O
A O
( O
CsA O
; O
50 O
mg O
/ O
kg O
) O
and O
Fujimycine O
( O
FK506 O
; O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
the O
related O
macrolide B
immunosuppressant O
rapamycin O
( O
5 O
mg O
/ O
kg O
) O
, O
caused O
a O
reduction O
of O
glomerular O
filtration O
rate O
, O
degenerative O
changes O
of O
proximal O
tubular O
epithelium O
, O
and O
hypertrophy O
of O
the O
juxtaglomerular O
apparatus O
in O
male O
Wistar O
rats O
when O
given O
for O
10 O
days O
. O

Clinical O
evaluation O
on O
combined O
administration O
of O
oral O
prostacyclin O
analogue O
beraprost B
and O
phosphodiesterase O
inhibitor O
cilostazol B
. O

Among O
various O
oral O
antiplatelets O
, O
a O
combination O
of O
a O
novel O
prostacyclin O
analogue O
beraprost B
( O
BPT B
) O
and O
a O
potent O
phosphodiesterase O
inhibitor O
cilostazol B
( O
CLZ B
) O
may O
result O
in O
untoward O
clinical O
effects O
due O
to O
possible O
synergistic O
elevation O
of O
intracellular O
cAMP B
( O
cyclic B
adenosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
) O
. O

Twelve O
healthy O
volunteers O
were O
assigned O
to O
take O
BPT B
/ O
CLZ B
in O
the O
following O
schedule O
; O
BPT B
: O
40 O
micrograms O
at O
day O
1 O
and O
120 O
micrograms O
t O
. O
i O
. O
d O
. O
from O
day O
7 O
to O
14 O
, O
CLZ B
: O
200 O
mg O
t O
. O
i O
. O
d O
. O
from O
day O
3 O
to O
14 O
. O

At O
various O
time O
intervals O
, O
physical O
examination O
and O
blood O
collection O
for O
ex O
vivo O
platelet O
aggregation O
and O
determination O
of O
intraplatelet O
cAMP B
were O
performed O
. O

Seven O
out O
of O
12 O
subjects O
experienced O
headache O
of O
a O
short O
duration O
accompanying O
facial O
flush O
in O
one O
and O
nausea O
in O
one O
, O
especially O
after O
ingestion O
of O
CLZ B
. O

Intraplatelet O
cAMP B
content O
was O
gradually O
but O
significantly O
increased O
to O
9 O
. O
84 O
+ O
/ O
- O
4 O
. O
59 O
pmol O
per O
10 O
( O
9 O
) O
platelets O
at O
day O
14 O
in O
comparison O
with O
the O
initial O
value O
( O
6 O
. O
87 O
+ O
/ O
- O
2 O
. O
25 O
pmol O
) O
. O

In O
conclusion O
, O
the O
combined O
administration O
of O
BPT B
/ O
CLZ B
is O
safe O
at O
doses O
used O
in O
the O
study O
, O
though O
the O
beneficial O
clinical O
effect O
of O
the O
combined O
administration O
has O
yet O
to O
be O
elucidated O
. O

Reversal O
of O
ammonia B
coma O
in O
rats O
by O
L O
- O
dopa O
: O
a O
peripheral O
effect O
. O

Ammonia B
coma O
was O
produced O
in O
rats O
within O
10 O
to O
15 O
minutes O
of O
an O
intraperitonealinjection O
of O
1 O
. O
7 O
mmol O
NH4CL B
. O

This O
coma O
was O
prevented O
with O
1 O
. O
68 O
mmol O
L O
- O
dopa O
given O
by O
gastric O
intubation O
15 O
minutes O
before O
the O
ammonium B
salt I
injection O
. O

The O
effect O
of O
L O
- O
dopa O
was O
correlated O
with O
a O
decrease O
in O
blood O
and O
brain O
ammonia B
, O
an O
increase O
in O
brain O
dopamine O
, O
and O
an O
increase O
in O
renal O
excretion O
of O
ammonia B
and O
urea O
. O

Intraventricular O
infusion O
of O
dopamine O
sufficient O
to O
raise O
the O
brain O
dopamine O
to O
the O
same O
extent O
did O
not O
prevent O
the O
ammonia B
coma O
nor O
affect O
the O
blood O
and O
brain O
ammonia B
concentrations O
. O

Bilateral O
nephrectomy O
eliminated O
the O
beneficial O
effect O
of O
L O
- O
dopa O
on O
blood O
and O
brain O
ammonia B
and O
the O
ammonia B
coma O
was O
not O
prevented O
. O

Thus O
, O
the O
reduction O
in O
blood O
and O
brain O
ammonia B
and O
the O
prevention O
of O
ammonia B
coma O
after O
L O
- O
dopa O
, O
can O
be O
accounted O
for O
by O
the O
peripheral O
effect O
of O
dopamine O
on O
renal O
function O
rather O
than O
its O
central O
action O
. O

Cholinergic O
toxicity O
resulting O
from O
ocular O
instillation O
of O
echothiophate B
iodide I
eye O
drops O
. O

A O
patient O
developed O
a O
severe O
cholinergic O
syndrome O
from O
the O
use O
of O
echothiophate B
iodide I
ophthalmic O
drops O
, O
presented O
with O
profound O
muscle O
weakness O
and O
was O
initially O
given O
the O
diagnosis O
of O
myasthenia O
gravis O
. O

Phase O
I O
trial O
of O
13 B
- I
cis I
- I
retinoic I
acid I
in O
children O
with O
neuroblastoma O
following O
bone O
marrow O
transplantation O
. O

PURPOSE O
: O
Treatment O
of O
neuroblastoma O
cell O
lines O
with O
13 B
- I
cis I
- I
retinoic I
acid I
( O
cis B
- I
RA I
) O
can O
cause O
sustained O
inhibition O
of O
proliferation O
. O

Since O
cis B
- I
RA I
has O
demonstrated O
clinical O
responses O
in O
neuroblastoma O
patients O
, O
it O
may O
be O
effective O
in O
preventing O
relapse O
after O
cytotoxic O
therapy O
. O

This O
phase O
I O
trial O
was O
designed O
to O
determine O
the O
maximal O
- O
tolerated O
dosage O
( O
MTD O
) O
, O
toxicities O
, O
and O
pharmacokinetics O
of O
cis B
- I
RA I
administered O
on O
an O
intermittent O
schedule O
in O
children O
with O
neuroblastoma O
following O
bone O
marrow O
transplantation O
( O
BMT O
) O
. O

PATIENTS O
AND O
METHODS O
: O
Fifty O
- O
one O
assessable O
patients O
, O
2 O
to O
12 O
years O
of O
age O
, O
were O
treated O
with O
oral O
cis B
- I
RA I
administered O
in O
two O
equally O
divided O
doses O
daily O
for O
2 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
, O
for O
up O
to O
12 O
courses O
. O

RESULTS O
: O
The O
MTD O
of O
cis B
- I
RA I
was O
160 O
mg O
/ O
m2 O
/ O
d O
. O

All O
toxicities O
resolved O
after O
cis B
- I
RA I
was O
discontinued O
. O

CONCLUSION O
: O
The O
MTD O
of O
cis B
- I
RA I
given O
on O
this O
intermittent O
schedule O
was O
160 O
mg O
/ O
m2 O
/ O
d O
. O

The O
DLT O
included O
hypercalcemia O
, O
and O
may O
be O
predicted O
by O
serum O
cis B
- I
RA I
levels O
. O

Monitoring O
of O
serum O
calcium O
and O
cis B
- I
RA I
levels O
is O
indicated O
in O
future O
trials O
. O

Time O
dependence O
of O
plasma O
malondialdehyde O
, O
oxypurines B
, O
and O
nucleosides O
during O
incomplete O
cerebral O
ischemia O
in O
the O
rat O
. O

Plasma O
extracts O
were O
analyzed O
by O
a O
highly O
sensitive O
high O
- O
performance O
liquid O
chromatographic O
method O
for O
the O
direct O
determination O
of O
malondialdehyde O
, O
oxypurines B
, O
and O
nucleosides O
. O

During O
ischemia O
, O
a O
time O
- O
dependent O
increase O
of O
plasma O
oxypurines B
and O
nucleosides O
was O
observed O
. O

The O
present O
data O
indicate O
that O
the O
determination O
of O
malondialdehyde O
, O
oxypurines B
, O
and O
nucleosides O
in O
peripheral O
blood O
, O
may O
be O
used O
to O
monitor O
the O
metabolic O
alterations O
of O
tissues O
occurring O
during O
ischemic O
phenomena O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Acute O
renal O
toxicity O
of O
doxorubicin O
( O
adriamycin O
) O
- O
loaded O
cyanoacrylate B
nanoparticles O
. O

Prostaglandin B
E2 I
- O
induced O
bladder O
hyperactivity O
in O
normal O
, O
conscious O
rats O
: O
involvement O
of O
tachykinins B
? O

In O
normal O
conscious O
rats O
investigated O
by O
continuous O
cystometry O
, O
intravesically O
instilled O
prostaglandin B
( I
PG I
) I
E2 I
facilitated O
micturition O
and O
increased O
basal O
intravesical O
pressure O
. O

The O
effect O
was O
attenuated O
by O
both O
the O
NK1 O
receptor O
selective O
antagonist O
RP B
67 I
, I
580 I
and O
the O
NK2 O
receptor O
selective O
antagonist O
SR B
48 I
, I
968 I
, O
given O
intra O
- O
arterially O
, O
suggesting O
that O
it O
was O
mediated O
by O
stimulation O
of O
both O
NK1 O
and O
NK2 O
receptors O
. O

Intra O
- O
arterially O
given O
PGE2 B
produced O
a O
distinct O
increase O
in O
bladder O
pressure O
before O
initiating O
a O
micturition O
reflex O
, O
indicating O
that O
the O
PG O
had O
a O
direct O
contractant O
effect O
on O
the O
detrusor O
smooth O
muscle O
. O

The O
effect O
of O
intra O
- O
arterial O
PGE2 B
could O
not O
be O
blocked O
by O
intra O
- O
arterial O
RP B
67 I
, I
580 I
or O
SR B
48 I
, I
968 I
, O
which O
opens O
the O
possibility O
that O
the O
micturition O
reflex O
elicited O
by O
intra O
- O
arterial O
PGE2 B
was O
mediated O
by O
pathways O
other O
than O
the O
reflex O
initiated O
when O
the O
PG O
was O
given O
intravesically O
. O

The O
present O
results O
thus O
suggest O
that O
intra O
- O
arterial O
PGE2 B
, O
given O
near O
the O
bladder O
, O
may O
initiate O
micturition O
in O
the O
normal O
rat O
chiefly O
by O
directly O
contracting O
the O
smooth O
muscle O
of O
the O
detrusor O
. O

However O
, O
when O
given O
intravesically O
, O
PGE2 B
may O
stimulate O
micturition O
by O
releasing O
tachykinins B
from O
nerves O
in O
and O
/ O
or O
immediately O
below O
the O
urothelium O
. O

These O
tachykinins B
, O
in O
turn O
, O
initiate O
a O
micturition O
reflex O
by O
stimulating O
NK1 O
and O
NK2 O
receptors O
. O

Prostanoids O
may O
, O
via O
release O
of O
tachykinins B
, O
contribute O
to O
both O
urge O
and O
bladder O
hyperactivity O
seen O
in O
inflammatory O
conditions O
of O
the O
lower O
urinary O
tract O
. O

Protective O
effect O
of O
misoprostol B
on O
indomethacin O
induced O
renal O
dysfunction O
in O
elderly O
patients O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
possible O
protective O
effects O
of O
misoprostol B
on O
renal O
function O
in O
hospitalized O
elderly O
patients O
treated O
with O
indomethacin O
. O

METHODS O
: O
Forty O
- O
five O
hospitalized O
elderly O
patients O
( O
> O
65 O
years O
old O
) O
who O
required O
therapy O
with O
nonsteroidal O
antiinflammatory O
drugs O
( O
NSAID O
) O
were O
randomly O
assigned O
to O
receive O
either O
indomethacin O
, O
150 O
mg O
/ O
day O
( O
Group O
A O
) O
, O
or O
indomethacin O
150 O
mg O
/ O
day O
plus O
misoprostol B
at O
0 O
. O
6 O
mg O
/ O
day O
( O
Group O
B O
) O
. O

Addition O
of O
misoprostol B
can O
minimize O
this O
renal O
impairment O
without O
affecting O
pain O
control O
. O

Dextromethorphan O
( O
DM O
) O
, O
the O
dextrorotatory O
isomer O
of O
3 B
- I
hydroxy I
- I
N I
- I
methylmorphinan I
, O
is O
the O
main O
ingredient O
in O
a O
number O
of O
widely O
available O
, O
over O
- O
the O
- O
counter O
antitussives O
. O

The O
effects O
of O
digitalis B
glycosides I
on O
myocardial O
oxygen O
supply O
and O
demand O
are O
of O
particular O
interest O
in O
the O
presence O
of O
obstructive O
coronary O
artery O
disease O
, O
but O
have O
not O
been O
measured O
previously O
in O
man O
. O

The O
safety O
and O
efficacy O
of O
combination O
N B
- I
butyl I
- I
deoxynojirimycin I
( O
SC B
- I
48334 I
) O
and O
zidovudine O
in O
patients O
with O
HIV O
- O
1 O
infection O
and O
200 O
- O
500 O
CD4 O
cells O
/ O
mm3 O
. O

We O
conducted O
a O
double O
- O
blind O
, O
randomized O
phase O
II O
study O
to O
evaluate O
the O
safety O
and O
activity O
of O
combination O
therapy O
with O
N B
- I
butyl I
- I
deoxynojirimycin I
( O
SC B
- I
48334 I
) O
( O
an O
alpha O
- O
glucosidase O
I O
inhibitor O
) O
and O
zidovudine O
versus O
zidovudine O
alone O
. O

Patients O
with O
200 O
to O
500 O
CD4 O
cells O
/ O
mm3 O
who O
tolerated O
< O
or O
= O
12 O
weeks O
of O
prior O
zidovudine O
therapy O
received O
SC B
- I
48334 I
( O
1000 O
mg O
every O
8 O
h O
) O
and O
zidovudine O
( O
100 O
mg O
every O
8 O
h O
) O
or O
zidovudine O
and O
placebo O
. O

The O
mean O
SC B
- I
48334 I
steady O
- O
state O
trough O
level O
( O
4 O
. O
04 O
+ O
/ O
- O
0 O
. O
99 O
micrograms O
/ O
ml O
) O
was O
below O
the O
in O
vitro O
inhibitory O
concentration O
for O
human O
immunodeficiency O
virus O
( O
HIV O
) O
. O

Prolonged O
paralysis O
due O
to O
nondepolarizing B
neuromuscular I
blocking I
agents I
and O
corticosteroids O
. O

The O
long O
- O
term O
use O
of O
nondepolarizing B
neuromuscular I
blocking I
agents I
( O
ND B
- I
NMBA I
) O
has O
recently O
been O
implicated O
as O
a O
cause O
of O
prolonged O
muscle O
weakness O
, O
although O
the O
site O
of O
the O
lesion O
and O
the O
predisposing O
factors O
have O
been O
unclear O
. O

We O
report O
3 O
patients O
( O
age O
37 O
- O
52 O
years O
) O
with O
acute O
respiratory O
insufficiency O
who O
developed O
prolonged O
weakness O
following O
the O
discontinuation O
of O
ND B
- I
NMBAs I
. O

The O
weakness O
in O
these O
patients O
is O
due O
to O
pathology O
at O
both O
the O
neuromuscular O
junction O
( O
most O
likely O
due O
to O
ND B
- I
NMBA I
) O
and O
muscle O
( O
most O
likely O
due O
to O
corticosteroids O
) O
. O

KF17837 B
: O
a O
novel O
selective O
adenosine O
A2A O
receptor O
antagonist O
with O
anticataleptic O
activity O
. O

KF17837 B
is O
a O
novel O
selective O
adenosine O
A2A O
receptor O
antagonist O
. O

Oral O
administration O
of O
KF17837 B
( O
2 O
. O
5 O
, O
10 O
. O
0 O
and O
30 O
. O
0 O
mg O
/ O
kg O
) O
significantly O
ameliorated O
the O
cataleptic O
responses O
induced O
by O
intracerebroventricular O
administration O
of O
an O
adenosine O
A2A O
receptor O
agonist O
, O
CGS B
21680 I
( O
10 O
micrograms O
) O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

KF17837 B
also O
reduced O
the O
catalepsy O
induced O
by O
haloperidol O
( O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
and O
by O
reserpine O
( O
5 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

Moreover O
, O
KF17837 B
( O
0 O
. O
625 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
potentiated O
the O
anticataleptic O
effects O
of O
a O
subthreshold O
dose O
of O
L O
- O
3 O
, O
4 O
- O
dihydroxyphenylalanine O
( O
L O
- O
DOPA O
; O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
plus O
benserazide B
( O
6 O
. O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

These O
results O
suggested O
that O
KF17837 B
is O
a O
centrally O
active O
adenosine O
A2A O
receptor O
antagonist O
and O
that O
the O
dopaminergic O
function O
of O
the O
nigrostriatal O
pathway O
is O
potentiated O
by O
adenosine O
A2A O
receptor O
antagonists O
. O

Furthermore O
, O
KF17837 B
may O
be O
a O
useful O
drug O
in O
the O
treatment O
of O
parkinsonism O
. O

They O
were O
then O
treated O
chronically O
with O
L B
- I
DOPA I
/ I
benserazide I
50 O
/ O
12 O
. O
5 O
mg O
/ O
kg O
given O
orally O
daily O
for O
2 O
months O
. O

Several O
drugs O
, O
including O
clonidine O
, O
physostigmine O
, O
methysergide B
, O
5 B
- I
MDOT I
, O
propranolol O
, O
and O
MK O
- O
801 O
, O
markedly O
reduced O
the O
dyskinetic O
movements O
but O
at O
the O
cost O
of O
a O
return O
of O
parkinsonian O
symptomatology O
. O

Baclofen B
was O
also O
useful O
in O
one O
monkey O
against O
a O
more O
dystonic O
form O
of O
dyskinesia O
. O

One O
commenced O
the O
closely O
related O
drug O
amlodipine B
3 O
years O
later O
, O
with O
recurrence O
of O
telangiectasia O
. O

The O
patient O
was O
treated O
with O
steroid O
pulse O
, O
plasmapheresis O
, O
cyclophosphamide O
and O
antiplatelet B
agents I
. O

In O
situ O
hybridization O
histochemistry O
, O
using O
a O
digoxigenin B
- O
labeled O
GAD O
cRNA O
probe O
, O
demonstrated O
a O
substantial O
decrease O
in O
the O
number O
of O
GAD O
mRNA O
- O
containing O
neurons O
in O
the O
hilus O
of O
the O
dentate O
gyrus O
in O
the O
pilocarpine O
- O
treated O
rats O
as O
compared O
to O
controls O
at O
all O
time O
intervals O
. O

Additional O
neuronanatomical O
studies O
, O
including O
cresyl B
violet I
staining O
, O
neuronal O
degeneration O
methods O
, O
and O
histochemical O
localization O
of O
glial O
fibrillary O
acidic O
protein O
, O
suggested O
that O
the O
decrease O
in O
the O
number O
of O
GAD O
mRNA O
- O
containing O
neurons O
was O
related O
to O
neuronal O
loss O
rather O
than O
to O
a O
decrease O
in O
GAD O
mRNA O
levels O
. O

BMT O
was O
used O
to O
treat O
severe O
aplastic O
anemia O
which O
was O
caused O
by O
gold B
in O
one O
case O
and O
D O
- O
penicillamine O
in O
the O
other O
. O

Seizures O
induced O
by O
combined O
levomepromazine B
- O
fluvoxamine B
treatment O
. O

We O
report O
a O
case O
of O
combined O
levomepromazine B
- O
fluvoxamine B
treatment O
- O
induced O
seizures O
. O

It O
seems O
that O
combined O
treatment O
of O
fluvoxamine B
with O
phenothiazines B
may O
possess O
proconvulsive O
activity O
. O

Case O
report O
: O
pentamidine B
and O
polymorphic O
ventricular O
tachycardia O
revisited O
. O

Pentamidine B
isethionate I
has O
been O
associated O
with O
ventricular O
tachyarrhythmias O
, O
including O
torsade O
de O
pointes O
. O

Pentamidine B
- O
induced O
torsade O
de O
pointes O
may O
be O
related O
to O
serum O
magnesium O
levels O
and O
hypomagnesemia O
may O
synergistically O
induce O
torsade O
. O

Torsade O
de O
pointes O
occurred O
after O
an O
average O
of O
10 O
days O
of O
treatment O
with O
pentamidine B
. O

In O
these O
patients O
, O
no O
other O
acute O
side O
effects O
of O
pentamidine B
were O
observed O
. O

Torsade O
de O
pointes O
can O
be O
treated O
when O
recognized O
early O
, O
possibly O
without O
discontinuation O
of O
pentamidine B
. O

MEASUREMENTS O
: O
Plasma O
total O
, O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
, O
and O
high O
- O
density O
lipoprotein O
( O
HDL O
) O
cholesterol O
, O
and O
triglycerides B
; O
and O
laboratory O
and O
clinical O
evidence O
of O
adverse O
events O
monitored O
periodically O
throughout O
the O
study O
. O

RESULTS O
: O
Among O
women O
, O
lovastatin O
( O
20 O
to O
80 O
mg O
/ O
d O
) O
produced O
sustained O
( O
12 O
- O
to O
48 O
- O
week O
) O
, O
dose O
- O
related O
changes O
( O
P O
< O
0 O
. O
001 O
) O
: O
decreases O
in O
LDL O
cholesterol O
( O
24 O
% O
to O
40 O
% O
) O
and O
triglycerides B
( O
9 O
% O
to O
18 O
% O
) O
, O
and O
increases O
in O
HDL O
cholesterol O
( O
6 O
. O
7 O
% O
to O
8 O
. O
6 O
% O
) O
. O

Clarithromycin B
- O
associated O
visual O
hallucinations O
in O
a O
patient O
with O
chronic O
renal O
failure O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
. O

Unreported O
in O
the O
literature O
is O
visual O
hallucinations O
occurring O
in O
association O
with O
the O
new O
macrolide B
antibiotic O
, O
clarithromycin B
. O

The O
combination O
of O
a O
relatively O
high O
dose O
of O
clarithromycin B
in O
face O
of O
chronic O
renal O
failure O
in O
a O
functionally O
anephric O
patient O
, O
with O
underlying O
aluminum B
intoxication O
, O
may O
have O
facilitated O
the O
appearance O
of O
this O
neurotoxic O
side O
effect O
. O

Although O
most O
of O
the O
hepatomas O
were O
well O
- O
differentiated O
tumors O
and O
contained O
a O
considerable O
number O
of O
peroxisomes O
, O
the O
tumor O
cells O
did O
not O
respond O
to O
ethyl B
- I
alpha I
- I
p I
- I
chlorophenoxyisobutyrate I
with O
proliferation O
of O
peroxisomes O
. O

No O
abnormal O
matrical O
inclusions O
of O
peroxisomes O
were O
formed O
in O
the O
cells O
of O
hyperplastic O
nodules O
by O
ethyl B
- I
alpha I
- I
p I
- I
chlorophenoxyisobutyrate I
unlike O
in O
the O
case O
of O
rats O
. O

Infusion O
of O
the O
central O
nervous O
system O
alpha2 B
- I
adrenergic I
receptor I
agonist I
clonidine O
also O
resulted O
in O
a O
greater O
reduction O
in O
MAP O
in O
both O
groups O
of O
SHR O
that O
were O
fed O
the O
high O
( O
compared O
with O
the O
basal O
) O
sodium O
chloride O
diet O
. O

Angioedema O
associated O
with O
droperidol B
administration O
. O

We O
report O
the O
case O
of O
a O
previously O
healthy O
19 O
- O
year O
- O
old O
man O
with O
no O
known O
drug O
allergies O
in O
whom O
angioedema O
with O
significant O
tongue O
swelling O
and O
protrusion O
developed O
within O
10 O
minutes O
of O
the O
administration O
of O
a O
single O
IV O
dose O
of O
droperidol B
. O

Cardiac O
function O
was O
assessed O
in O
long O
- O
term O
survivors O
of O
malignant O
bone O
tumors O
who O
were O
treated O
according O
to O
Rosen B
' I
s I
T5 I
or I
T10 I
protocol I
, O
both O
including O
doxorubicin O
. O

Increased O
sulfation O
and O
decreased O
7alpha O
- O
hydroxylation O
of O
deoxycholic B
acid I
in O
ethinyl O
estradiol O
- O
induced O
cholestasis O
in O
rats O
. O

Deoxycholic B
acid I
conjugation O
, O
transport O
capacity O
, O
and O
metabolism O
were O
compared O
in O
control O
and O
ethinyl O
estradiol O
- O
treated O
rats O
. O

Control O
rats O
were O
found O
to O
have O
a O
lower O
capacity O
to O
transport O
deoxycholic B
acid I
than O
taurodeoxycholic B
acid I
, O
and O
both O
were O
decreased O
by O
ethinyl O
estradiol O
treatment O
. O

During O
[ O
24 O
- O
14C O
] O
sodium B
deoxycholate I
infusion O
, O
[ O
14C O
] O
biliary O
bile B
acid I
secretion O
increased O
, O
but O
bile O
flow O
did O
not O
change O
significantly O
in O
either O
control O
or O
ethinyl O
estradiol O
- O
treated O
rats O
. O

Ethinyl O
estradiol O
- O
treated O
animals O
excreted O
significantly O
less O
14C O
as O
taurocholic B
acid I
than O
did O
control O
animals O
, O
consistent O
with O
an O
impairment O
of O
7alpha O
- O
hydroxylation O
of O
taurodeoxycholic B
acid I
. O

Ethinyl O
estradiol O
treatment O
did O
not O
impair O
conjugation O
of O
deoxycholic B
acid I
, O
but O
did O
result O
in O
an O
increase O
in O
sulfation O
of O
taurodeoxycholic B
acid I
from O
1 O
. O
5 O
% O
in O
controls O
to O
nearly O
4 O
. O
0 O
% O
( O
P O
less O
than O
0 O
. O
01 O
) O
. O

These O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
rat O
has O
a O
poorer O
tolerance O
for O
deoxycholic B
acid I
than O
do O
certain O
other O
species O
. O

Furthermore O
, O
the O
rat O
converts O
deoxycholic B
acid I
, O
a O
poor O
choleretic O
, O
to O
taurocholic B
acid I
, O
a O
good O
choleretic O
. O

When O
this O
conversion O
is O
impaired O
with O
ethinyl O
estradiol O
treatment O
, O
sulfation O
may O
be O
an O
important O
alternate O
pathway O
for O
excretion O
of O
this O
potentially O
harmful O
bile B
acid I
. O

Influence O
of O
diet O
free O
of O
NAD B
- O
precursors O
on O
acetaminophen O
hepatotoxicity O
in O
mice O
. O

Recently O
, O
we O
demonstrated O
the O
hepatoprotective O
effects O
of O
nicotinic O
acid O
amide O
, O
a O
selective O
inhibitor O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
; O
EC O
2 O
. O
4 O
. O
2 O
. O
30 O
) O
on O
mice O
suffering O
from O
acetaminophen O
( O
AAP O
) O
- O
hepatitis O
, O
suggesting O
that O
the O
AAP O
- O
induced O
liver O
injury O
involves O
a O
step O
which O
depends O
on O
adenoribosylation O
. O

The O
present O
study O
investigates O
the O
effects O
of O
a O
diet O
free O
of O
precursors O
of O
NAD B
, O
the O
substrate O
on O
which O
PARP O
acts O
, O
in O
female O
NMRI O
mice O
with O
AAP O
hepatitis O
and O
evaluates O
the O
influence O
of O
simultaneous O
ethanol O
consumption O
in O
these O
animals O
. O

Liver O
injuries O
were O
quantified O
as O
serum O
activities O
of O
glutamate O
- O
oxaloacetate B
transaminase O
( O
GOT O
) O
and O
glutamate O
- O
pyruvate B
transaminase O
( O
GPT O
) O
. O

While O
AAP O
caused O
a O
117 O
- O
fold O
elevation O
of O
serum O
transaminase O
activities O
in O
mice O
kept O
on O
a O
standard O
laboratory O
diet O
, O
which O
was O
significantly O
exacerbated O
by O
ethanol O
and O
inhibited O
by O
nicotinic O
acid O
amide O
( O
NAA O
) O
, O
adverse O
effects O
were O
noted O
in O
animals O
fed O
a O
diet O
free O
of O
precursors O
of O
NAD B
. O

Our O
results O
provide O
evidence O
that O
the O
AAP O
- O
induced O
hepatitis O
and O
its O
exacerbation O
by O
ethanol O
can O
either O
be O
reduced O
by O
end O
- O
product O
inhibition O
of O
PARP O
by O
NAA O
or O
by O
dietary O
depletion O
of O
the O
enzyme O
' O
s O
substrate O
NAD B
. O

Nightmares O
and O
hallucinations O
after O
long O
- O
term O
intake O
of O
tramadol B
combined O
with O
antidepressants O
. O

Tramadol B
is O
a O
weak O
opioid O
with O
effects O
on O
adrenergic O
and O
serotonergic O
neurotransmission O
that O
is O
used O
to O
treat O
cancer O
pain O
and O
chronic O
non O
malignant O
pain O
. O

Fifty O
- O
six O
days O
after O
initiation O
of O
the O
treatment O
the O
patient O
presented O
hallucinations O
that O
only O
stopped O
after O
the O
withdrawal O
of O
psycho O
- O
active O
drugs O
and O
tramadol B
. O

Effect O
of O
calcium O
chloride O
and O
4 B
- I
aminopyridine I
therapy O
on O
desipramine O
toxicity O
in O
rats O
. O

CaCl2 O
and O
4 B
- I
aminopyridine I
. O

In O
a O
second O
experiment O
, O
rats O
received O
tricyclic O
antidepressant O
desipramine O
IP O
followed O
in O
15 O
min O
by O
4 B
- I
aminopyridine I
or O
saline O
. O

CaCl2 O
and O
4 B
- I
aminopyridine I
failed O
to O
improve O
blood O
pressure O
. O

CONCLUSION O
: O
The O
administration O
of O
CaCl2 O
or O
4 B
- I
aminopyridine I
did O
not O
reverse O
tricyclic O
antidepressant O
- O
induced O
hypotension O
in O
rats O
. O

Valsartan B
, O
a O
new O
angiotensin O
II O
antagonist O
for O
the O
treatment O
of O
essential O
hypertension O
: O
a O
comparative O
study O
of O
the O
efficacy O
and O
safety O
against O
amlodipine B
. O

OBJECTIVE O
: O
To O
compare O
the O
antihypertensive O
efficacy O
of O
a O
new O
angiotensin O
II O
antagonist O
, O
valsartan B
, O
with O
a O
reference O
therapy O
, O
amlodipine B
. O

METHODS O
: O
One O
hundred O
sixty O
- O
eight O
adult O
outpatients O
with O
mild O
to O
moderate O
hypertension O
were O
randomly O
allocated O
in O
double O
- O
blind O
fashion O
and O
equal O
number O
to O
receive O
80 O
mg O
valsartan B
or O
5 O
mg O
amlodipine B
for O
12 O
weeks O
. O

After O
8 O
weeks O
of O
therapy O
, O
in O
patients O
whose O
blood O
pressure O
remained O
uncontrolled O
, O
5 O
mg O
amlodipine B
was O
added O
to O
the O
initial O
therapy O
. O

RESULTS O
: O
Both O
valsartan B
and O
amlodipine B
were O
effective O
at O
lowering O
blood O
pressure O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
. O

For O
the O
primary O
variable O
the O
difference O
was O
0 O
. O
5 O
mm O
Hg O
in O
favor O
of O
valsartan B
( O
p O
= O
0 O
. O
68 O
; O
95 O
% O
confidence O
interval O
, O
- O
2 O
. O
7 O
to O
1 O
. O
7 O
) O
. O

Responder O
rates O
at O
8 O
weeks O
were O
66 O
. O
7 O
% O
for O
valsartan B
and O
60 O
. O
2 O
% O
for O
amlodipine B
( O
p O
= O
0 O
. O
39 O
) O
. O

The O
incidence O
of O
drug O
- O
related O
dependent O
edema O
was O
somewhat O
higher O
in O
the O
amlodipine B
group O
, O
particularly O
at O
a O
dose O
of O
10 O
mg O
per O
day O
( O
2 O
. O
4 O
% O
for O
80 O
mg O
valsartan B
; O
3 O
. O
6 O
% O
for O
5 O
mg O
amlodipine B
; O
0 O
% O
for O
valsartan B
plus O
5 O
mg O
amlodipine B
; O
14 O
. O
3 O
% O
for O
10 O
mg O
amlodipine B
) O
. O

CONCLUSIONS O
: O
The O
data O
show O
that O
valsartan B
is O
at O
least O
as O
effective O
as O
amlodipine B
in O
the O
treatment O
of O
mild O
to O
moderate O
hypertension O
. O

The O
results O
also O
show O
valsartan B
to O
be O
well O
tolerated O
and O
suggest O
that O
it O
is O
not O
associated O
with O
side O
effects O
characteristic O
of O
this O
comparator O
class O
, O
dihydropyridine B
calcium O
antagonists O
. O

Measures O
of O
pupillary O
oscillation O
were O
able O
to O
significantly O
distinguish O
a O
group O
of O
abstinent O
crack B
cocaine I
abusers O
endorsing O
past O
CIP O
( O
n O
= O
32 O
) O
from O
another O
group O
of O
crack B
addicts O
who O
denied O
past O
CIP O
( O
n O
= O
29 O
) O
. O

Serotonin O
syndrome O
from O
venlafaxine O
- O
tranylcypromine B
interaction O
. O

We O
report O
a O
venlafaxine O
- O
MAOI O
interaction O
that O
resulted O
in O
the O
serotonin O
syndrome O
in O
a O
23 O
- O
y O
- O
old O
male O
who O
was O
taking O
tranylcypromine B
for O
depression O
. O

A O
phase O
I O
clinical O
study O
of O
the O
antipurine B
antifolate O
lometrexol B
( O
DDATHF B
) O
given O
with O
oral O
folic O
acid O
. O

Lometrexol B
is O
an O
antifolate O
which O
inhibits O
glycinamide B
ribonucleotide I
formyltransferase O
( O
GARFT O
) O
, O
an O
enzyme O
essential O
for O
de O
novo O
purine O
synthesis O
. O

Extensive O
experimental O
and O
limited O
clinical O
data O
have O
shown O
that O
lometrexol B
has O
activity O
against O
tumours O
which O
are O
refractory O
to O
other O
drugs O
, O
notably O
methotrexate O
. O

However O
, O
the O
initial O
clinical O
development O
of O
lometrexol B
was O
curtailed O
because O
of O
severe O
and O
cumulative O
antiproliferative O
toxicities O
. O

Preclinical O
murine O
studies O
demonstrated O
that O
the O
toxicity O
of O
lometrexol B
can O
be O
prevented O
by O
low O
dose O
folic O
acid O
administration O
, O
i O
. O
e O
. O
for O
7 O
days O
prior O
to O
and O
7 O
days O
following O
a O
single O
bolus O
dose O
. O

This O
observation O
prompted O
a O
Phase O
I O
clinical O
study O
of O
lometrexol B
given O
with O
folic O
acid O
supplementation O
which O
has O
confirmed O
that O
the O
toxicity O
of O
lometrexol B
can O
be O
markedly O
reduced O
by O
folic O
acid O
supplementation O
. O

Associated O
studies O
demonstrated O
that O
lometrexol B
plasma O
pharmacokinetics O
were O
not O
altered O
by O
folic O
acid O
administration O
indicating O
that O
supplementation O
is O
unlikely O
to O
reduce O
toxicity O
by O
enhancing O
lometrexol B
plasma O
clearance O
. O

Pemoline B
induced O
acute O
choreoathetosis O
: O
case O
report O
and O
review O
of O
the O
literature O
. O

BACKGROUND O
: O
Pemoline B
is O
an O
oxazolidine B
derivative O
that O
is O
structurally O
different O
from O
amphetamines B
and O
used O
in O
the O
treatment O
of O
attention O
deficit O
disorder O
. O

Pemoline B
has O
not O
been O
commonly O
associated O
in O
the O
literature O
as O
a O
cause O
of O
acute O
movement O
disorders O
. O

The O
following O
case O
describes O
two O
children O
acutely O
poisoned O
with O
pemoline B
who O
experienced O
profound O
choreoathetosis O
. O

CASE O
REPORT O
: O
Two O
, O
3 O
- O
year O
- O
old O
male O
, O
identical O
twin O
siblings O
presented O
to O
the O
emergency O
department O
after O
found O
playing O
with O
a O
an O
empty O
bottle O
of O
pemoline B
originally O
containing O
59 O
tablets O
. O

This O
was O
their O
first O
day O
of O
pemoline B
therapy O
. O

CONCLUSION O
: O
Pemoline B
associated O
movement O
disorder O
has O
been O
rarely O
reported O
in O
the O
acute O
toxicology O
literature O
. O

The O
possibility O
of O
choreoathetoid O
movements O
should O
be O
considered O
in O
patients O
presenting O
after O
pemoline B
overdose O
. O

Superoxide O
and O
hydrogen O
peroxide O
production O
in O
neutrophils O
stimulated O
with O
formyl B
- I
methionyl I
- I
leucyl I
- I
phenylalanine I
( O
fMLP B
) O
from O
a O
further O
18 O
ALF O
patients O
was O
unaffected O
compared O
with O
control O
neutrophils O
. O

Cholesteryl B
hemisuccinate I
treatment O
protects O
rodents O
from O
the O
toxic O
effects O
of O
acetaminophen O
, O
adriamycin O
, O
carbon O
tetrachloride O
, O
chloroform B
and O
galactosamine B
. O

In O
addition O
to O
its O
use O
as O
a O
stabilizer O
/ O
rigidifier O
of O
membranes O
, O
cholesteryl B
hemisuccinate I
, O
tris B
salt I
( O
CS B
) O
administration O
has O
also O
been O
shown O
to O
protect O
rats O
from O
the O
hepatotoxic O
effects O
of O
carbon O
tetrachloride O
( O
CCl4 O
) O
. O

To O
further O
our O
understanding O
of O
the O
mechanism O
of O
CS B
cytoprotection O
, O
we O
examined O
in O
rats O
and O
mice O
the O
protective O
abilities O
of O
CS B
and O
the O
non O
- O
hydrolyzable O
ether O
form O
of O
CS B
, O
gamma B
- I
cholesteryloxybutyric I
acid I
, O
tris B
salt I
( O
CSE B
) O
against O
acetaminophen O
- O
, O
adriamycin O
- O
, O
carbon O
tetrachloride O
- O
, O
chloroform B
- O
and O
galactosamine B
- O
induced O
toxicity O
. O

The O
results O
of O
these O
studies O
demonstrated O
that O
CS B
- O
mediated O
protection O
is O
not O
selective O
for O
a O
particular O
species O
, O
organ O
system O
or O
toxic O
chemical O
. O

A O
24 O
- O
h O
pretreatment O
of O
both O
rats O
and O
mice O
with O
a O
single O
dose O
of O
CS B
( O
100mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
resulted O
in O
significant O
protection O
against O
the O
hepatotoxic O
effects O
of O
CCl4 O
, O
CHCl3 B
, O
acetaminophen O
and O
galactosamine B
and O
against O
the O
lethal O
( O
and O
presumably O
cardiotoxic O
) O
effect O
of O
adriamycin O
administration O
. O

Maximal O
CS B
- O
mediated O
protection O
was O
observed O
in O
experimental O
animals O
pretreated O
24 O
h O
prior O
to O
the O
toxic O
insult O
. O

These O
data O
suggest O
that O
CS B
intervenes O
in O
a O
critical O
cellular O
event O
that O
is O
an O
important O
common O
pathway O
to O
toxic O
cell O
death O
. O

The O
mechanism O
of O
CS B
protection O
does O
not O
appear O
to O
be O
dependent O
on O
the O
inhibition O
of O
chemical O
bioactivation O
to O
a O
toxic O
reactive O
intermediate O
( O
in O
light O
of O
the O
protection O
observed O
against O
galactosamine B
hepatotoxicity O
) O
. O

However O
, O
based O
on O
the O
data O
presented O
, O
we O
can O
not O
exclude O
the O
possibility O
that O
CS B
administration O
inhibits O
chemical O
bioactivation O
. O

Our O
findings O
do O
suggest O
that O
CS B
- O
mediated O
protection O
is O
dependent O
on O
the O
action O
of O
the O
intact O
anionic O
CS B
molecule O
( O
non O
- O
hydrolyzable O
CSE B
was O
as O
protective O
as O
CS B
) O
, O
whose O
mechanism O
has O
yet O
to O
be O
defined O
. O

Although O
the O
neuroactive O
steroids O
were O
considerably O
less O
potent O
than O
the O
benzodiazepine O
clonazepam B
in O
protecting O
against O
pilocarpine O
seizures O
, O
steroids O
with O
the O
5 O
alpha O
, O
3 O
alpha O
- O
configuration O
had O
comparable O
or O
higher O
protective O
index O
values O
( O
TD50 O
for O
motor O
impairment O
divided O
by O
ED50 O
for O
seizure O
protection O
) O
than O
clonazepam B
, O
indicating O
that O
some O
neuroactive O
steroids O
may O
have O
lower O
relative O
toxicity O
. O

Risperidone O
, O
a O
benzisoxazole B
derivative O
antipsychotic O
, O
has O
high O
serotonin O
5 O
- O
HT2 O
receptor O
blockade O
and O
dose O
- O
related O
D2 O
receptor O
blockade O
. O

The O
syndrome O
reversed O
after O
discontinuing O
risperidone O
and O
starting O
treatment O
with O
dantrolene B
and O
bromocriptine O
. O

The O
attenuating O
effect O
of O
carteolol B
hydrochloride I
, O
a O
beta O
- O
adrenoceptor O
antagonist O
, O
on O
neuroleptic O
- O
induced O
catalepsy O
in O
rats O
. O

Therefore O
, O
the O
effects O
of O
carteolol B
, O
a O
beta O
- O
adrenoceptor O
antagonist O
, O
on O
haloperidol O
- O
induced O
catalepsy O
in O
rats O
were O
behaviorally O
studied O
and O
compared O
with O
those O
of O
propranolol O
and O
biperiden B
, O
a O
muscarinic O
receptor O
antagonist O
. O

Carteolol B
, O
as O
well O
as O
propranolol O
and O
biperiden B
, O
inhibited O
the O
haloperidol O
- O
induced O
catalepsy O
. O

The O
inhibitory O
effect O
of O
carteolol B
was O
almost O
comparable O
to O
that O
of O
propranolol O
, O
but O
was O
weaker O
than O
that O
of O
biperiden B
. O

Carteolol B
did O
not O
evoke O
postsynaptic O
dopamine O
receptor O
- O
stimulating O
behavioral O
signs O
such O
as O
stereotypy O
and O
hyperlocomotion O
in O
rats O
. O

Carteolol B
did O
not O
antagonize O
the O
inhibitory O
effects O
of O
haloperidol O
on O
apomorphine O
- O
induced O
stereotypy O
and O
locomotor O
activity O
in O
rats O
. O

In O
addition O
, O
carteolol B
did O
not O
evoke O
5 O
- O
HT1A O
receptor O
- O
stimulating O
behavioral O
signs O
such O
as O
flat O
body O
posture O
and O
forepaw O
treading O
and O
did O
not O
inhibit O
5 O
- O
hydroxytryptophan O
- O
induced O
head O
twitch O
in O
rats O
. O

Finally O
, O
carteolol B
did O
not O
inhibit O
physostigmine O
- O
induced O
lethality O
in O
rats O
. O

These O
results O
strongly O
suggest O
that O
carteolol B
improves O
haloperidol O
- O
induced O
catalepsy O
via O
its O
beta O
- O
adrenoceptor O
antagonistic O
activity O
and O
is O
expected O
to O
be O
effective O
in O
the O
treatment O
of O
akathisia O
without O
attenuating O
neuroleptic O
- O
induced O
antipsychotic O
effects O
due O
to O
its O
postsynaptic O
dopamine O
receptor O
antagonistic O
activity O
. O

Effects O
of O
NIK B
- I
247 I
on O
cholinesterase O
and O
scopolamine O
- O
induced O
amnesia O
. O

The O
effects O
of O
NIK B
- I
247 I
on O
cholinesterase O
, O
scopolamine O
- O
induced O
amnesia O
and O
spontaneous O
movement O
were O
examined O
and O
compared O
with O
those O
of O
the O
well O
- O
known O
cholinesterase O
inhibitors O
tacrine B
and O
E B
- I
2020 I
. O

NIK B
- I
247 I
, O
tacrine B
and O
E B
- I
2020 I
all O
strongly O
inhibited O
acetylcholinesterase O
( O
AChE O
) O
in O
human O
red O
blood O
cells O
( O
IC50s O
= O
1 O
. O
0 O
x O
10 O
( O
- O
6 O
) O
, O
2 O
. O
9 O
x O
10 O
( O
- O
7 O
) O
and O
3 O
. O
7 O
x O
10 O
( O
- O
8 O
) O
M O
, O
respectively O
) O
. O

In O
addition O
, O
NIK B
- I
247 I
and O
tacrine B
, O
but O
not O
E B
- I
2020 I
, O
strongly O
inhibited O
butyrylcholinestrase O
( O
BuChE O
) O
in O
human O
serum O
. O

Moreover O
, O
the O
inhibitory O
effect O
of O
NIK B
- I
247 I
on O
AChE O
was O
reversible O
. O

These O
findings O
suggest O
that O
NIK B
- I
247 I
at O
a O
low O
dose O
( O
0 O
. O
1 O
- O
1 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
improves O
scopolamine O
- O
induced O
amnesia O
but O
does O
not O
affect O
spontaneous O
movement O
. O

The O
findings O
suggest O
that O
NIK B
- I
247 I
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

Potential O
therapeutic O
use O
of O
the O
selective O
dopamine O
D1 O
receptor O
agonist O
, O
A B
- I
86929 I
: O
an O
acute O
study O
in O
parkinsonian O
levodopa O
- O
primed O
monkeys O
. O

The O
therapeutic O
use O
of O
selective O
DA O
D1 O
receptor O
agonists O
such O
as O
SKF B
- I
82958 I
( O
6 B
- I
chloro I
- I
7 I
, I
8 I
- I
dihydroxy I
- I
3 I
- I
allyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzaze I
pine I
hydrobromide I
) O
and O
A B
- I
77636 I
( O
[ O
1R O
, O
3S O
] O
3 O
- O
[ O
1 O
' O
- O
admantyl O
] O
- O
1 O
- O
aminomethyl O
- O
3 O
, O
4 O
- O
dihydro O
- O
5 O
, O
6 O
- O

dihydroxy O
- O
1H O
- O
2 O
- O
benzo O
pyran O
hydrochloride O
) O
seems O
limited O
because O
of O
their O
duration O
of O
action O
, O
which O
is O
too O
short O
for O
SKF B
- I
82958 I
( O
< O
1 O
hr O
) O
and O
too O
long O
for O
A B
- I
77636 I
( O
> O
20 O
hr O
, O
leading O
to O
behavioral O
tolerance O
) O
. O

We O
therefore O
conducted O
the O
present O
acute O
dose O
- O
response O
study O
in O
four O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
MPTP O
) O
- O
exposed O
cynomolgus O
monkeys O
primed O
to O
exhibit O
levodopa O
- O
induced O
dyskinesias O
to O
evaluate O
the O
locomotor O
and O
dyskinetic O
effects O
on O
challenge O
with O
four O
doses O
( O
from O
0 O
. O
03 O
to O
1 O
. O
0 O
mg O
/ O
kg O
) O
of O
A B
- I
86929 I
( O
[ O
- O
] O
- O
[ O
5aR O
, O
11bS O
] O
- O
4 O
, O
5 O
, O
5a O
, O
6 O
, O

7 O
, O
11b O
- O
hexahydro O
- O
2 O
- O
propyl O
- O
3 O
- O
thia O
- O
5 O
- O
+ O
+ O
+ O
azacyclopent O
- O
1 O
- O
ena O
[ O
c O
] O
phenathrene O
- O
9 O
- O
10 O
- O
diol O
) O
, O
a O
selective O
and O
full O
DA B
D1 O
- O
like O
receptor O
agonist O
with O
an O
intermediate O
duration O
of O
action O
. O

Levodopa O
and O
the O
DA O
D2 O
- O
like O
receptor O
agonist O
, O
LY B
- I
171555 I
( O
[ B
4aR I
- I
trans I
] I
- I
4 I
, I
4a I
, I
5 I
, I
6 I
, I
7 I
, I
8 I
, I
8a I
, I
9 I
- I
o I
- I
dihydro I
- I
5n I
- I
propyl I
- I
2H I
- I
pyrazo I
lo I
- I
3 I
- I
4 I
- I
quinoline I
hydrochloride I
) O
were O
also O
used O
for O
comparison O
. O

Acute O
administration O
of O
A B
- I
86929 I
was O
as O
efficacious O
in O
alleviating O
MPTP O
- O
induced O
parkinsonism O
as O
levodopa O
and O
LY B
- I
171555 I
, O
but O
was O
less O
likely O
to O
reproduce O
the O
levodopa O
- O
induced O
dyskinesias O
in O
these O
animals O
than O
with O
either O
LY B
- I
171555 I
or O
subsequent O
challenge O
of O
levodopa O
. O

Potent O
DA O
D1 O
receptor O
agents O
with O
an O
intermediate O
duration O
of O
efficacy O
such O
as O
A B
- I
86929 I
( O
approximately O
4 O
hr O
at O
higher O
doses O
tested O
) O
are O
potential O
therapeutic O
tools O
in O
PD O
and O
merit O
further O
attention O
. O

Clarithromycin B
- O
induced O
ventricular O
tachycardia O
. O

Clarithromycin B
is O
a O
relatively O
new O
macrolide B
antibiotic O
that O
offers O
twice O
- O
daily O
dosing O
. O

Although O
the O
side O
- O
effect O
profile O
of O
erythromycin O
is O
established O
, O
including O
gastroenteritis O
and O
interactions O
with O
other O
drugs O
subject O
to O
hepatic O
mixed O
- O
function O
oxidase O
metabolism O
, O
experience O
with O
the O
newer O
macrolides B
is O
still O
being O
recorded O
. O

Cardiotoxicity O
has O
been O
demonstrated O
after O
both O
intravenous O
and O
oral O
administration O
of O
erythromycin O
but O
has O
never O
been O
reported O
with O
the O
newer O
macrolides B
. O

We O
report O
a O
case O
of O
ventricular O
dysrhythmias O
that O
occurred O
after O
six O
therapeutic O
doses O
of O
clarithromycin B
. O

Value O
of O
methylprednisolone O
in O
prevention O
of O
the O
arthralgia O
- O
myalgia O
syndrome O
associated O
with O
the O
total O
dose O
infusion O
of O
iron B
dextran I
: O
a O
double O
blind O
randomized O
trial O
. O

The O
safety O
and O
efficacy O
of O
total O
dose O
infusion O
( O
TDI O
) O
of O
iron B
dextran I
has O
been O
well O
documented O
. O

We O
conclude O
that O
125 O
mg O
i O
. O
v O
. O
MP O
should O
be O
given O
routinely O
before O
and O
after O
TDI O
of O
iron B
dextran I
. O

Prolongation O
of O
QT O
interval O
, O
torsades O
de O
pointes O
, O
and O
sudden O
cardiac O
death O
have O
been O
reported O
after O
concomitant O
administration O
with O
erythromycin O
or O
azole B
antifungal O
agents O
, O
but O
not O
with O
other O
CYP3A4 O
inhibitors O
. O

5 B
, I
7 I
- I
dichlorokynurenic I
acid I
( O
5 B
, I
7 I
- I
DCKA I
) O
, O
a O
selective O
glycine O
site O
antagonist O
, O
injected O
in O
doses O
of O
2 O
. O
5 O
and O
4 O
. O
5 O
microg O
/ O
0 O
. O
5 O
microl O
bilaterally O
, O
into O
the O
rostral O
region O
of O
the O
striatum O
, O
decreased O
both O
the O
haloperidol O
- O
induced O
muscle O
rigidity O
( O
MMG O
) O
and O
the O
enhanced O
electromyographic O
activity O
( O
EMG O
) O
. O

5 B
, I
7 I
- I
DCKA I
injected O
bilaterally O
in O
a O
dose O
of O
4 O
. O
5 O
microg O
/ O
0 O
. O
5 O
microl O
into O
the O
intermediate O
- O
caudal O
region O
of O
the O
striatum O
of O
rats O
not O
pretreated O
with O
haloperidol O
had O
no O
effect O
on O
the O
muscle O
tone O
. O

Moreover O
, O
significant O
amounts O
of O
platinum B
were O
detected O
in O
the O
dorsal O
root O
ganglia O
and O
kidney O
after O
CBDCA O
treatment O
. O

Chronic O
effects O
of O
a O
novel O
synthetic O
anthracycline O
derivative O
( O
SM B
- I
5887 I
) O
on O
normal O
heart O
and O
doxorubicin O
- O
induced O
cardiomyopathy O
in O
beagle O
dogs O
. O

This O
study O
was O
designed O
to O
investigate O
the O
chronic O
cardiotoxic O
potential O
of O
SM B
- I
5887 I
and O
a O
possible O
deteriorating O
effect O
of O
SM B
- I
5887 I
on O
low O
- O
grade O
cardiotoxicity O
pre O
- O
induced O
by O
doxorubicin O
in O
beagle O
dogs O
. O

In O
the O
chronic O
treatment O
, O
beagle O
dogs O
of O
each O
sex O
were O
given O
intravenously O
once O
every O
3 O
weeks O
, O
either O
a O
sublethal O
dose O
of O
doxorubicin O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
or O
SM B
- I
5887 I
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
. O

Animals O
which O
received O
over O
six O
courses O
of O
doxorubicin O
demonstrated O
the O
electrocardiogram O
( O
ECG O
) O
changes O
, O
decrease O
of O
blood O
pressure O
and O
high O
- O
grade O
histopathological O
cardiomyopathy O
, O
while O
animals O
which O
were O
terminally O
sacrificed O
after O
the O
SM B
- I
5887 I
administration O
did O
not O
show O
any O
changes O
in O
ECG O
, O
blood O
pressure O
and O
histopathological O
examinations O
. O

To O
examine O
a O
possibly O
deteriorating O
cardiotoxic O
effect O
of O
SM B
- I
5887 I
, O
low O
- O
grade O
cardiomyopathy O
was O
induced O
in O
dogs O
by O
four O
courses O
of O
doxorubicin O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
. O

Nine O
weeks O
after O
pre O
- O
treatment O
, O
dogs O
were O
given O
four O
courses O
of O
either O
doxorubicin O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
or O
SM B
- I
5887 I
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
once O
every O
3 O
weeks O
. O

On O
the O
contrary O
, O
the O
SM B
- I
5887 I
treatment O
did O
not O
progress O
the O
grade O
of O
cardiomyopathy O
. O

In O
conclusion O
, O
SM B
- I
5887 I
does O
not O
have O
any O
potential O
of O
chronic O
cardiotoxicity O
and O
deteriorating O
effect O
on O
doxorubicin O
- O
induced O
cardiotoxicity O
in O
dogs O
. O

Risk O
for O
valvular O
heart O
disease O
among O
users O
of O
fenfluramine O
and O
dexfenfluramine B
who O
underwent O
echocardiography O
before O
use O
of O
medication O
. O

BACKGROUND O
: O
Because O
uncontrolled O
echocardiographic O
surveys O
suggested O
that O
up O
to O
30 O
% O
to O
38 O
% O
of O
users O
of O
fenfluramine O
and O
dexfenfluramine B
had O
valvular O
disease O
, O
these O
drugs O
were O
withdrawn O
from O
the O
market O
. O

OBJECTIVE O
: O
To O
determine O
the O
risk O
for O
new O
or O
worsening O
valvular O
abnormalities O
among O
users O
of O
fenfluramine O
or O
dexfenfluramine B
who O
underwent O
echocardiography O
before O
they O
began O
to O
take O
these O
medications O
. O

PATIENTS O
: O
46 O
patients O
who O
used O
fenfluramine O
or O
dexfenfluramine B
for O
14 O
days O
or O
more O
and O
had O
echocardiograms O
obtained O
before O
therapy O
. O

RESULTS O
: O
Two O
patients O
( O
4 O
. O
3 O
% O
[ O
95 O
% O
CI O
, O
0 O
. O
6 O
% O
to O
14 O
. O
8 O
% O
] O
) O
receiving O
fenfluramine O
- O
phentermine B
developed O
valvular O
heart O
disease O
. O

In O
the O
present O
study O
, O
the O
possible O
enhancement O
by O
isoniazid O
of O
bradycardia O
induced O
by O
beta O
- O
adrenoceptor O
antagonists O
was O
determined O
in O
rats O
anaesthetised O
with O
chloralose B
- O
urethane O
. O

Isoniazid O
significantly O
increased O
bradycardia O
after O
propranolol O
, O
pindolol B
, O
labetalol O
and O
atenolol B
, O
as O
well O
as O
after O
clonidine O
, O
but O
not O
after O
hexamethonium O
or O
carbachol O
. O

Enhancement O
was O
not O
observed O
in O
rats O
pretreated O
with O
methylatropine B
or O
previously O
vagotomised O
. O

